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ABSTRACT
EGF receptor was first implicated in the prognosis of breast cancer patients in 
1987. It has since been extensively studied, both in terms of its clinical 
significance and its role in tumour biology. Despite this, the mechanism of its 
prognostic influence remains unclear, as is its relationship with established 
prognostic indicators. Inaccuracies in the methods used to measure receptor 
expression may, in part, be responsible. This thesis addresses this issue, and then 
broaches the possibility that receptor mediated tumour cell invasion might account 
for its effect on prognosis.
Receptor measurement using a quantitative radioimmunohistochemical assay 
(Rihc) was compared with the most commonly used conventional methods. Using 
Rihc, receptor could be measured in 92% of tumours, as opposed to 38% and 
42%, with ligand binding (Lb) and conventional immunohistochemistry (Cihc), 
respectively. The conventional methods, categorising tumours as positive or 
negative, showed a high level of correlation (p=0.0006) but for 26% of the 
tumours did not concur. This level o f disparity may account for some o f the 
confusion over the role of EGF receptor in breast cancer. Rihc was compared with 
the other methods using a Spearman rank analysis. Limiting this analysis to 
tumours receptor positive using the conventional technique, Rihc and Cihc had a 
better correlation (p<0.0005), than Rihc and Lb (p=0.702). Despite the correlation 
between the immunohistochemical methods, Cihc failed to detect receptor in 52% 
of the tumours, a group in which receptor expression varied by 10 fold using Rihc. 
Overall, Rihc proved more sensitive and more accurate.
In total, 203 breast cancers were analysed using Rihc. The vast majority (98%) 
had levels of receptor below those in normal (reduction mammoplasty) breast. In 
keeping with the consensus, there was a strong inverse correlation between EGF 
receptor and oestrogen receptor (p<0.0005). There was also a direct association 
with poorer histological grade (p=0.005), but none to either T-stage (p=0.392) or 
nodal status (p=0.074). Additionally, the accuracy of Rihc allowed identification 
of an inverse correlation between the levels of oestrogen and EGF receptor (rank 
analysis p=0.032), and also a direct correlation with maximal tumour size, in 
millimetres (rank analysis p=0.049). To assess the relationship with outcome, 
tumours were divided into groups determined by receptor expression. Using a 
univariate analysis, EGF receptor predicted death (from all causes) and also 
disease free survival; tumours studied in 2 groups (p=0.0429, p=0.0446,
respectively), 3 groups (p=0.0047, p=0.0072, respectively), and 4 groups 
(p=0.0009, p=0.0013, respectively). However, in multivariate analysis, oestrogen 
receptor (relative risk 4.7, 95%CI 2.5-8.7), then nodal status (relative risk 3.0, 
95%CI 1.6-5.7), followed by tumour size (TNM) (relative risk 1.8, 95%CI 1.1- 
2.8), were included in the outcome model for all deaths, and EGF receptor was the 
least significant predictor of outcome.
It has been hypothesised that EGF receptor signalling promotes tumour cell 
motility and invasion. A novel invasion assay, using the basement membrane 
substitute Matrigel, was developed and applied to breast cancer cell lines 
expressing a range of receptor densities. Invasion, into the Matrigel layer, was 
promoted by EGF and ascertained using confocal microscopy coupled to image 
analysis. The MDA-MB-231 cell line invaded up to 30pm, with a clear dose 
response curve (p=0.0005). Invasion, also evident for the MCF7 Adriamycin 
resistant and BT20 cell lines, did not simply reflect proliferation. It occurred more 
frequently in the cell lines expressing more EGF receptor, but this relationship 
was not absolute, indicating that other factors were important. Monoclonal 
antibody, ICR 16, directed to the EGF receptor and inhibiting EGF binding 
abrogated invasion, as did the tyrosine kinase inhibitor, 
4,5-Dianilinophthalimide (DAPH). These results indicated that breast tumour cell 
invasion was, at least partly, modulated by EGF receptor.
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PARTI
HISTORICAL REVIEW 
AND
BACKGROUND INFORMATION
Chapter 1
Chapter 1: 
Basic science of the epidermal growth factor receptor
Section i: EGF receptor and the type I  tyrosine kinase receptors
From the earliest days of tissue culture, there has been considerable interest in the 
mechanisms regulating the proliferation of cells. Early work indicated that 
specific proteins, called growth factors, interacted with receptors stimulating cell 
division. The discovery, in the early 1980's, o f retroviral oncogenes, their cellular 
equivalents, and the subsequent realisation that these genes had extensive 
homology with those coding for growth factor receptors, intensified this interest. 
Consequent studies of these molecules, and their role in cell biology, have lead 
us to begin to unravel the functional nature of the molecular lesions which give 
rise to cancer.
In the 1930's, the causative agent of avian erythroblastosis and fibrosarcoma was 
identified, but not until much later was it realised that this was the retrovirus and 
oncogene, erb-B. Subsequently, this gene was found to exhibit extensive 
homology with the human EGF receptor gene. The resultant interest in the 
type I tyrosine kinase receptors, o f which the epidermal growth factor receptor is 
the paradigm, means these are perhaps the most extensively studied growth factor 
receptors.
EGF receptor, or c-erbB-\, was the first identified member of the type I growth 
factor receptor family; the others are c-erbB-2, c-erbB-^ and c-erbB-4. All are 
cell surface glycoprotein receptors that signal via very highly conserved tyrosine 
kinases. All have been associated with anomalous expression in a variety of 
human tumours (reviewed in Prigent 1992).
Purification of EGF, one of the EGF receptor ligands, made possible the isolation 
o f the latter from the squamous carcinoma cell line, A431, in which it is hugely 
overexpressed (Wrann 1979). Thereafter, the receptor's cDNA sequence (Xu 
1984, Downward 1984, Lin 1984 and Ullrich 1984) and then its genomic 
structure (Haley 1987) were determined. Using this information, low stringency 
probing o f human cDNA libraries with both sequences from the EGF receptor 
gene and its avian viral analogue, v-erbB, allowed identification of the other 
members of the type I growth factor receptor family.
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Figure 1.1 : Amino acid homology in the type I tyrosine kinase receptor family.
N H 2
(i)
C ys te ine  rich (ii) 
(iii)
C y s te in e  rich (iv)
i ii iii iv TK
EGFR / c-erbB-2 42 46 45 41 82
EGFR / c-enbB-3 40 46 46 50 60
% amino acid homology
T ra n s m e m b ra n e
c-enbB-2 / c-enbB-3 40 45 44 41 62
EGFR / c-enbB-4 46 51 42 45 79
T y ro s in e  k in a se  fTK) c-enbB-2 / c-enbB-4 46 46 39 34 77
c-erbB-3 / c-erbB-4 50 67 60 49 63
C y top lasm ic  tail
COOH
The table shows the amino acid homologies of the four receptors of this family. Domains i 
and iii represent the sequences between the two cysteine rich regions, ii and iv. TK is the 
tyrosine kinase domain. Modified from Type I growth factor receptors: an overview of 
recent developments', Mason S and Gullick WJ, The Breast, 4:11-8,1995.
Section ii: Structure o f  EGF receptor
The EGF receptor is a 170 kiloDalton transmembrane glycoprotein receptor that 
is expressed on the surface o f all cell types, with the exception of differentiated 
haematopoietic cells. It comprises 1186 amino acids that are encoded by the 
cellular oncogene c-erbB-X, located on human chromosome 7q21. It can 
conveniently be thought of as having three domains: a 621 amino-acid 
extracellular domain responsible for ligand recognition; a 23 amino acid 
hydrophobic transmembrane region; and a 542 amino-acid intracellular region 
containing the highly conserved tyrosine kinase domain. This topology means 
that, unlike water soluble allosteric enzymes, the ligand binding and tyrosine 
kinase domains are separated by the cell membrane. Therefore, receptor 
activation due to extracellular ligand must be translated, across the membrane 
barrier, into activation in the intracellular domain.
The extracellular moiety is substantially glycosylated and comprises two pairs o f 
putative domains; globular, or L, and cysteine-rich, or S. It is proposed that these 
pairs of subunits form a ligand 'pocket'. Ligand binding alters the interaction 
between these subunits, thus allowing transfer of an allosteric conformational 
transition to the internal domain (reviewed in Ullrich 1990). A single amino acid
3
Chapter 1
helix forms the transmembrane domain. Its main function is to anchor the 
receptor to the plasma membrane, thereby connecting the extracellular 
environment with the internal compartments of the cell. The protein kinase 
domain is located in the intra-cellular portion. A kinase negative mutant o f the 
receptor was unable to propagate intracellular signalling when bound by ligand 
(Honegger 1987, 19871, Chen 1987), inferring that EGF receptor signalling is 
dependent on tyrosine phosphorylation of cellular substrates. Thus, the tyrosine 
kinase domain is prerequisite for signal transduction and induction o f both early 
and delayed cellular responses; including mitogenesis and transformation.
Figure 1 2 : Proposed structure-function topology of the EGF receptor.
EGF
IV
in <*>
TTT
i i i
TTT
iii
Y
DOMAIN
Extracellular <
FUNCTION
ligand binding 
dimerisation
Transmembrane membrane anchor
Juxtam embrane negative control 
(thr 654)
Tyrosine kinase ^
substra te  binding 
catalytic activities
* t  Carboxy terminal signal regulation
tail
Subdomains, ii and iv, represent the cysteine rich regions of the extracellular domain. 
Most of the structural determinants that define EGF binding are proposed to be located in 
the pocket formed by subdomains i and iii. Far left is a top view of the external domain 
(not to scale). The symbols, S and R, represent proposed interaction sites for substrates 
and regulatory factors respectively. Modified from 'Signal transduction by receptors with 
tyrosine kinase activity' Ullrich A and Schlessinger J, Cell 61:203-12,1990.
Within the intra-cellular portion, flanking the protein kinase domain, are the 
juxta-membrane region and the carboxy-terminus tail, both of which may 
influence the receptor's tyrosine kinase activity. The former includes regions, 
with serine and threonine residues, that can be phosphorylated by intracellular 
protein kinases, such as mitogen-activated (MAP) kinase and protein kinase C 
(PKC). Phosphorylation of these sites may regulate EGF receptor activity,
4
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internalisation rate and ligand affinity, however, the subtleties o f signal 
regulation, both in terms of phosphorylation sites, and serine/threonine kinases, 
are still to be determined.
The carboxy-terminus tail is thought to interact with the protein kinase region 
modulating its capacity to interact with exogenous substrate. This may be 
effected by competition, for binding of the signal transducing tyrosine kinase 
region, between intrinsic (carboxy-terminus tail) autophosphorylation sites and 
exogenous substrate. Such signal modulation has been observed in other tyrosine 
kinase receptors where carboxy-terminal tail sequences exert a negative control 
on receptor signalling (Roussel 1987). Adding support to this proposal are 
studies of mutant receptors with altered autophosphorylation sites, these were 
mitogenically more responsive to lower doses of EGF when compared to wild 
type receptors (Honegger 19881). Similarly, other receptor types with carboxy- 
terminal deletions have increased oncogenic capacity (Khazaie 1988).
Section iii: EGF receptor ligands
There are five cognate ligands to the EGF receptor; EGF, TGF-a, heparin- 
binding EGF, betacellulin and amphiregulin (Davies 1996). Initially isolated 
from extracts of mouse submaxillary glands, EGF is a 53 amino acid peptide 
(Savage 1972). It is characterised by its ability to stimulate precocious eyelid 
opening and incisor eruption by stimulation of epidermal growth and 
keratinisation (Carpenter 1979). Subsequently, the human equivalent, 
urogastrone, was isolated from urine (Gregory 1975).
EGF binds exclusively to EGF receptor and does not directly interact with the 
other type I tyrosine kinase receptors. It is a potent stimulator of cell proliferation 
and has effects on the differentiation and function of a variety o f cell types 
(Gregory 1975, Hommel 1991). It has also been shown to reduce gastric acid 
secretion, to protect against mucosal damage in the gastrointestinal tract, and to 
have functions in embryo/foetal development (reviewed in Prigent 1992 and in 
Wiley 1995). Less is known of its role in neoplasia although there are reports o f 
elevated levels of expression in a variety of carcinomas, including gastric and 
breast (reviewed in Prigent 1992).
Sequence analysis of the EGF molecule has revealed the presence of six cysteine 
residues which participate in the formation of three disulfide bonds which
5
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produce a three-ringed conformation in the peptide molecule (Savage 1973). This 
three looped structure characterises all members o f the EGF receptor ligand 
family. Besides conserving the cysteine residues that confer this loop structure, 
all five ligands conform to the motif; X nC X yC X ^C X ] oCXCX5 GX2 CXn, 
where X is any non-cysteine residue and n is a variable number (Prigent 1992).
TGFa, a 50 amino-acid peptide that exhibits approximately 40% homology to 
the EGF molecule, also functions exclusively through the EGF receptor (Todaro 
1990). This ligands relationship to the neoplastic process is better documented 
than that of EGF. An increase in the synthesis and secretion o f TGFa occurs in a 
number o f carcinoma cell lines, including human breast lines (Perroteau 1986, 
Bates 1988), and has been reported in fibroblasts and epithelial cells that have 
been transformed with a number of different oncogenes (Salomon 1990, 
Jakowlew 1988, Ciardiello 1990). In up to 70% of breast cancers, wild type 
TG Fa can be localised to the malignant cells (Ciardiello 1989). Further, 
compared to TGFa levels in benign breast tissues, those in pre-malignant and 
malignant breast are 2-3 times higher (Parkam 1992, Macais 1989, Lundy 1991, 
Umekita 1992).
In-vitro , TGFa is a potent mitogen for normal and malignant mammary epithelial 
cells, and in-vivo it stimulates lobulo-alveolar development of the mouse 
mammary gland (Bates 1990, Vondherhaar 1987). Oestrogen receptor negative 
cell lines, models for clinically aggressive oestrogen receptor negative breast 
cancers, tend to express more TGFa than do oestrogen receptor positive breast 
cell lines (Perroteau 1986, Bates 1988). Futher, in oestrogen receptor positive 
lines, oestrogen treatment enhances TGFa expression (Bates 1988), an effect that 
can be blocked by anti-oestrogens (Bates 1988, Murphy 1989). Finally, breast 
cancer patients treated with the anti-oestrogen Tamoxifen demonstrated a 10 fold 
reduction of tumour levels of TGFa (Gregory 1989). Summated, these findings 
implicate TGFa in the progression of malignant breast disease.
Like TGFa, amphiregulin exerts its biological activity through the EGF receptor 
(Johnson 1993). High levels of this protein have been found in a number o f 
normal human mammary epithelial cell lines (Kenny 1993, Shoyab 1989) where 
it is thought to stimulate proliferation via an autocrine loop. This hypothesis is 
leant support by the finding that, EGF-independent, autonomous proliferation of 
these cell strains is completely blocked by the addition of heparin which binds 
amphiregulin inhibiting its interaction with EGF receptor (Li 1992, cook 1992).
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Additionally, TGFa functions as an autocrine growth factor in c-Ha-ras 
transformed MCF-10A cells, and an antisense oligonucleotide to amphiregulin 
DNA blocked anchorage dependent and independent growth in these cells 
(Ciardiello 1990). The implication is that autocrine loops might induce chronic 
receptor stimulation and that activation of such loops could be important in the 
progression to malignancy. This concurs with the results of experimental work; 
elevated levels of both ligand and receptor being associated with cell 
transformation (Lippman 1986, DiMarco 1989). Furthermore, the majority o f 
breast cancers that produce high levels of TGFa coexpress EGF receptors, 
suggesting that an autocrine loop may be operative in-vivo (Lundy 1991, 
Umekita 1992).
Autocrine loops may be more prevalent than is presently appreciated since there 
may be unrecognised EGF receptor ligands. Additionally, ligands may signal by 
juxtacrine stimulation, a from of cell to cell communication proposed by 
Massague (1990). The mRNA for EGF encodes a 1217 amino acid precursor 
molecule which resembles a transmembrane receptor (reviewed in Prigent 1992). 
In a membrane bound form, this is capable of stimulating EGF receptors on 
adjacent cells (Dobashi 1991). This scenario is pertinent for the other cognate 
EGF receptor ligands, all of which are cleaved from larger precursor molecules 
which resemble cell surface receptors. Consequently, these ligands may mediate 
cell-cell interactions in-vivo, a role which has been confirmed for the membrane 
bound TGF-a precursor which functions in a juxtacrine fashion during vertebrate 
development (Paria 1994).
Section iv: Signal transduction
Extracellular ligand binds the monomeric receptor, inducing receptor 
dimerisation (Schlessinger 1988). This action increases the catalytic activity of 
the receptor tyrosine kinase (Yarden 1987) and results in the formation, at the 
cell membrane, of a multi-molecular complex containing cytoplasmic signalling 
proteins. Signal transduction is achieved by ligand dependent 
autophosphorylation of, at least, three major sites; tyrosine residue numbers 
1068, 1148 and 1173 (Downward 19841). Mutational analysis experiments 
indicate that phosphorylation of all of these sites is required for substrate access 
to the receptor's catalytic site (Velu 1989, Helin 1991). Once activated, the kinase 
phosphorylates a number of intracellular substrates, including, amongst others, 
phospholipase C-y, MAP kinase, Raf-1 and GAP (reviewed in Merlino 1990 and
7
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in Wiley 1995). Phosphorylation of these effector substrates, together with 
changes in the intracellular milieu, precipitate nuclear signals activating the 
transcription of early genes, like fo s  and ju n , that code for proteins capable of 
modulating changes in gene expression (Heldin 1987, Nigg 1990). Subversion of 
these regulatory pathways has been shown to result in malignant transformations 
(Heldin 1987, Nigg 1990, Fidler 1990).
After ligand binding, receptors on the cell surface are internalised into coated 
vesicles and rapidly degraded in the lysosomal compartment (Schlessinger 1988). 
This process of excluding the receptor from the cell surface may provide a 
mechanism of control over receptor function; truncated receptor, unable to 
internalise but with normal kinase activity, caused increased transforming 
activity (Wells 1990). Similarly, a single point mutation, in the transmembrane 
region o f the c-er&B-2 receptor, caused cellular transformation, possibly by 
stabilising receptor dimerisation in the absence of ligand (Weiner 1989).
The above outline of ligand binding receptor producing a given signal, is a gross 
oversimplification of ligand-induced EGF receptor stimulation. It is clear that the 
EGF receptor is at the hub of a web of intracellular signals, many of which 
remain to be elucidated. It is also clear that the receptor signal can be induced in 
a number of complex manners and that, once generated, signal impinges on a 
myriad cellular processes. Some o f the complexities of EGF receptor signalling 
are outlined below.
Why does one receptor have five ligands? As a result of variations in their 
amino-acid content, the different ligands have different isoelectric points. 
Therefore, the local environment, which is often chemically hostile e.g. gut or 
infection sites, will determine the cells' ability to respond to a certain ligand 
(reviewed in Davies 1996). Ligands may also differentially influence receptor 
signalling via their variable N-terminus. The N-terminus of heparin-binding EGF 
functions in this manner; binding it to cell surface molecules, thus increasing 
EGF receptor binding affinity by up to two orders of magnitude (reviewed in 
Davies 1996). Different ligands may also evoke different biological responses. 
Amphiregulin, unlike
TGF-a and EGF, fails to synergize with TGF-P to promote anchorage 
independent growth (Shoyab 1989). Similarly, amphiregulin fails to stimulate 
epidermal to mesenchymal transition in colon cancer cells lines that respond in 
this manner to EGF (Solic 1995). Also, the different ligands are the products of
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different cellular processes and ligand stimulation of EGF receptor may reflect 
only one o f the outcomes o f these processes.
Untangling the intracellular signalling, and biological outcome o f receptor 
stimulation, is further complicated by the EGF receptor's ability to 
heterodimerise with other members of the type I tyrosine kinase receptor family. 
Heterodimerisation was first demonstrated between the EGF receptor and 
c-erbB-2. Kokai and colleagues showed that NIH3T3 cells were not transformed 
by moderate levels o f c-erbB-2 unless accompanied by similar levels of EGF 
receptor expression (Kokai 1989), implying that the receptors were acting 
synergistically. These receptors were then observed to form heterodimers in a 
ligand-dependent manner (Spivak-Kroizman 1992, Quain 1992). In a similar 
fashion, EGF receptor can interact with other type I tyrosine kinase receptors 
(Soltoff 1994).
Heterodimeric associations may influence downstream signalling in various ways 
(reviewed in Earp 1995). In comparison to homodimers, heterodimers may:
i. expand available substrate options thus broadening potential signalling 
pathways,
ii. promote interaction of substrates that would not be juxtaposed by homodimer 
receptor associations,
iii. alter duration o f receptor signalling; altering rates of internalisation, kinase 
activation, ligand loss etc.,
iv. alter rates of receptor phosphorylation and dephosphorylation.
By any of these mechanisms, individually or in combination, EGF receptor signal 
transduction may be modified (Wada 1990).
Interpretation of ligand/receptor interaction may be further complicated by events 
at the receptor level. By a process termed transmodulation, heterologous ligands 
can phosphorylate threonine residues on the EGF receptor. By this mechanism, 
platelet-derived growth factor has been shown to influence activity o f the EGF 
receptor (Lin 1986). Similarly receptor inhibition and internalisation have been 
linked to phosphorylation at threonine 654 (Countaway 1990) and 669 
(Heisermann 1990) respectively.
All o f the above levels of EGF receptor control are at the extracellular and 
membrane levels. There is evidence that suggests a further level o f control occurs 
at the cytoplasmic level, via specific cytoplasmic signal transducers, e.g. the non­
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receptor protein tyrosine phosphatase SHP-2/Corkscrew (Allard 1996, Perkins 
1996) which has been implicated in a number of receptor tyrosine kinase 
signalling pathways. At present, relatively little is known of this level of signal 
control but these may further add to the complexities of unravelling EGF receptor 
function.
Figure 1.3 is a diagrammatic summary of the events following ligand/receptor 
binding.
Section v: Effect o f  Signalling
The processes regulated by receptor tyrosine kinases and their ligands are also 
diverse. They include regulation of cell growth, differentiation, migration, 
viability and homeostasis. Some receptor tyrosine kinases are cell type specific 
and are devoted to a single function, e.g. drosophila Sevenless which specifies the 
differentiation of one photo-receptor in the adult eye. Conversely, signalling by 
others is implicated in a myriad processes. The EGF receptor conforms to the 
latter category; in drosophila, during just the embryo phase, it is involved in the 
establishment of ventral cell fates, maintenance of amnioserosa, and ventral 
neuroectodermal cells, germ band retraction, cell fate specification in the nervous 
system and production of cuticle (reviewed in Perrimon 1997).
How does a single tyrosine kinase receptor regulate such a diversity of 
processes? It has been suggested that multiple ligands might provide modulation 
o f  EGF receptor activity (Shoyab 1989, Solic 1995). Diversity in the expression 
o f  these ligands as well as a control over their activity has increased the 
repertoire of receptor functions (reviewed in Perrimon 1997). Alternative 
hypotheses are: that EGF receptor function is the result o f a balance o f negative 
and positive feedback loops which will vary in their emphasis dependent on the 
particular cells in question, this has been demonstrated by work on cell fate in 
drosophila ventral ectoderm (Golembo 1996); or that the EGF receptor may 
function as an on-off switch with the result o f its activation determined by the 
cells on which it acts, as seen in gene expression patterns in the ventral ectoderm 
of drosophila, (Golembo 1996).
The sections above focus on the molecular level of EGF receptor function. Much 
remains to be learnt of the functional significance of EGF receptor stimulation 
before its clinical importance will be appreciated. To date, most attention has
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focused on the promotion of mitogenesis since there is good evidence from 
in-vitro studies that EGF receptor stimulation effects this response (Stoscheck 
1986, Hamburger 1981, Singletary 1987). Further, the growth of A431 cells 
transplanted to athymic mice correlates directly to the degree of gene 
amplification and the concentration of EGF receptors (Santon 1986) and the 
growth of human gastric carcinoma xenografts, speeded by the addition o f EGF, 
can be suppressed by sialoadenectomy (Okuda 1994). The implication is that 
EGF stimulation of EGF receptor results in proliferation. However this may be 
simplistic. Chorioepithelioma xenografts in nude mice treated with EGF 
demonstrate a biphasic response; low EGF concentrations promoting 
proliferation whilst this response is inhibited by higher concentrations (Myachi 
1990). Also, addition of EGF to subcutaneous tissues adjacent a breast cancer 
xenograft inhibits its growth (Murayama 1990) and both EGF and TGFa can 
inhibit proliferation of some cell lines depending on the presence of other growth 
factors and the levels of EGF receptor (Shoyab 1988). Therefore, the EGF/EGF 
receptor axis mediates effects more complex than a simple promotion of 
mitogenesis.
Examination of the events following receptor stimulation does not clarify the 
situation. Nerve growth factor (NGF), also a tyrosine kinase growth factor 
receptor implicated in oncogenesis, stimulates differentiation but inhibits 
proliferation of the rat phaeochromocytoma clone, PC 12 (Tischler 1975). The 
same clone is stimulated to proliferate by EGF (Huff 1981). However, there are 
no discernible differences in the early response genes activated by stimulation of 
both receptors (Greenberg 1985, Bartel 1989) and a variety of diverse reactions 
appear similarly induced; membrane ruffling (Seeley 1984), Na+/K+ transport 
(Boonstra 1983), cell adhesion and deoxy-glucose uptake (Huff 1981). Even the 
pattern of tyrosine phosphorylation of cellular proteins is very much alike (Maher
1988). Put simply, NGF and EGF trigger the same set of early responses, none of 
which are wholly specific for EGF or NGF. Therefore, the steps in signalling for 
neurotrophic effects appear to involve the same molecules used for the 
transduction of mitogenic signals. How then is the specificity of growth 
factor/receptor signalling achieved? It is possible that it is a consequence of 
parallel discriminatory events that have not been elucidated or events further 
downstream that are more important in determining the divergence of the 
signalling pathways. Equally, EGF receptor function may be determined, or 
influenced, by the particular cellular context. Amongst other functions are an 
immunosuppressive effect, reducing host resistance and accelerating cancer
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growth and metastasis (Koch 1984), or increased tumour cell invasiveness, a 
possibility that is considered further in Chapter 4.
Since its discovery in 1984, a great deal has been learnt of the EGF receptor and 
its signalling, however much remains to be elucidated. From the account above, 
it is clear that we have an incomplete comprehension of the ligand-receptor 
interaction event, the resultant signal, its modulation and also its functional 
effect. Overall, our knowledge of the functional significance of expression levels 
o f receptor, in malignant and indeed normal, tissues remains crude.
13
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Chapter 2: 
EGF receptor expression in breast cancer
Section i: Early studies o f  EGF receptor in breast cancer
Beatson, as early as 1896, had hinted at the hormonal dependence of some breast 
cancers (Beatson 1896). Subsequently, oestrogen receptor expression was 
observed to influence breast tumour progression; oestrogen receptor positive 
tumours having improved prognosis over oestrogen receptor negative tumours. 
Oestrogen receptor status also influenced the site at which metastases tended to 
develop; oestrogen receptor negative tumours metastasised to liver and brain 
whereas those of oestrogen receptor positive tumours showed a propensity for 
soft tissue and bone (Stewart 1981). With these findings, there was growing 
evidence that tumour cell biology was, at least partly, regulated through receptor 
signalling.
Cooke (1982) used thymidine labelling to demonstrate that oestrogen receptor 
negative tumour cells proliferated more rapidly than their receptor positive 
counterparts. Yet EGF was a more potent mitogen than oestrogen in breast cancer 
cell lines (Osborne 1980). Further, during breast development and maturation, 
EGF was present, at high levels, in both tissue and plasma, and human milk was 
also rich in this moiety (Carpenter 1980). EGF receptor, therefore, has a role in 
normal breast development, but, with its substantial homology to the 
v-erbB  oncogene product, was it also functioning in breast tumour biology?
The first reports of EGF receptor expression in human breast cancers were in 
1985 (Sainsbury 1985, Sainsbury 19851). By demonstrating a higher frequency 
o f receptor posisitvity in metastatic lymph node specimens than in primary breast 
tumours, Sainsbury's group suggested that its expression correlated with 
metastatic potential. They also reported an inverse relationship between 
oestrogen receptor and EGF receptor expression and proposed that the growth of 
a proportion of oestrogen receptor negative tumours might be regulated via the 
EGF receptor. This publication concluded that it might be possible to regulate the 
growth of some human breast cancers by interfering with EGF receptor function.
In the same year, Sainsbury reported that there was a strong correlation between 
EGF receptor expression and Bloom and Richardson score; p<0.01 in a series of 
108 ductal carcinomas. This led to the hypothesis that measurement o f EGF 
receptor might provide a useful prognostic indicator (Sainsbury 19851). In 1987
14
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the same group published the results of follow-up on a prospective series o f 135 
patients (Sainsbury 1987). They observed that relapse free survival and overall 
survival were significantly worse in those patients with EGF receptor positive 
carcinomas, as opposed to those that were receptor negative. The converse was 
shown for oestrogen receptor status. Further, a subgroup of patients with 
oestrogen receptor negative/EGF receptor positive tumours had the poorest 
prognosis. Multivariate analysis showed that, in lymph node negative tumours, 
EGF receptor was the single most important predictor for relapse-free and overall 
survival, and that in node positive disease it was the second most important, after 
nodal involvement. They concluded that EGF receptor expression was the most 
important variable for predicting relapse-free and overall survival (Sainsbury 
1987).
Section ii: EGF receptor; relationship with other prognostic factors
Since these early studies, EGF receptor expression, and function, in breast 
carcinoma have been studied extensively. Despite this, there is still no clear 
consensus on the clinical relationships and prognostic value of the measurement 
o f this receptor in breast cancer. Its clinical significance in this pathology is most 
thoroughly reviewed by Klijn et al (1992). This author trawled the literature for 
data on clinical parameters and receptor expression, the resultant publication 
reports the study of 5232 patients from studies by 40 different research groups. 
Such meta-analysis can be difficult to interpret (Ioannidis 1998), but by limiting 
the analysis to the largest and most recent studies and by combining only the 
results of comparable studies, Klijn has provided a useful overview.
a) Relationship to oestrogen receptor
Despite a wide variation in the reported levels of both oestrogen receptor, 
34-82%, and EGF receptor, 14-91%, at least twenty-eight different groups 
(reviewed in Klijn 1992) have reported an inverse relationship between these 
receptors. Similarly, twelve of nineteen groups reported an inverse relationship 
between progesterone and EGF receptors. Subsequent to Klijn's review, 
Koenders et al (1991) published on steroid hormone and EGF receptor levels in 
531 breast cancers, easily the largest single series. They observed that not only 
was EGF receptor positivity more frequent in oestrogen receptor negative 
tumours (p<0.0001) but that levels of EGF receptor were also significantly higher 
in this group (p<0.0001). In the same paper, a similar relationship was reported 
between EGF and progesterone receptors. Thus there is a relative concensus
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regarding the relationship between expression of EGF receptor and steroid 
hormone receptors.
b) Relationship to tumour size
With regard to tumour size, fourteen groups failed to identify any association 
with receptor density. However, two groups, including Sainsbury's, found a 
direct correlation between receptor expression and tumour diameter. 
Contradicting this are the reports of three groups, including Klijn's (Foekens
1989), each o f which reported an inverse relationship between these parameters.
c) Relationship to lymph node metastasis
Following breast cancer surgery, the presence of lymph node metastasis has 
traditionally provided the best indication of prognosis (Valagussa 1978, Fisher
1983). For this reason considerable interest has focused on the relationship 
between lymph node metastases and EGF receptor levels, however, this is one of 
the areas where there is greatest contradiction in the literature. In his 1987 
publication, Sainsbury, observed that the frequency of EGF receptor positivity 
was higher in node-positive disease than in node negative cancers. It is however 
worth noting that, in this series, only 52.6% o f patients had lymph nodes 
biopsied; the study protocol required that all patients undergoing local excision 
have nodes biopsied, but if undergoing mastectomy, only those patients with 
palpable nodes had these biopsied. In accord with this report are the findings of 
Battaglia (1988), who reported 77.7% EGF receptor positivity in node positive 
carcinoma, as opposed to only 25.7% in node negative disease. Bolufer (1990) 
demonstrated a similar relationship but only in oestrogen receptor positive 
carcinomas. Others have suggested a linear relationship between levels of 
receptor, or gene transcript, and numbers of involved nodes, in all tumours 
(Hainsworth 1991) and in non-inflammatory breast cancers (Guerin 1989). 
Contradicting these observations was the report of Grimaux (1989), finding that 
EGF receptor levels were elevated in those tumours with less than four involved 
nodes. Perhaps more significantly, a further fifteen groups failed to demonstrate 
any correlation between, either nodal involvement, or numbers o f involved 
nodes, and receptor levels.
As is indicated above, Sainsbury's initial paper reported higher levels of receptor 
expression in lymph node metastases than in primary cancers, an observation 
used to promote the hypothesis that receptor expression correlated with 
metastatic potential. This finding, of higher receptor expression in metastases
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than primary disease, is less contentious than the relationship between receptor 
and nodal status. It enjoys the support of several other publications (Battaglia 
1985, Macais 1986) but once more there is controversy; Grimaux et al (1989), 
studying a series of 55 breast cancers, could not confirm this relationship.
d) Relationship to histological type
The vast majority of invasive breast cancers are histologically classified as ductal 
carcinomas, the next largest subgrouping is lobular carcinoma, accounting for 
approximately 12% of all breast cancers (Wright 1986). The remaining sub-types 
o f breast cancer make up only a small percentage of total cases. A number of 
studies have reported higher EGF receptor expression in ductal carcinomas than 
in lobular types but equally others have failed to confirm this association 
(reviewed in Klijn 1992). Better differentiated breast tumours, including tubular 
and mucoid cancers, have been reported as expressing EGF receptor, but usually 
at lower levels than ductal carcinomas (Skoog 1986, Sainsbury 1988). An 
exception, is the well differentiated breast carcinoma of medullary type. In 
Klijn's review, only eight of 831 histologically typed carcinomas, were classified 
as medullary but seven were considered EGF receptor positive. However, using 
an immunohistochemical estimation o f EGF receptor, Moller (1989) found 
receptor positivity in only one of seven medullary carcinomas.
The 831 patients, reviewed by Klijn, encompass the results of six separate 
studies. In summary; 658 tumours were classified as ductal and the proportion of 
EGF receptor positive tumours ranged from 23% to 58% (overall 35%), 85 were 
classified as invasive lobular carcinoma, with receptor positivity in 0% to 57% 
(overall 28%), with 43 carcinomas classified as 'other', EGF receptor positivity 
ranging from 13% to 67% (overall 37%). Thus, there was no clear relationship 
between EGF receptor expression and the histological type of breast cancer.
e) Relationship to hitological grade
Histologically, invasive ductal carcinoma varies considerably. In 1957, Bloom 
and Richardson proposed a histological grading system (Bloom 1957), and 
subsequently showed this grade to be of prognostic significance (Bloom 1971). A 
modification of this system, remains the basis of breast tumour grading, as 
advocated by the World Health Organisation (WHO 1968). Tumours are graded, 
from one to three, depending on three features o f the carcinoma cells; tubular 
formation, mitotic index and nuclear pleomorphism. Higher grade is associated 
with poorer prognosis; 81%, 54% and 34% five year survival for grades one, two
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and three respectively (Bloom 1971). O f the 40 reports reviewed by Klijn (1992), 
19 included studies of tumour grade. Ten of these reports described a statistically 
significant association between poorer grade and EGF receptor expression, 
however, eight failed to determine such an association. In the remaining report, 
this relationship was observed only in those tumours that were oestrogen receptor 
negative (Bolufer 1990).
f)  Relationship to other parameters
Klijn also reviewed EGF receptor expression in terms o f other, less frequently 
used, prognostic indicators. These included flow-cytometric assessment o f 
tumour ploidy and parameters of cellular proliferation. Seven studies addressed 
the association between receptor expression and ploidy. The numbers of tumours 
in these studies was relatively low, and maybe not surprisingly, given the 
variation of reported associations between receptor expression levels and the 
more commonly measured prognostic indicators, there was some discord 
between these studies. Whilst all seven suggested that EGF receptor levels were 
higher in aneuploid tumours, in only one study was this statistically significant 
(Walker 1986). In total 367 tumours were analysed, overall 35% of aneuploid 
tumours, and only 15% of diploid tumours, were reported as receptor positive. 
Klijn (1992) used this combined analysis to suggest that EGF receptor positivity 
occurred more frequently in aneuploid tumours, and that individual investigators 
had failed to find this association statistically significant due to the small size of 
their respective studies. This is a problem that afflicts many of the publications 
on EGF receptor.
A number o f parameters reflecting cellular proliferation rates have been 
described, these include thymidine labelling index, S-phase fraction and Ki-67. 
Klijn reviewed nine reports of indices of proliferation. Three studies identified 
statistically significant associations with EGF receptor expression. In one, Ki-67 
staining was observed at higher levels in EGF receptor positive tumours (Toi
1990). However, this publication reported on just 27 tumours, and three larger 
studies have failed to confirm this finding. In another, S-phase fraction correlated 
with receptor expression (Walker 1986) but two subsequent studies failed to 
confirm this observation. The last of the statistically significant reports, showed a 
correlation between numbers of mitoses, counted by light microscopy, and EGF 
binding (Spitzer 1987), but, in a report the following year, this author indicated 
that this association was chiefly in node positive tumours (Spitzer 1988). 
Reports, subsequent to those in Klijn, have left the relationship, between EGF
18
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receptor expression and indices of proliferation, no less confused. Ki-67 staining 
has been reported to correlate with EGF receptor expression by some groups 
(Nicholson 1993, Gasparini 1992, Charpin 1993), but not by others (Gasparini
1991).
S-phase fraction is subject to the same incongruities; new studies (Gasparini 
1991, Minckwitz 1993) failing to confirm that of Walker (1986).
In summary, of the universally applied prognostic criteria only the relationship 
between EGF receptor and steroid hormone receptor status seems to be clear. 
There is no consensus regarding EGF receptor expression and either tumour size 
or nodal status, but it would appear that receptor levels are higher in metastatic 
than primary disease. Tumour grade is increasingly frequently reported in routine 
pathology, and there appears to be an association between poorer grade and 
receptor expression. O f the less frequently measured prognostic indicators the 
literature abounds with conflicting reports, but this may, in part, reflect the small 
size o f many of these studies and variation in the means of determining EGF 
receptor positivity. Overall, for most routinely assessed prognostic indicators, 
there is some inter-study concordance, but individual publications are frequently 
at odds.
Section iii: EGF receptor; relationship with outcome in breast cancer
a) Critique o f  published reviews
The relationship between EGF receptor and outcome is also controversial. Klijn's 
review of outcome, both overall survival and disease free survival, encompassed 
the results of eleven studies from nine research groups, including that o f 
Sainsbury (1987). Klijn reports a wide range of both the duration o f follow up 
and the published levels of EGF receptor positivity; median of 12 to 66 months 
and 14% to 55% of tumours respectively. This stated, using univariate analysis, 
five of these groups found a statistically significant relationship between receptor 
positivity and relapse free survival or overall survival (Rios 1988, Nicholson 
1990, Costa 1988, Grimaux 1989, Lewis 1990). Macais (1987) had previously 
reported a study of 72 patients but had failed to observe a significant association 
between receptor levels and outcome, and although this groups' second report 
(Rios 1988) identified a relationship between receptor positivity and outcome it 
could be criticised for its short duration of follow-up (maximum of 30 months).
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A similar complaint may be levelled at the studies of Costa et al (1988) and 
Lewis et al (1990), with median follow-up of 12 and 18 months respectively.
Two o f these five groups were able to confirm statistical significance o f the 
relationship between receptor expression and outcome using a multivariate 
analysis (Sainsbury 1987, Lewis 1990). However, the only study to identify a 
statistically significant relationship with overall survival using a multivariate 
analysis was that of Sainsbury (1987). This publication states that EGF receptor 
expression was the single most important predictor of disease free, and overall, 
survival. As indicated above, this may, in part, be due to the study protocol 
which did not require that nodes be biopsied in all patients. This complaint might 
also be levelled against a later report from the same group (Nicholson 1990); in 
this study lymph nodes were biopsied only if  palpable (56% of cases) and for the 
purposes of the multivariate analysis impalpable nodes were assumed to be 
negative. It is not stated in Sainsbury's 1987 publication if  tumours with 
clinically impalpable nodes were considered node negative, but, if  so, this could 
bias the multivariate analysis, particularly given the difficulties o f assessing 
axillary lymph node involvement clinically (Smart 1978). Harris (1989) hinted at 
the frailty o f this approach but defended it on the premise that not all surgeons 
performed routine axillary lymph node biopsy and therefore the prognostic 
features which could be determined from the primary should be considered 
paramount. This publication (Harris 1989), of a series o f 203 ductal carcinomas, 
reported a multivariate analysis including tumour size, grade, EGF receptor and 
oestrogen receptor status, only EGF receptor and size proved of predictive value. 
However, lymph node biopsy was not performed in 97 of the 203 patients. 
Excluding this cohort, node status was the only predictor of overall survival and 
disease free survival, size predicted disease free survival and EGF receptor status 
only showed a trend toward predicting disease free survival. This second analysis 
is also difficult to interpret. It cannot be considered to reflect the results that 
might be obtained for all cancers since it includes only those patients undergoing 
lumpectomy or those with palpable nodes proceeding to mastectomy. The criteria 
used to determine the surgical procedure, mastectomy of lumpectomy, are not 
made clear, and the analysis was performed on a cohort likely to have a higher 
incidence of lymph node metastasis than the study series as a whole.
Subsequent to Klijn's review, Fox et al (1994), reported on a series of 370 
carcinomas, observing that, in multivariate analysis, lymph node status was the 
only independent prognostic indicator of overall survival. Lymph node status and
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oestrogen receptor status predicted for disease free survival and EGF receptor 
was an independent prognostic indicator only for disease free survival in node 
negative disease. In this study lymph nodes were biopsied in all cases. Gasparini 
(1994) reported a series of 165 cases, all with lymph node status available, EGF 
receptor positivity was a significant predictor of disease free survival in node 
positive and node negative disease but failed to predict death.
In their 1994 review, Fox et al (1994) collated the results o f 16 studies of EGF 
receptor expression and outcome, both disease free survival and overall survival. 
These included reports from the groups reviewed by Klijn (1992), in total, results 
from 3009 patients were reviewed (compared with 1653 in Klijn's 1992 paper). 
O f these 16 studies, in 10, using univariate analysis, there was a statistically 
significant association between receptor positivity and reduced disease free 
survival or overall survival. Multivariate analysis was rarely performed; five o f 
nine studies employing this technique reported reduced relapse free survival in 
EGF receptor positive patients, but one group later reported (Gasparini 1994) that 
with longer follow-up, five years as opposed to three, the significance of EGF 
receptor expression was lost. In only one of five studies was there a statistically 
significant relationship between receptor levels and overall survival (Grimaux
1989). Fox hypothesised that, in many studies, lack o f an adequate duration of 
follow-up might be responsible for this observation. His argument is supported 
by the observation that receptor positivity is more frequently reported to be 
associated with recurrence than overall survival, but must be tempered by the 
observation that the discriminative prognostic power of the EGF receptor may 
reduce with longer follow-up. This observation has been reported for oestrogen 
receptor (Kinsel 1989), and can also be extrapolated from the published results of 
Nicholson (1991) where the survival curves approximate with longer follow-up.
b) Analysis o f  patient subgroups
Many researchers have endeavoured to identify patient subgroups in which EGF 
receptor expression correlates with outcome. This is most usually addressed by 
analysing EGF receptor expression in subgroups determined by oestrogen 
receptor status or lymph node status. The results of these analyses are variable. 
Some publications report a prognostic significance o f EGF receptor expression in 
oestrogen receptor positive tumours (Nicholson 1990, Rios 1988) others in 
oestrogen receptor negative tumours (Sainsbury 1987, Lewis 1990, Nicholson
1990), yet others fail to observe a statistically significant relationship in either 
subgroup (Grimaux 1989, Foekens 1989). For lymph node positive and negative
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subgroups there are similar incongruities. Some groups found a statistically 
significant relationship between outcome and receptor positivity in node negative 
carcinomas (Sainsbury 1987, Nicholson 1990, Spyratos 1990, Fox 1994) others 
failed to confirm these findings (Macais 1987, Foekens 1989). The contradictory 
nature o f these reports is apparent, not only between studies, but within studies. 
Fox's study (1994) of 370 patients, reported a statistically significant association 
between EGF receptor and oestrogen receptor in node-positive tumours, in terms 
o f relapse free survival but not overall survival. Conversely, in node-negative 
tumours this association was significant for overall survival but not for relapse 
free survival.
EGF receptor expression has also been analysed in conjunction with less 
established prognostic indicators. For example, Gasparini et al (1994) found that 
the prognostic significance of EGF receptor was enhanced when combined with 
measurement of S-phase fraction. In tumours with low S-phase fraction EGF 
receptor was not useful for predicting relapse, but in those tumours with higher 
S-phase fraction recurrence was predicted by higher receptor levels. However, 
they concluded that this finding needed confirmation in a larger, and ideally, 
prospective series.
One dilemma in the management of breast cancer patients is deciding who should 
proceed to systemic adjuvant therapy. Those with more advanced disease clearly 
require further treatment, but identifying those with earlier disease who would 
benefit from additional systemic treatment remains problematic. This has 
prompted analysis of this cohort in subgroups defined by perceived risk o f 
relapse. As noted above, in node negative, early disease, Nicholson et al (1991) 
reported that EGF receptor expression identified a cohort of patients who did 
poorly and might, therefore, have benefited from adjuvant therapy. Two hundred 
and
thirty-one patients were followed-up for a median of 45 months, in those with 
node negative disease EGF receptor expression was superior to oestrogen 
receptor in predicting recurrence and survival. Multivariate analysis o f EGF and 
oestrogen receptor, tumour size and grade, revealed only EGF receptor to be a 
significant predictor of disease free survival and overall survival in this subgroup. 
However, Bolla et al (1994) published a series o f 229 T1/T2, N0/N1 breast 
cancers with a median follow-up of 34 months. In this study, no EGF receptor 
cut-off value proved significant in univariate analysis. Multivariate analysis 
revealed only tumour size, nodal status and grade to prove significant predictors
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of disease free survival. Included in this analysis were measurement o f oestrogen 
receptor and progesterone receptor, EGF receptor expression proved the least 
significant prognostic variable.
c) Response to endocrine therapy
Although patients with oestrogen receptor positive tumours live longer than their 
oestrogen receptor negative counterparts, the role o f oestrogen receptor in 
predicting disease free survival and death is controversial (Howell 1984). This is 
partly due to the fact that oestrogen receptor positive tumours tend to respond 
much better to endocrine therapies; 65% responding as opposed to 15% of 
oestrogen receptor negative tumours (DeSombre 1980). If  oestrogen receptor 
positive tumours fail to respond to endocrine therapy then the outcome is similar 
to that of oestrogen receptor negative tumours (Howell 1984). The same problem 
may apply to interpretation of EGF receptor expression. Wright et al (1992) 
published a study showing a lack of response to Tamoxifen therapy in those 
breast cancer recurrences expressing EGF receptor. Nicholson (1994) found this 
loss o f endocrine sensitivity in primary disease and reported that it was at least 
partly quantitative; tumours with higher EGF receptor density responding less 
than those with some receptor expression, these in turn showing a propensity to 
relapse more quickly than receptor negative tumours. It is tempting to attribute 
these results to the inverse relationship between EGF and oestrogen receptors. 
Yet, although Nicholson's study reported this well established inverse 
relationship, it also noted that within oestrogen receptor positive and negative 
cohorts EGF receptor expression maintained its predictive effect. They also 
found oestrogen receptor negative/EGF receptor positive cells that did respond to 
endocrine therapy, postulating that they did so through a paracrine effect, or 
through reversal in phenotype, as is seen with ZR75-9al breast cancer cells on 
treatment with Tamoxifen (Long 1992). It is worth recalling that normal breast 
cells, whilst hormonally sensitive, are often oestrogen receptor negative (Walker 
1991, Walker 1992), and it may be that in some circumstances endocrine 
response may be ambivalent with respect to receptor expression. In the same 
study endocrine response was better in tumours with low rates of cell 
proliferation, as measured by Ki-67 staining, and the authors concluded that there 
were a multiplicity of factors influencing a tumours response to endocrine 
therapy.
The results o f EGF receptor measurement in the primary breast tumours of more 
than 10 000 patients have been published (Harris 1994). Still there is no
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consensus over the role o f EGF receptor in prognosis. Our poor understanding of 
the relationship between this receptor and both other prognostic factors and 
outcome is, at least partly, due to the small study size in many of the published 
series; o f the forty studies reviewed in Klijn (1992) only three included more 
than 200 patients. However, more pertinent may be vagaries in study design, and 
in particular lack of standardised criterion for determining receptor positivity 
(Koenders 1992, Klijn 1992, Fox 1994).
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Chapter 3: 
Measuring EGF receptor expression
Section i: Review o f  EGF receptor measurement in breast cancer
Much o f the discrepancy in the relationships between EGF receptor expression 
and various prognostic indicators and also outcome may relate to the techniques 
used to measure this receptor.
In the vast majority of studies, EGF receptor has been measured utilising ligand 
binding or immunohistochemical methods; 23 and 11 reports respectively in the 
review o f 40 study groups by Klijn (1992) and all but one of the studies, 
reporting on follow-up, reviewed by Fox (1994). Other methods have been 
applied to receptor measurement (Klijn 1992). These include; autoradiography 
(Spitzer 1988, Reubi 1989), immunoenzymatic assays (Grimaux 1990), 
measurement of EGF receptor transcripts (Guerin 1989, Coombes 1990), but the 
mean levels of receptor positivity have varied little from those reported for ligand 
binding or immunohistochemical methods (Klijn 1992). The only method that 
produced significantly different levels of receptor positivity, 91%, was that 
measuring EGF receptor phosphotyrosine kinase activity (Baugnet-Mahieu 
1990).
Although more established than the other methods, both ligand binding and 
immunohistochemical techniques may be criticised. Ligand methods provide 
objective measurement of receptor but are performed on membrane preparations 
that will include non-tumour components - a deficiency that applies to all 
methods performed on preparations of tumour samples. Conversely, 
immunohistochemistry allows specific assessment of tumour cells but is not truly 
quantitative. Toi et al (1994) studied a series o f breast cancers using both 
methods and compared the results. Univariate analysis showed EGF receptor 
positivity was a significant predictor of relapse free survival using either method. 
The ligand methodology produced a greater discriminative effect, p < 0.01 
compared to p < 0.05. It also allowed separation of the EGF receptor positive 
tumours into statistically distinct, high and low, risk groups. This was not 
possible with the immunohistochemical protocol. Despite this, the authors 
concluded that the methods were complementary and that neither was superior.
Review of the literature reveals no real differences in the rates of receptor 
positivity produced by radio-ligand studies and immunohistochemical studies,
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but between individual studies, using either technique, there is considerable 
variation. Ligand based studies show EGF receptor expression in a mean of 49% 
of cases with an inter-study range of 16-91% (Klijn 1992). A review of 
immunohistochemical studies shows that about 40% of breast tumours express 
EGF receptor but here also is a wide inter-study range of 14-65% (Klijn 1992). 
For both of these techniques, this level of disparity is likely to be due largely to 
methodological variation.
Section ii: Measurement protocols lack standardisation
Lack o f protocol standardisation, and its potential influence on receptor studies, 
has not gone unnoticed. In fact, a number o f investigators have made pleas for 
standardised assay procedures (Koenders 1992, Klijn 1994, Fox 1994). Whilst it 
has also been suggested that a lack of standardisation makes comparison of 
literature data 'precarious' (Koenders 1992).
Ligand studies predominate and the objective nature of receptor measurement by 
this technique has allowed the intricacies of protocol variation to be explored.
a) Defining receptor positivity
Receptor expression is normally reported as positive or negative. The arbitrary 
nature o f this categorisation is clearly demonstrated, although not specifically 
reported on, by Fox (1994); the 12 ligand binding based studies he reviewed have 
a cut-off for receptor positivity that varies from any measurable receptor to 
50fmol/mg membrane protein (see Figure 3.1).
It might be expected that there would be an inverse relationship between the level 
taken to represent receptor positivity and the percentage of tumours in the series 
that proved positive. If the sensitivity o f receptor measurement in each study was 
similar then a plot of these parameters should produce a smooth curve. That it 
does not (Figure 3.1) indicates that the results of the different studies may not be 
directly comparable. Adding weight to this argument, Koenders et al (1991) 
reported that, within individual studies, the wide variation in EGF receptor 
expression rates was not reflected by a similar variation of oestrogen receptor 
positivity rates. This, in the light of a well documented inverse relationship 
between these two receptors (see Chapter 2), suggests that methodological 
differences may be responsible.
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Figure 3.1: Relationship between the 'cut-off* for receptor positivity and the 
percentage of tumours positive for EGF receptor.
% receptor 
positive
The figure shows the results for 12 studies utilising ligand binding techniques (Fox 
1994). On the x-axis is plotted the cut-off value (fmol/mg membrane protein) above 
which the tumours were considered EGF receptor positive. On the y-axis is the 
percentage of EGF receptor positive tumours in the series. Where more than one 
study used the sam e cut-off value the mean percentage of receptor positivity is 
shown.
b) Assay sensitivity
The lack of an accepted level for receptor positivity assumes greater significance 
when the sensitivity of the technique is considered. Koenders et al (1991) applied 
a ligand binding method to a series of 531 tumours. In doing so, they identified a 
direct correlation between receptor positivity and cell membrane protein levels. 
This relationship was strongest at the lowest membrane protein levels and was 
interpreted as indicating that the lower limit of the assay sensitivity had been 
exceeded. Below a cell membrane protein concentration of 0.2mg/ml (equating to 
a wet weight o f biopsy sample of 300mg), the rate of false-negative assays was 
higher. Applying this limit excluded 27% of the 531 tumour specimens from 
analysis, and on this basis, they reported a 57% receptor positivity. This is one of 
the highest rates reported. Clearly, by incorrectly classifying EGF receptor 
positive cancers as negative, other investigators may have obscured the 
association between receptor, other pathological variables and outcome.
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c) Variable assay design
There are a myriad of variations in EGF receptor measurement protocols. All of 
the 18 ligand based reports reviewed by Leake et al (1993) differed in 
methodology.
Variation was cited in the:
♦ method of preparation of the membrane component,
♦ method of radioiodination of the ligand,
♦ incubation conditions during the assay,
♦ ligand concentrations used,
♦ use of single point or multiple point assays,
♦ method of separating bound and unbound ligand.
Concerns over the effects of this variability have led to increased efforts to 
establish standardised protocols. The EORTC Receptor Study Group have 
declared the hydroxyapatite method as that of choice for separating bound from 
free ligand (Benraad 1990). Koenders et al (1991) have advocated that ligand 
assays be applied only to membrane preparations containing more than 0.2mg/ml 
membrane protein, thereby reducing the incidence of false negatives. Foekens 
(1991) also pointed out that using a multi-point assay technique, as opposed to 
single point assays, allowed extrapolation of the binding data to the abscissa of 
the Scatchard plot, producing more accurate assessment of receptor levels. A 
multi-point assay is now the preferred technique of the EORTC receptor group 
(Leake 1993). These efforts have culminated in the Commission for European 
Communities, directorate-general Science, Research and Development, definitive 
EGF receptor measurement protocol (Leake 1993).
The subjective nature of immunohistochemistry makes the effects o f 
methodological variation more difficult to ascertain but it is likely to be no less 
important than for ligand binding. The deficiencies o f ligand protocols, in terms 
o f defining receptor positivity, assay sensitivity and assay variation, pertain 
equally to immunohistochemical studies. For instance, if  immunohistochemical 
staining is to be categorised as present, or absent, there is reasonable observer 
accord, but this concordance disappears if staining is to be graded (van Diest 
1996). Similarly, primary antibodies are variable and the signal they produce can 
be amplified by a multitude of methods. Also, many studies have been performed 
on formalin-fixed, paraffin embedded tissues. This type of assay suffers from a 
number of limitations. Firstly, routinely processed material may be fixed for
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times ranging from a few hours to over a weekend which is likely to result in 
variable antigenicity. Furthermore, tissue in the centre o f a large block will have 
a lesser degree of fixation compared to tissue at the periphery and this may 
explain the variation in staining commonly seen across a section. Our own group 
has reported on this problem in relation to the c-erbB-2 encoded receptor (Reeves 
1996).
Application o f a standardised ligand binding protocol will hopefully allow future 
studies to clarify some of the confusions surrounding our understanding of this 
receptor. However, standardised protocols, for ligand and immunohistochemical 
studies, will not solve all the problems.
Section iii: Conventional measurement techniques are flaw ed
Standardised ligand binding protocols will not obviate the inherent flaw of this 
technique. That is, that ligand studies are performed on membrane preparations 
that are derived from tumour biopsies which will include, besides malignant 
cells, non-tumour elements, including normal breast, in-situ disease, connective 
tissue and lymphoid cells. This may not represent a significant problem for the 
study of tumour types with high EGF receptor levels, e.g. squamous carcinoma 
of the head and neck (Stanton 1994), but for breast cancers where EGF receptor 
expression may be closer to, or less than, normal breast tissue (Dittadi 1993), 
these contaminants may be important. Conventional immunohistochemical 
methods also fail to escape flaw. The subjective nature of scoring 
immunohistochemical sections results in a high degree of inter-observer variation 
and this detracts from the results o f this technique (Sallinen 1994, van Diest 
1996).
A further problem, for both methods, is the categorical, positive or negative, 
fashion of reporting receptor status. In cancers, the normal distribution of 
receptor expression may well be distorted, but, with the caveat of the 3% of 
tumours with amplification of the EGF receptor coding gene, a simple dichotomy 
to positive and negative will be arbitrary and is likely to vary depending on the 
measurement protocol. That a simple dichotomy is almost universally applied 
probably indicates poor sensitivity, or paucity of accuracy, o f receptor 
quantification using conventional measurement methods. This categorisation 
simplifies statistical analysis but dilutes the statistical power of a continuum of 
data. A more accurate measurement method would allow accurate categorisation
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of cancers or could allow analysis of receptor expression as a continuous 
variable.
Section iv: Introducing radioiimunohistochemistry
Clearly, the problems associated with the EGF receptor assays may compromise 
the accuracy of the data obtained from these studies, and therefore, our 
understanding of the precise relationship between receptor expression, patho- 
clinical variables and the biology of breast cancer. We have therefore developed 
a quantitative radioimmunohistochemical method for the measurement o f EGF 
receptor in frozen tissue sections. This assay uses radio iodinated anti-receptor 
monoclonal antibody to label the receptors and computer assisted image analysis 
to quantify the bound antibody to combine the objective quantification o f ligand 
binding analysis with the specificity of immunohistochemistry.
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Chapter 4: 
Breast tumour cell invasion and EGF receptor
Section i: Review o f  evidence o f  EGF receptor mediated metastasis
There is good evidence that breast tumours with cells expressing higher levels of 
EGF receptor (reviewed in Klijn 1992) and tumours with concomitant high EGF 
content and high EGF receptor expression (Karameris 1993) are associated with 
poor prognosis. However, the mechanism of this prognostic influence remains 
unclear.
Death from breast cancer is not usually the result o f locally aggressive disease but 
rather occurs due to the development of metastatic disease. This raises the 
possibility that EGF receptor exerts its prognostic effect via an influence on 
metastasis. There is some evidence to support this hypothesis: the gene coding for 
EGF receptor is commonly amplified in glioblastomas but is not so in 
encapsulated gliomas (Schlegel 1994, Collins 1993); invasive bladder cancers 
express higher levels of EGF receptor than non-invasive counterparts (Neal 1985, 
Nguyen 1994); breast cancer patients whose tumours have elevated levels o f EGF 
receptor more frequently have lymph node metastasis and reduced survival 
(reviewed in Klijn 1992, Sainsbury 1987). Metastasis can be broken down into a 
series of events (reviewed in Fidler 1990), early amongst these is the cancer cells' 
acquisition o f an invasive phenotype. Part of this thesis explores the possibility 
that EGF receptor has a role to play in tumour cell invasion.
Carcinomas develop from epithelial tissues which are separated from adjacent 
stroma by a basement membrane layer (Vracko 1974). In normal tissues basement 
membrane forms a continuous barrier to movement of macromolecules and cells 
(reviewed in Liotta 1986). This remains true of benign pathologies, including 
those characterised by epithelial disorganisation and proliferation, however, 
adjacent cancers of epithelial origin this barrier becomes resorbed (Burtin 1982, 
Siegal 1981). Basement membrane is, therefore, the first physical barrier to 
malignant cells and invasion through this layer is a pathological prerequisite of 
carcinoma (Liotta 1984). The cancer cells' ability to invade this layer is clearly of 
crucial importance; after escape from the primary tumour, malignant cells must 
interact with host basement membranes at various stages of the metastatic cascade 
- entry to, and exit from, blood or lymphatic channels and invasion of distant 
organs. For these reasons a great deal of attention has focused on the genetic
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events that lead to the tumour cell phenotype responsible for invasion of basement 
membrane.
The principle components o f basement membranes are laminin, collagen IV and a 
heparan sulfate proteoglycan (Timpl 1979, Laurie 1982). These molecules bind to 
one another and form an integrated supra-molecular structure of 5-1 Onm cords 
(Inoue 1983). Ultrastructural, chemical and biologic analyses indicate that this 
structure forms a physical sheet which resists the penetration o f cells (Liotta 
1986). To effect tumour cell invasion a cascade of enzymes must degrade the 
various components that together comprise basement membrane (Reich 1988). 
Cell surface expression of these enzymes plays a critical role in this degradation 
process (Stroppelli 1986). The potency of this local process, mediated by cell 
bound enzymes, is testified to by the fact that trypsin and bacterial collagenase 
have much less degrading effect (Parish 1992).
The process o f tumour cell invasion is summarised in Figure 4.1.
In-vitro evidence suggests that ligand binding of the EGF receptor induces an 
invasive response which is independent of a similarly induced mitogenic response 
(Chen 1994). Also, ligand activation of EGF receptor has been shown to signal 
production of proteolytic enzymes (Yoshida 1990, Matrisian 1990), proteins 
modifying interaction with extracellular matrix (Thome 1987, Lichtener 1993), 
and to enhance cell motility (Chen 1994, Chen 19941). In-vivo evidence is less 
compelling.
Sequential interaction of neoplastic cells with tumour neo-vasculature is believed 
to be one o f the most significant steps in metastasis (Rice 1988). In a study o f 165 
patients, with median follow-up of 51 months, an analysis of EGF receptor levels 
added to the discriminatory power of a measurement of tumour angiogenesis in 
determining outcome; predicting disease free survival, in all women and in node 
positive women (Weidner 1994). A similar finding, but in node negative patients, 
has also been described (Fox 19941). jn these studies, EGF receptor's prognostic 
power could derive from receptor mediated modulation o f tumour cell invasion 
into tumour neovasculature. Adding to this evidence is a study of the cell adhesion 
molecule E-Caherin. Tumour cell detachment form the primary lesion is an 
important step in the process of invasion (Coman 1947) and E-Cadherin has a 
critical role in initiating and maintaining cell to cell adhesion in epithelia 
(Takeichi 1988). Walker et al (1996) were able to demonstrate a significant
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S tep  1: A ttachm ent
n u c leu s
b a se m e n t  m em b ran e
Cell attachment to the basement membrane. This is probably mediated by specific 
attachment factors which form a bridge between cell surface and elem ents of the 
basem ent membrane matrix.
S tep  2: D egradation
cell
n u c leu s
b a se m e n t m em brane
Local degradation of matrix by tumour cell associated proteases. Localisation may 
be achieved by the amount of cell produced active enzym e out-balancing the 
natural protease inhibitors of the basem ent membrane matrix.
Step  3: L ocom otion
cell
n u c leu s
b a se m e n t m em b rane
Tumour cell locomotion into the region of matrix modified by proteolysis. The 
direction of locomotion may be modified by chemotactic factors.
Figure 4.1: Three-step hypothesis of tumour cell invasion. Schematic diagram, not to 
scale, modified from Tumour invasion and metastasis - role of extracellular matrix: Rhoads 
memorial lecture' Liotta LA, Cancer Res 46, page 2, 1986.
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relationship between reduced levels of E-cadherin and EGF receptor expression 
and between reduced membrane expression of the former and lymph node 
metastases. Therefore, it could be postulated that EGF receptor stimulation 
induces tumour cell detachment. These citations provide only indirect evidence 
that EGF receptor influences tumour cell invasion, but such an influence could 
account for the prognostic significance of EGF receptor expression.
Direct evidence, that up-regulated EGF receptor signalling leads to increased 
tumour cell invasiveness, is scarce. One report is of a prostate cancer model (Xie 
1995). Cells o f the human prostate carcinoma cell line, DU-145, were transfected 
with either wildtype (WT) EGF receptor or a truncated, mitogenically active but 
motility deficient, EGF receptor. The truncated receptor lacked the carboxy 
terminus of the EGF receptor, including all its auto-phosphorylation sites. Ligand 
binding o f this receptor has been shown to produce a full mitogenic signal but the 
receptor fails to internalise (Chen 1994). The parental DU-145 line produces EGF 
receptor and also the EGF receptor ligand TGF-a. Increased invasion occurred in 
the WT transfection and reduced invasion in the cells transfected with truncated 
receptor. The latter, it was postulated, resulted because o f down regulation o f the 
parental cell lines expression o f EGF receptor. Monoclonal antibody, inhibitory to 
the EGF receptor, reduced invasion to a similar level for WT transfected, parental 
and truncated transfected lines.
Work using a colorectal model lends further support to the argument. The cell 
line, AA/C1, derived from a colonic adenoma, is clonogenic but not metastatic. 
From this parent line a metastatic variant has been produced, AA/C1/SB10. 
Brunton has reported (Brunton 1997) that EGF can stimulate invasion of this line, 
but not the parent line, into a Matrigel barrier. The invasive phenotype was 
associated with increased EGF receptor expression. This model is of particular 
interest as the adenoma to invasive carcinoma sequence in the progression of 
human colorectal neoplasia is well established and there are parallels with breast 
neoplasia, where carcinoma in-situ is thought to progress to invasive carcinoma.
The precise relationship between EGF receptor and outcome in breast cancer 
remains unclear, as is any causal link between its stimulation and the metastatic 
process. However, it would seem reasonable to speculate that, in human breast 
cancers, activation of EGF receptor, possibly by an autocrine loop, might promote 
tumour cell invasiveness and that this could be, partly or wholly, responsible for 
the poor prognosis of patients whose tumours have higher levels of this receptor.
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Section ii: Review o f  models o f  breast cancer invasion
Since the time course of breast cancer evolution is typically 5-30 years, 
epidemiological protocols to study progression from in-situ to invasive disease 
would span 10-15 years (Holt 1993). Without considering ethical implications, 
this precludes meaningful or reproducible human studies and emphasises the need 
to develop appropriate experimental models of human breast cancer. However, 
development of systems which accurately reflect human disease poses difficulties.
Use of animal models is limited (Taylor-Papadimitriou 1993, Weaver 1995); cell 
lineages will vary from those of human disease and the molecules functioning in 
the biology o f benign and malignant disease in study animals will show species 
variation. Nude mouse models are limited by the difficulties o f growing human 
tumours in these animals compounded by the fact that those that will grow are 
frequently not representative of human disease (Fidler 1990). Transgenic mouse 
experiments circumvent the former of these problems but the tumours are of 
mouse origin. Whilst some investigators are attempting to genetically engineer 
these tumours to be more representative of human disease it is unclear how 
successful these efforts will be. A further concern with the use o f murine models 
is that mouse breast anatomy is dissimilar to that of the human mamma (Ronnov- 
Jensen 1995).
Beyond the difficulties outlined above is the problem of interpreting the results o f 
in-vivo studies. The individual steps, that together constitute the metastatic 
process, cannot be isolated, therefore the responsible genotypic and phenotypic 
changes cannot easily be elucidated. These difficulties make a cogent case for 
establishing in-vitro assay systems to study human material.
a) In-vitro invasion assays
A variety of increasingly refined assays have been developed to assess tumour cell 
invasion. These include chick heart models (Mareel 1979), urinary bladder (Hart 
1978, Poste 1980), blood vessels (Poste 1980), lens capsule (Starkey 1984), chick 
chorioallantoic membrane (Poste 1980, Ossowski 1980) and the human amnion 
(Liotta 1980, Mignatti 1986).
The most commonly used of these has been the human amnion assay. There are, 
however, a number of problems with this technique: difficulties obtaining fresh 
samples after delivery, differences in membrane thicknesses and consistency, 
evaluation of micro-tears in the amnion, problems associated with radiolabelling
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tumour cells or matrix, variations in culture conditions for assays and anxiety of 
handling potentially blood contaminated samples when isolating the amniotic 
membrane (Basson 1985, Mignatti 1986, and reviewed by Hendrix 1987).
Each of the alternative assays also has disadvantages. The lens capsule assay, 
whilst using sturdier basement membrane, that is easier to manipulate than 
amnion, retains all o f the disadvantages of an inconsistent biological membrane. 
Further, invasion is measured as an increase in permeability, thereby assessing 
membrane resorption and not strictly invasion or metastasis (Starkey 1984). In the 
chick embryo assay, metastatic load, determined by assay for human protein 
within the embryo, is used as a measure of invasion; separating the invasive 
component from a proliferative one is therefore difficult. Additionally metastatic 
mass varied with the mass o f inoculum and embryo age at inoculation (Ossowski 
1980).
All these systems make use o f biological tissues. This is considered to be an 
advantage by some authors (Starkey 1984) since it may provide a better reflection 
o f events in-vivo than systems which rely on artificial barriers. However, it also 
introduces problems; biological tissues are not uniform and this can lead to 
problems with data interpretation and reproducibility (reviewed in Hendrix 1989). 
Also, methodologies for these assays are complex and time consuming. These 
difficulties, and the fact that there are strong correlations between a cell's ability to 
degrade collagen IV, its invasive capacity in-vitro and its metastatic potential in 
nude mice or syngeneic hosts (Liotta 1986, Liotta 1991), have led to the 
development o f reconstituted basement membrane assays.
b) Reconstituted basement membrane assays
Reconstituted basement membrane assays allow study of a specific part of the 
metastatic process - tumour cell invasion. This has caused them to be described as 
reductionist by some authors, however, they do provide some advantages over the 
biological barrier methodologies. Hendrix compared human amnion assays to 
reconstituted basement membrane assays (Hendrix 1989) and found that:
1. the measurable invasion in the former was less; human amnion is 
architecturally complex compared to reconstituted basement membrane,
2. invasion, measured in the latter, was considerably less variable; relating most 
probably to the variable thickness of the amnion barrier (Hendrix 1985).
Similar concerns have been mooted by other authors (Cresson 1986). A further 
advantage of reconstituted basement membrane assays is that the invasive cells
36
Chapter 4
can be recovered for further study. Thus, whilst not entirely replaced, the initial 
biological barrier techniques have been largely superseded by the reconstituted 
basement membrane assays.
The use of a compressed disc, comprising Laminin and collagen types I and IV, as 
basement membrane substitute to assess tumour cell invasion, was first described 
in 1986 (Terranova 1986). Concomitantly Kleinmann reported the development of 
Matrigel as a reconstituted basement membrane (Kleinmann 1982, Kleinmann 
1986). Matrigel has a similar composition to the basement membrane associated 
with vascular and lymphatic conduits and thus provides a good means o f studying 
tumour cell intravasation and extravasation. In the following year, there was the 
first description o f the use o f a contained in-vitro assay system for the study o f the 
invasive potential o f tumour cells; this incorporated both Matrigel, as a basement 
membrane substitute, and a filter barrier. (Albini 1987).
In this first assay, polycarbonate filters were coated with Matrigel, study cells 
were then placed above this filter, with chemoattractant below, and, after a period 
o f incubation, invasion was determined as the number of cells that had crossed the 
filter. Subsequent investigators have maintained these basic features but have 
introduced a myriad modifications. Some of the features which have varied are the 
barrier mass, its preparation and the incubation period. Other basement membrane 
substitutes have also been described, but Matrigel remains the one with which 
greatest experience has been gained. The method of assay analysis has also 
undergone frequent modification, possibly reflecting lack o f a satisfactory method 
o f measuring invasion.
Section iii: Measuring invasion
Accurate measurement of invasion, in in-vitro Matrigel systems, is recognised to 
be difficult (Mackinnon 1992, Hendrix 1989, Parish 1992). As a result a large 
number of different methods have been reported; these include counting the mean 
number o f cells crossing the filter in random optical fields (Albini 1987) and 
counting all cells that cross the filter (Hendrix 1989, Mackinnon 1992). These 
methods are disadvantaged in that they are tedious, may be subjective, and are 
prone to error; MacKinnon et al (1992) report results where the standard deviation 
frequently approaches the mean value despite multiple repetitions o f their 
experiments.
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Indirect methods of measuring tumour cell invasion have also been employed. 
These techniques include measurement of tumour cell degradation of the Matrigel 
barrier by quantifying radiolabelled molecules crossing the filter (Repesh 1989, 
Parish 1992). This incurs the inherent safety problems of working with 
radioactivity, also background radiation can make quantifying small invasive 
responses very difficult, and perhaps for this reason, the technique has been shown 
to offer no improvement on microscopic evaluation o f invasion (Hendrix 1989). 
Matrigel degradation has also been determined using fluorescent dextran (Parish
1992). Proponents of these indirect methods of measuring invasion argue that they 
are reproducible and superior to cell counting as they focus on a single event in 
the metastatic cascade; basement membrane degradation. Others question the 
validity o f this measure of tumour cell invasiveness, arguing that tumour cells can 
invade Matrigel barriers without producing significant degradation of the Matrigel 
layer (Noel 1991). Equally, since cell migration is necessary for tumour cell 
invasion measurement o f Matrigel degradation may not correlate with cell 
invasion (Jones 1980).
Colorimetric methods overcome some of these difficulties. The most widely 
reported method employs 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) (Mossmann 1983). This chemical is converted to a dark blue 
pigment, formazan, by mitochondrial dehydrogenase, the absorbance o f which can 
then be measured using spectrometry. Its application to Matrigel assay systems 
was pioneered by Schlechte (1990) and later modified by Imamura (1994). This 
technique has a number of potential limitations. Only living cells will produce 
formazan, with longer assay times some cells crossing the filter may die and these 
will not be counted using this method. Non-invading cells must be removed prior 
to treatment with MTT and this may include cells which have entered the Matrigel 
layer but have not crossed the filter (Imamura 1994). Further, in our hands 
removing non-invading cells from the filter surface, in 6.5mm inserts, proved 
technically demanding and could not be achieved with confidence. A final 
consideration is that no information regarding cellular morphology is acquired.
Section iv: Using confocal microscopy to measure invasion 
In the year prior to commencement of this study, Dr B Ozanne's group at the 
Beatson Institute for Cancer Research, Garscube, had developed a modification of 
the Matrigel/Boyden chamber assay. This used a confocal microscope to measure 
tumour cell invasion.
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Confocal microscopy was invented by the father of artificial intelligence, Marvin 
Minsky (Lichtman 1994). Minsky wanted to map neuronal connections but was 
aware that cutting thin sections of neural tissues introduced the technical 
difficulties o f producing thin sections and problems of interpreting three 
dimensional structure. Imaging the depths of thick sections, using conventional 
microscopy, posed two main problems. To obtain a high resolution image o f a 
single plane, ideally light from this plane alone should return to the detector. 
Using conventional microscopy light from planes above and below the plane of 
interest returns to the detector leading to blurring. The second problem is scatter, 
which causes reduction in contrast with light caroming randomly from particle to 
particle prior to returning to the detector. This scattered light conveys no 
meaningful information and confuses the light signal from the plane o f interest.
Confocal microscopy overcomes both these problems. The illuminating light is 
focused into an hour-glass shaped beam, a point in the plane o f interest is 
illuminated by the most intense part of this beam, that at the 'waist', and this 
reduces the scatter effect. By interposing a pin-hole aperture between reflected 
light and the detector most o f the light from planes above and below that of 
interest can be excluded, thus reducing blurring (White 1987, Wilson (editor)
1990). This arrangement provides an image of a single focus point within a thick 
section. To acquire an image of a plane the focus point must move over the 
section; this is scanning confocal microscopy. The development of lasers, which 
can be focused precisely, and of computer assisted image processing has meant 
that confocal microscopy has come a long way since Minsky's original work.
Dr Ozanne's group realised that computer assisted laser-scanning confocal 
microscopy could be used to accurately analyse stacked optical sections o f the 
fragile Matrigel layer without its disruption. This overcomes many o f the 
problems eluded to above: measurement would be of cell invasion not barrier 
degradation; computer assisted analysis could provide accurate quantification 
whilst overcoming the tedium of conventional measurement methods; since cells 
would be visualised morphology could be assessed and cells would not need to be 
alive to be detected.
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Figure 4.2 : Schematic diagram demonstrating the principles of confocal microscopy
Detector
Pinhole aperture
Beam  splitting  
mirrorLight
source
Objective
Sp ecim en
Plane of focus
Light is focused by the objective lens to illuminate maximally the point of interest in the 
specimen. Light reflected from this point is focused so as to pass through a pinhole 
aperture to reach the detector. The pinhole prevents light reflected from other points 
(above and below the plane of focus) in the specimen from reaching the detector. By 
rapidly moving the light an image of the plane of focus is obtained. In the diagram, the 
outer cones represent light from the light source, the inner cones are reflected light from a 
point in the plane of focus. The arrows indicate the direction of light travel.
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STATEMENT
OF
AIMS
The introduction to this thesis reviews the biology of the EGF receptor and 
implies a role for it in breast cancer. It could be summarised as reporting that 
patients whose breast cancers express higher levels of EGF receptor have a 
poorer outcome, but an accurate understanding of this relationship, and its 
mechanism are not clear. This results from;
♦ The lack of an accurate method of measuring expression of EGF receptor in 
breast cancers.
♦ An imprecise understanding of the consequences of receptor stimulation.
This thesis examines these problems.
The specific aims may be stated as:
♦ To establish levels of EGF receptor expression in a series of primary breast 
carcinomas using a quantitative method - radioimmunohistochemistry.
♦ To assess the validity and reproducibility of this method by comparing it to 
conventional measurement techniques.
♦ To determine the significance of receptor density, so measured, in terms of its 
relationship to traditional prognostic factors and to clinical outcome.
♦ To address the prognostic mechanism of the EGF receptor; by exploring the 
relationship between receptor expression and tumour cell invasion.
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PART 2
MEASURING EGF RECEPTOR 
USING
RADIOIMMUNOHISTOCHEMISTRY
Introduction to the experimental parts of the thesis
Two distinct sections of experimental work address the aims of this thesis. The 
first attempts to examine EGF receptor measurement and its relationship to 
clinical variables including outcome. In the second, a novel invasion assay is 
established and is then used to study the relationship between EGF receptor and 
invasion.
Overview of receptor measurement studies
Receptor was measured accurately in a panel of greater than 200 primary breast 
cancers using a radioimmunohisochemical technique. To confirm the validity of 
this measurement method, a proportion of these tumours were also analysed by 
ligand binding and conventional immunohistochemical techniques. The results of 
the techniques, along with the techniques themselves, are then discussed.
Clinical data, for the tumours studied using radioimmunohistochemistry, were 
collected into a database. The aims of this section were completed by 
determining if the accuracy of the radioimmunohistochemical method imparted a 
clinical advantage.
Parts of this experimental work have been published in the paper 'Quantitative 
estimation of epidermal growth factor receptor and c-erbB-2 in human breast 
cancer' Robertson KW, Reeves JR, Smith G, Keith WN, Ozanne BW, Cooke TG 
and Stanton PD, Cancer Research 56:3823-3830,1996
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Chapter 5: 
EGF receptor measurement
Section i: Tissues available
Tumour tissues, from patients with breast cancers treated surgically at Glasgow 
Royal Infirmary between 1984 and 1994, were used for these studies. Tissues 
identified macroscopically as tumour, either in theatre or in pathology 
immediately after resection, were taken into and stored in liquid nitrogen (-70°C). 
To confirm the presence of tumour, 5jam cryostat sections, cut and stained with 
Haemotoxylin and Eosin (H&E), were examined using light microscopy. Those 
tumour pieces which did not contain significant tumour tissue were discarded.
Sections for both the radioimmunohistochemical method and for conventional 
immunohistochemistry were cut at the same time. The ligand binding method was 
performed some time after the others. It has been reported (Koenders 1991) that at 
lower membrane protein concentrations the ligand binding technique may lose 
sensitivity. Therefore, to ensure that an adequate amount of membrane protein 
would be available for study, only tumour sections o f 2 0 0 mg or greater were used 
for the ligand studies reported here.
The radioimmunohistochemical method was applied to 203 primary breast 
cancers. Fifty o f these tumours were studied using ligand binding and 
conventional immunohistochemistry.
Section ii: Radioimmunohistochemistry
This is a quantitative immunohistochemical method that was pioneered in 
squamous tumours by Fred Hendler in Dallas and latterly Louisville (Hendler
1984). The technique uses a radiation detection system, quantified by emulsion 
autoradiography. Under the auspices of Professor P Stanton and Dr B Ozanne, this 
methodology has been established in the Department of Surgery at Glasgow Royal 
Infirmary (Stanton 1994). The technique, as applied to breast tumours, is given in 
detail in the following section.
a) Antibody
The antibody used for these experiments was the EGFR1 mouse monoclonal that 
was used for the conventional immunohistochemistry studies. This antibody was 
radio-idoninated by the iodogen technique (Harlow 1988); 15jag of EGFR1 was
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iodinated using 250pCi o f 125j (Amersham). Antibody bound iodine was 
separated from free ^ 5 j  by sephadex G25 gel filtration. Levels of activity o f the 
iodinated antibody were of the order of 500MBq/mg (500 counts per second per 
ng of antibody). Activity at time of use was ascertained from a standard decay 
table for 125p Antibody was used not later than one month after iodination.
b) Incubation
For each tumour specimen three sections were studied, duplicate test sections and 
a negative control. 5pm thick frozen sections were cryostat cut onto silane coated 
slides and stored in airtight packaging at -70°C until use. A further sequential 
section was stained with H&E to confirm the presence of tumour.
Sections to be analysed were pre-fixed in absolute acetone for 10 minutes and then 
washed twice with PBS (lOmM sodium phosphate, 140mM sodium chloride, pH 
7.4).
Application of antibody followed pre-incubation with a lOOpl volume of a 1:1 
mixture of PBS and normal rabbit serum. This pre-incubation was conducted for 
one hour, after which, 125j labelled antibody was added to each section and mixed 
by pipetting. The specific activity of iodinated antibody was adjusted with 
unlabelled antibody so that 50 ng (4 KBq) of iodinated antibody was added to the 
pre-incubation mixture in a volume made up to lOpl with 1:1, PBS : normal rabbit 
serum. Incubations were carried out for 3 hours in humidified chambers at 22°C, 
at the midpoint of incubation the solution on the slide was mixed by pipetting with 
a Gilson pipette. Sections were then washed through three 10 minute changes of 
PBS, fixed for 10 minutes in 2% formaldehyde and washed through 3 changes of 
distilled water before being air dried.
c) Film autoradiography
The slides were secured into an X-ray cassette and overlaid with X-ray film 
(Dupont Cronex) which was exposed for about 72 hours at 4°C. This film was 
used as a guide to the activity of each section, in order to determine how long to 
expose each trio of tumour sections once these were coated with radiographic 
emulsion. In this manner it was possible to ensure an appropriate grain density for 
counting. Details of this aspect of the assay are included in the section pertaining 
to grain counting.
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d) Emulsion autoradiography
Autoradiographic emulsion, Kodak NTB-2 diluted 1:1 with distilled water at 
43°C, was used to coat the slides. This procedure was carried out in a dark room 
with the use o f a Kodak No. 2 safelight. Blank slides were dipped in the emulsion 
to ensure it was bubble free. The test slides were then dipped, stood on end to dry 
in perspex racks, and then placed in standard metal slide-staining racks. The slides 
were then stacked in a metal tin with freshly desiccated silica gel in its base. The 
tin was sealed, wrapped in a thick, black plastic bag, and stored at 4°C. It has been 
our practice to mount sections toward the end of the slide, thereby only a small 
part of the slide was immersed in emulsion to coat the section. The radiographic 
emulsion is the most expensive consumable item in this protocol.
The radiographic emulsion was exposed to the sections for a period determined by 
the autoradiographic film; highly expressing tumours and cell lines being exposed 
for 4 hours, the intermediate tissues for 24 and 48 hours and the weakly 
expressing specimens for 4 to 7 days.
The radiographic emulsion was then developed and fixed. In the darkroom, a 
waterbath was filled with ice/water slurry, and in this were placed 4 slide staining 
dishes, containing the developing and fixing agents. The ice/water slurry ensures 
the developer is kept at approximately 10°C. After the appropriate duration of 
exposure, slides were retrieved from the sealed tin under darkroom conditions and 
immersed, sequentially, in each dish as below.
dish 1 Kodak D 19 developer (1:1 
in distilled water) 
dish 2 distilled water 
dish 3 Kodak Unifix fixer 
dish 4 distilled water 
Slides were then thoroughly washed for 20 
distilled water.
e) Counter staining
Sections were stained 'through' the emulsion with 0.12% Safranin O for 5 minutes 
before being washed in tap water and mounted in DPX. Safranin (Basic Red) is a 
red nuclear dye, its use allowed sections to be oriented by comparison with the 
sequential H&E section. It is however difficult to use. Even when stored with 
acetate buffer (9:1, 0.1M Na acetate : 0.1M acetic acid), its shelf life is short,
4 minutes
1 minute
5 minutes 
1 minute
minutes through four changes of
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maximum one month. Further, it was necessary to use longer staining intervals as 
the solution aged. The dye also washes out rapidly, and staining had to be brief 
and carefully monitored. Finally, staining must be light, otherwise the Safranin 
can produce sufficient opacity to appear as grains to the image analysis system. If 
light microscopy revealed the counterstain to be excessive, the coverslips were 
removed and the sections destained with water before re-analysis.
An example of the finished product, Figure 5.1, is shown overleaf.
f)  Controls and standards
From each tumour three sections were studied, duplicate test sections and a 
negative control. The control section was incubated with a 100 fold excess o f cold 
antibody (5pg/section) compared to hot (iodinated) sections. The cold antibody 
was added to the pre-incubation mixture, that is before its hot counterpart. 
Analysis o f this section provided an estimate of non-specific binding.
With each batch of tumours, a set of standard sections was tested; normal breast 
from a reduction mammoplasty and 5pm sections of cell line pellets, including 
A431 (produced as described in the ligand binding studies section of this chapter). 
These standards were processed in the same manner as tumour sections.
g) Grain counting
The radioimmunohistochemical method assumes that the density of silver grains 
developed in the emulsion layer reflects the amount of iodinated antibody bound 
to receptor, and that, in turn, this reflects the level of receptor expression. 
Saturating amounts of iodinated antibody are used to ensure the latter. The second 
assumption, that the emulsion will respond to 125j disintegrations in a linear 
fashion with time, was confirmed by including two cell line pellet controls: the 
relative level of silver grains for the two controls remained constant for the range 
o f exposure times required for the tumour specimens (the effect of 125j decay was 
ignored given that the maximum exposure period was one week).
A Joyce-Loebl MiniMagiScan image analysis system connected to an Olympus 
OM-2 microscope was used for estimation of silver grain density. This process 
required that the operator outline areas o f tumour in the section which was viewed 
with a 40x objective. Identification of tumour was facilitated by examination of 
the serial H&E section. The analysis system then calculated both the area outlined 
and silver grain density within the area. This process was repeated for at least ten
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Chapter 5
fields in any tumour section. Data was stored, by the system, for subsequent 
analysis.
The image analysis system worked by determining the optical density of each of 
the 512 vertical by 512 horizontal pixels which made up the optical field. If  the 
optical density exceeded a certain threshold then the pixel was counted as positive. 
Since a silver grain could encroach on more than one pixel, the image analysis 
system was capable of identifying discrete objects, that is all touching 'positive' 
pixels were counted as though part of a single object. A thick emulsion layer 
might result in a number of overlapping silver grains, making grain counting 
difficult. To reduce this effect, the emulsion was diluted with water (1:1), 
allowing slide dipping to produce a thin emulsion layer. Thus there was an 
optimal range of grain density for counting and the film autoradiography stage of 
the protocol was included so that the investigator could make an estimation of the 
period of emulsion exposure required to achieve this grain density.
h) Calculation o f  receptor expression
Results were calculated as silver grains per unit area, these were converted to 
silver grains per unit area per hour o f emulsion exposure, averaged over the 2 0  
fields on the duplicate sections of each tumour. From this score was subtracted the 
counts (per unit area, per hour) for the negative control section, taken to represent 
non-specific binding. This final result was expressed as a % of the receptor 
expression for the cell lines, run as standards with each batch of tumours (see 
Controls and standards). Tumour results were subsequently converted to a % of 
counts for normal breast based on the average count in the 9 normal breast 
samples (tissue taken from reduction mammoplasty specimens).
Table 5.1 provides an example showing grain counts for duplicate sections o f one 
o f the normal breast specimens. Hot section indicates treatment with an excess of 
radio-iodinated antibody, two sections for each specimen, and the negative control 
is the cold section.
This example is for normal breast but results for tumour specimens were 
generated in a similar fashion. To allow results from different tumour batches to 
be directly compared they were expressed as a % of the measure o f the A431 grain 
counts for the A431 section included in that batch. A panel of 9 reduction 
mammoplasty specimens were also studied using the radioimmunohistochemical 
method, by using the mean value of these results (range: 5.28 - 9.70% of A431
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levels), it was possible to compare tumour EGF receptor expression with that in 
normal breast tissue.
Table 5.1: Calculating EGF receptor expression in normal breast.
slide Area counted Grains counted
Hot section 1 
Hot section 2 
Cold section
3.40
2.94
3.22
890
946
232
Total area of interest:
Total grain cou n t:
Emulsion exposure tim e:
.-. For the hot sections, mean grains/10"2mm2A-lr:
For the cold section, mean grains/10'^mm^Hr: 232/3.22/17.5 = 4.12  
.-.For this section, net grains/10'^mm^Hr: 16.55 - 4.12 = 12.43
3.40 + 2.94 = 6.34 x 10_2mm2 
890 + 946 = 1836 
17.5 Hrs
1836/6.34/17.5 = 16.55
Section iii: Ligand binding
a) Reagents
The protocol used for these experiments was based on that advocated by the 
Commission of the European Communities; 'Detailed methodologies of the 
development o f assays for growth factors and growth factor receptors' Leake, RE, 
Foekens JA and Benraad TJ. Commission of the European Communities, 
EUR14799EN, 1993. The reagents used are those advocated by this protocol 
unless otherwise stated.
Buffer A
This buffer was a 0.01M phosphate buffer with a pH of 7.4. The final buffer 
solution comprised; 0.01M K2 HPO4 , 0.01 M KH2 PO4 , 0.0015M Disodium 
EDTA, 0.003M NaN3 , 0.01 M monothioglycerol, 10% glycerol (v/v) (Leake 
1993).
Buffer B
This was a 0.02M phosphate buffer with a final pH of 7.4. It comprised; 0.02M 
K2 HPO4 , 0.02M KH2 PO4 , 0.15M NaCl and 70pg/ml Bacitracin (Koenders
1991).
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HAP slurry
The EORTC Receptor Study Group has proposed that the hydroxyapatite (HAP) 
assay be used as standard for measurement of EGF receptors in human breast 
cancers (Benraad 1990). BIO RAD DNA grade Bio-Gel® HTP was used. This 
reagent has found a variety of uses in fractionation and purification processes 
(Gorbunoff 1984, Gorbunoff 19841). HAP absorbs EGF receptor protein when the 
HAP-slurry is prepared in a Bacitracin-containing buffer. In this manner, EGF 
receptor bound l^^I-EGF can be separated form unbound 125j_egF by low speed 
centrifugation. Prior to the use of HAP, this separation had generally been 
achieved using high speed centrifugation (10 000 - 100 000 g). The slurry was 
made as described by Benraad et al (1990); the dry HAP powder is mixed with 
buffer B so as to produce a product which is buffer/HAP, 3:2, volume for volume.
E G F /125I-EGF
Mouse epidermal growth factor was used. This ligand was labelled using the 
iodogen method (Harlow 1988). The authors of the European Communities 
Commission report (Leakel993), suggested that this method could cause 
oxidation o f EGF with resultant non-equivalent binding behaviour of labelled 
ligand in comparison to unlabelled ligand. They advocated the iodine 
monochloride method (two other satisfactory methods were described but these 
required reagents that have subsequently been withdrawn from the market). There 
are, however, a number o f reports of EGF receptor expression rates in breast 
cancers which have utilised a ligand binding assay with EGF iodinated using the 
iodogen method. Our laboratory has had considerable experience of the iodogen 
method but none with the iodine monochloride technique. The latter technique is 
also technically more demanding and expensive. For these reasons the iodogen 
method was used for this series of experiments.
This part of the procedure was performed in a lab fume hood specifically 
designated for radioactive work. Briefly, 2pg of the mouse-EGF in phosphate 
buffered saline (PBS) was added to an Iodogen coated tube. 250jaCi o f 
125i0dine (125j) (Amersham) was then added and the reactants were incubated 
for 5 minutes. By adding excess o f protein, in this case foetal calf serum, the 
reaction was stopped. A Gel filtration Sephadex G25 column (NAP-10) was then 
used to elute the 125j bound EGF. The column effects this separation as the larger 
molecule ^25j bound EGF passes through the column more quickly than low 
molecular weight unbound 125j Radio-iodinated EGF was stored in aliquots 
under suitable radioactive shielding at -20°C.
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It was assumed that the first peak of activity eluted from the Sephadex G25 
column contained only iodinated EGF. The specific activity of this fraction was 
determined using a gamma-counter. Assuming 80% counting efficiency, counts 
per minute were converted to pCi for use in the LIGAND program.
Care was taken to ensure that contaminated materials were disposed of in a safe 
manner and appropriate paperwork for handling of radioactive materials was 
completed.
b) Obtaining the membrane component
The protocol assays membrane bound EGF receptor and therefore the membrane 
component of the homogenate must be separated from the remainder. Tumour 
pieces were retrieved from the liquid nitrogen tumour bank and presence of 
tumour confirmed as described above.
♦ In a universal container, the specimen was immersed in approximately 1.5ml 
o f Buffer A.
♦ Using an Ultraturrax, with 3 x ten second bursts of maximum speed, 
specimens were homogenated.
Throughout this part of the procedure tissues were kept on ice and between each 
specimen the Ultraturrax blade was cleaned with alcohol.
♦ The resultant homogenates were centrifuged at 500rpm for 5 minutes at 4°C, 
this 'pelleted' the heavier nuclear debris.
♦ Membrane containing supernatant was decanted to eppendorfs, the remainder 
was discarded.
♦ Membrane component was then retrieved by ultracentrifuging the eppendorfs 
at 15 OOOrpm for 30 minutes at 4°C.
♦ Supernatant was discarded and the 'pelleted' membrane component was 
resuspended in Buffer B to a total volume o f 1.25ml.
c) Protein estimation
A modification of the spectrophotometric method described by Bradford (1976) 
was used. This technique is based on the observation that the absorbance 
maximum for an acidic solution of Coomassie Brilliant Blue G250 shifts from 
465nm to 595nm when protein binding occurs.
♦ lOOpl o f each membrane suspension was made up to 2ml with Buffer B.
♦ From this, 1ml aliquots of 1:2, 1:5, 1:10, 1:50 and 1:100 dilutions were made 
using Buffer B.
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♦ In a Rohen tube, 800pl volumes of each of these dilutions was added to 200jal 
of BioRad protein estimation reagent.
♦ After vortexing twice and decanting to a cuvette, optical density at 595nm was 
measured.
♦ Bovine serum albumen (BSA) was used to make a panel of protein standards. 
800pl aliquots o f 0, 1, 2, 5, 10, 20, 50 and lOOpg BSA in Buffer B were used.
♦ Protein concentration in the membrane suspension was estimated by 
comparing optical density readings for the tumour membrane with those 
obtained from the panel of BSA standards.
d) Sample storage
Using the protein estimation data, the remaining 1.15ml o f membrane suspension 
was diluted to 1.1 mg of protein/ml using Buffer B. To 1ml aliquots lOOpl o f 1.1% 
BSA (in Buffer B) was added as described by Benraad (1990). It has previously 
been demonstrated that these membrane suspensions can then be stored in liquid 
nitrogen for subsequent analysis without compromising results (Grimaux 1990, 
Koenders 1991).
e) Assay protocol
♦ Stored membrane suspension samples were retrieved and thawed.
♦ Samples were vortexed and split into ten lOOjul aliquots in eppendorfs. For 
each sample there were 1 0  eppendorf tubes; tubes 1 to 8  were assay tubes, 
tubes 9 and 10 were control tubes.
♦ Added to these tubes was a 30pl volume of Buffer B with the l^^I-EGF 
concentration indicated in the table below.
tube 1 2 5 I-EGF (nM)
1 0.72
2 1 . 6
3 3.2
4 4.0
5 4.8
6 6.4
7 1 2 . 0
8 16
9 (control) 4.8
1 0  (control) 4.8
Table 5.2: Concentrations of 125 l-EGF 
in the ligand binding protocol.
To minimise pipetting error 3 stock  
solutions were produced; for tubes 1 and 
2, for 3 to 6, 9 and 10, and tubes 7 and 
8. A minimum pipetting volume of 10pl 
was used.
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♦ To assay tubes (1 to 8 ) 10pl of Buffer B was added, to control tubes (9 and 10) 
an excess of unlabelled EGF; 1 Ojj.1 of 3.6mM unlabelled EGF producing a 
final assay concentration of 150nM in 240pl.
♦ Eppendorfs, all o f which now contained a volume of 240 j l x 1, were incubated for 
16-20 hours at 4°C.
♦ After incubation, lOOpl of HAP slurry was added to each eppendorf.
♦ Eppendorfs were incubated, at 4°C, for a further 1 hour during which each was 
vortexed 3 times.
♦ To pellet the HAP slurry eppendorfs were centrifuged at 800rpm for 2 minutes 
at 4°C. The HAP slurry trapped the membrane component including the 
membrane bound EGF receptor and any amount of 125i_EGF bound to it.
♦ Supernatant was discarded and the pellet washed in 1ml of Buffer B. 
Eppendorfs were then centrifuged for a further 2 minutes at 800rpm at 4°C.
♦ This wash step was repeated three times.
♦ The tips were then cut from the eppendorfs into pony vials using a eppendorf 
tip guillotine. Care was taken to ensure the whole HAP slurry pellet was 
transferred to the pony vial and that the tubes, 1 to 1 0 , were kept in sequence.
♦ Pony vials were transferred, in sequence, to a gamma counter.
The gamma counter used for these experiments was a Coulter machine which 
could be programmed to automatically assay the pony vials producing a print-out 
o f the counts detected over a one minute period.
f )  Non specific binding
Control tubes, 9 and 10, provided an estimate of non-specific binding. The 
unlabelled EGF competed, with its iodinated counterpart, to bind EGF receptor. 
However, the former was added to enormous excess (1.2mM), effectively 
preventing receptor binding by iodinated ligand (4.8nM). These tubes were 
assayed in a similar manner to those containing no unlabelled EGF (tubes 1 to 8 ).
g) Data Analysis
The binding data were analysed with the curve fitting computer program LIGAND 
(Peter Munson, NIH Bethesda, MD 20892, USA), version 2.3-March '8 8 . This 
program offers many advantages over the often inadequate graphical methods of 
treating binding isotherms. These advantages and a description of the advantages 
of the features of LIGAND are discussed in detail by Munson (1983).
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Briefly, LIGAND fits the data by weighted non-linear least squares regression to 
exact mathematical models representing the binding of ligand to receptor. In its 
simplest form, one ligand binding to one receptor with single affinity, the model 
fits three parameters to the data describing the affinity of the interaction, number 
o f binding sites present and the level of non-specific binding. The program 
calculates values for each parameter and estimates the degree of accuracy to which 
they have been determined. As EGF receptor is known to exist in two affinity 
states in many tissues, the data were also analysed using the more complex two 
binding site model. A variance ratio test was used to determine whether this two- 
site model was superior to the simple one-site model (Munson 1980). For most 
tumours the single-site model was better and therefore this model was used for 
each of the breast tumour specimens and also for the tumour cell lines.
LIGAND has a facility for pooling results from several experiments. This meant 
that results from separate experiments could be combined. The program assumes 
that the affinity of the binding reaction is the same for each experiment and that 
the number o f binding sites varies over and above any previous corrections for cell 
number or membrane concentration. The program introduces correction factors for 
each curve and common parameters are then used to describe binding in the 
pooled experiments. Data treated in this way can provide more accurate 
estimations o f the parameter values than is achieved by considering experiments 
separately (Munson 1983).
h) Reference preparations
Human placental tissue, rich in EGF receptor, was used. This tissue had been 
stored in liquid nitrogen and was treated in a similar manner to the tumour tissues. 
In comparison to tumour specimens, large amounts of this tissue was available 
allowing a standard placental sample to be assayed with each tumour series. By 
this means results from each tumour series could be compared. Placental tissue 
expresses large amounts of EGF receptor and, to prevent ligand depletion, smaller 
concentrations of placental membrane protein suspension, than for the tumour 
samples, were used.
i) Tumour cell lines
The ligand binding assay was used to estimate EGF receptor expression in the 
breast cancer cell lines used for the invasion studies.
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The tumour cell lines were grown to sub-confluence in large flasks. They were 
then harvested by scraping them from the plastic, trypsin was not used as this 
would have cleaved the EGF receptor binding site from the cell surface. Cells 
were then transferred from the culture flasks to universal containers in which they 
were centrifuged at 500rpm for 5 minutes at 4°C. The supernatant was aspirated 
and the universal container was then dipped in liquid nitrogen to snap freeze the 
tumour cell pellet at its base. Pellets were retrieved by sharply tapping the 
universal container, they were then stored in liquid nitrogen until their use. In the 
ligand binding protocol cell line pellets replaced the tumour sections. Several 
studies of each tumour cell line were made.
Section iv: Conventional immunohistochemistry
a) Antibody
The antibody used for these experiments was the EGFR1 IgG2b mouse 
monoclonal originally described by Waterfield et al (1982), provided by 
Dr B Ozanne of the Beatson Institute for Cancer Research. This antibody 
recognises an epitope in the extracellular domain o f the EGF receptor. Receptor 
measurement in paraffin fixed tissues presents technical difficulties when 
expression levels are low, as is the case with EGF receptor in breast tumours, 
since the sensitivity of the assay can be insufficient (Reeves 1996). These studies 
were performed on frozen sections of tumour.
b) Method
Three step streptavidin-biotin-peroxidase (SABC) immunohistochemistry was 
performed on frozen sections. 5pm sections were thawed onto silanised slides, 
stored at -70°C in airtight packaging, and allowed to warm to room temperature 
before opening. The sections were fixed in 100% acetone and washed in PBS. As 
we had previously identified that endogenous biotin was a problem in some breast 
tumours this was routinely suppressed by incubating the sections with 50% egg 
white for 30 minutes (Reeves 1994). Further non-specific binding was inhibited 
with serum blocking solution (10 minutes), containing 25% human serum and 
25% rabbit serum in PBS, this was then aspirated off and replaced with 
EGFR1 (lpg/m l) supplemented with 0.02% free biotin. After 2 hours, as the 
second component of the endogenous biotin block, the sections were washed and 
incubated for 30 minutes with biotinylated anti-mouse immunoglobulins at a 
1:400 dilution (Dako Ltd., High Wycombe, Berks.). The third SABC layer 
(conventional streptavidin biotin peroxidase complex) was applied for a further
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30 minute incubation. After washing, the peroxidase signal was developed with a 
10 minute exposure to 0.07% NiCl2 .6 H2 0 , 0.025% diaminobenzidine 
tetrahydrochloride, and 0.01% H2 O2 , producing a black precipitate. Nuclei were 
counterstained red with safranin before dehydration and mounting through 
standard solutions. Parallel control sections were processed similarly, with the 
mouse monoclonal antibody being replaced with non-immune mouse IgG2 b at a 
concentration o f 1 pg/ml.
c) Scoring
All sections were scored by a single investigator (Dr J Reeves) who was blind to 
results o f both ligand binding and radioimmunohistochemistry. The percentage of 
tumour cells falling into negative, weakly positive, and strongly positive 
categories was qualitatively assessed. The sum of (1 x % weakly positive) + 
(2 x % moderately positive) + (3 x % strongly positive) was used as a histoscore, 
with a maximum of 300.
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Chapter 6: 
Results of measurement studies
Section i: Radioimmunohistochemistry
a) Normal breast
Nine reduction mammoplasty tissue specimens were used as normal controls for 
comparison with tumour samples. This allowed EGF receptor levels to be 
expressed relative to the mean of levels in this normal tissue. Expression levels 
above or below this mean are reported as over or under expression respectively. 
EGF receptor levels in the normal specimens were expressed as a percentage of 
receptor density of the cell line standard (A431 cells, known to have 2 x 1 0 ^ EGF 
receptors per cell (Hendler 1984, Stanton 1996)) which was processed with each 
batch o f tissue samples (see Appendix 2). The normal levels ranged from 5.28 to 
9.70% with a mean of 7.6% of the A431 levels (see Appendix 2).
b)Breast cancers
Results of receptor estimation by radioimmunohistochemistry are summarised in 
the histogram (Figure 6.1). Median tumour receptor expression was 4.8% of 
normal breast levels (range, 0 to 707%). All but 5 (3%) of the tumours had lower 
levels o f expression than control breast reduction sections. 91% had less than half 
the normal number of receptors, and 70% less than 10% of this value. Thus the 
majority o f breast cancers showed levels of EGF receptor expression that were 
much lower than normal, and only a very small percentage showed levels of 
expression greater than normal. Results for each tumour are given in Appendix 2.
0.0 0.5 1.0
EGF reoeptor ( x rnrmBl)
Figure 6.1: EGF receptor expression measured by radioimmunohistochemistry 
Frequency histogram of EGF receptor expression in breast cancers. The results are 
expressed relative to the mean level in normal breast.
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Section ii: Receptor measured by three methods
Fifty o f the tumours, designated tl to t50, were assayed for EGF receptor by each 
of the three measurement techniques; ligand binding, conventional 
immunohistochemistry and radioimmunohistochemistry. Breast cancer cell lines 
used in the invasion studies were also studied using the ligand binding and 
radioimmunohistochemical methods. Complete listings o f the data from each 
method are included in Appendix 1.
a) Ligand binding studies
The mean membrane protein concentration was 792pg/ml. Using a similar assay, 
with the same membrane protein estimation technique, Koenders et al (1991) 
proposed a lower assay sensitivity threshold, of 200pg/ml. O f the 50 tumours in 
this report only two, tl 3 and t38, produced membrane protein concentrations less 
than this and one of these was determined to be receptor positive.
The LIGAND program used the binding data produced by the assay, along with 
estimations of non-specific binding, to produce a measurement of EGF receptor. 
Using this software, 19 (38%) of the tumours were EGF receptor positive (had 
measurable receptor levels), the range of expression was 1.6 to 472 fmol/mg 
membrane protein (mean 52.4 fmol/mg). The program was unable to fit a curve to 
the binding data for 31 (62%) of the tumours. For the purposes o f this study these 
were considered EGF receptor negative. The results of each batch o f tumours 
could be standardised using results for the placenta standard (see Appendix 1).
b) Conventional immunohistochemistry
All tumours were scored by a single investigator (Dr J Reeves) who was unaware 
o f the results of either radioimmunohistochemical or ligand binding studies. 
Twenty four, 48%, of the tumours were scored as positive for EGF receptor. The 
mean histoscore in this group was 114, range 5 to 280. Twenty six tumours, 52%, 
did not stain for EGF receptor using this protocol.
c) Radioimmunohistochemistry
Results for all tumours analysed with this method are given in section i o f this 
chapter. The following are the results for the 50 tumours analysed by all three 
methods. EGF receptor could be measured in all but 4 tumours, that is, in 92% of 
the tumour specimens. For tumours with measurable receptor, the range was 0.1 to 
53.8% (mean 3.58%) of the grain counts for the A431 cell line.
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Table 6.1: EGF receptor measurement in breast cancers
our Lb Cihc Rihc tumour Lb Cihc Rihc
(fmol/mg) (histoscore) (%A431) (fmol/mg) (histoscore) (%A431)
t1 136 0 0.1 t26 - 70 1.19
t2 23 0 0.39 t27 - 0 0.12
t3 - 0 0.17 t28 - 0 2.05
t4 - 0 0.48 t29 - 0 0
t5 32 135 5.5 t30 - 0 0.53
t6 - 96 1.98 t31 - 100 1.82
t7 - 0 0.13 t32 - 0 0.36
t8 - 0 0.12 t33 - 0 0.33
t9 - 0 0.44 t34 - 15 0.89
t10 - 100 5.4 t35 - 5 0.74
t11 - 0 0.31 t36 - 0 0.19
t12 - 0 0.21 t37 - 0 0.17
t13 - 0 0.19 t38 9 270 13.36
t14 - 0 0.32 t39 32 12 0
t15 - 0 0.52 t40 - 50 1.44
t16 31 120 3.08 t41 14 110 3.85
t17 - 0 0.41 t42 15 150 2.45
t18 - 0 0.36 t43 472 150 25.28
t19 - 0 0.33 t44 4 250 18.56
t20 14 59 1.48 t45 2 210 3.61
t21 5 0 0 t46 73 50 1.28
t22 11 0 0.39 t47 - 100 1.44
t23 - 0 0 t48 37 190 4.84
t24 79 280 53.8 t49 - 40 0.27
t25 3 82 1.77 t50 4 100 1.85
Lb refers to the ligand binding method, results are shown as femto-moles of receptor per 
milligram membrane protein. The s y m b o l m e a n s  that the LIGAND program could not fit a 
curve to the data from the assay, these a ssays all produced a very low value for R1 
indicating very low receptor levels. Conventional immunohistochemistry, Cihc, results are 
shown as a histoscore, defined in the protocol, giving a range of 0 to 300. Rihc refers to 
the results of the radioimmunohistochemical technique. These are shown as a percentage 
of the grain counts obtained for the A431 cell line.
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Section in: Statistical comparison o f  methods
Only the 50 tumours evaluated with all three measurement methods were 
considered. Using both conventional immunohistochemistry and ligand binding, 
EGF receptor measurement is usually dichotomised; positive or negative. Ligand 
binding results were coded as positive if  the LIGAND program produced a 
measurable value for EGF receptor and conventional immunohistochemistry was 
considered positive if the histoscore was greater than zero. This dichotomy splits 
the tumours into roughly equal groups and may aid statistical analysis. However, 
the distribution of radioimmunohistochemical results offers no such simple 
dichotomy. Therefore, the results of this method were assessed as a continuum.
Results of conventional immunohistochemistry and ligand binding were compared 
using a Chi-square analysis, the results of which are shown below.
ligand
binding
immunohistochemistry
negative positive
negative 22 9
positive 4 15 d.f. = 1, p = 0.0006
Mann-Whitney U tests, comparing the results of radioimmunohistochemistry with 
both ligand binding and conventional immunohistochemistry, are shown in the 
table below.
n median r-ihc score (%A431) 
ligand binding - negative 31 0.36
ligand binding - positive 19 2.45 d.f. = 1, p = 0.0019
immunohistochemistry - negative 26 0.32
immunohistochemistry - positive 24 1.92 d.f. = 1, p < 0.00005
As noted, the above analyses were performed with ligand binding and 
conventional immunohistochemical results evaluated as positive or negative. A 
better impression of the comparability o f the techniques might be obtained by 
comparing measured values for each tumour by each measurement technique. The 
following plots provide a graphical impression of this comparison which is 
analysed statistically in the accompanying tables.
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Conventional immunohistochemistry and ligand binding.
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Figure 6.2 : Plot of ligand binding and conventional immunohistochemistry results. 
Ligand binding (Lb) results, in fmol/mg membrane protein, from the LIGAND 
program are plotted on the y-axis. Note there is a break in this axis, this allows a 
useful presentation of the data set whilst including the single very high result. 
Conventional immunohistochemistry (Cihc) is plotted on the x-axis using the 
histoscore as outlined in the conventional immunohistochemistry protocol.
This relationship was analysed by Spearman rank correlation analysis.
exclusion criteria n r2 P
none 50 0.312 < 0.0005
tumours with zero receptor by Cihc 24 0.208 0.025
tumours with zero receptor by Lb 19 0.002 0.869
Table 6.2: Comparison of conventional immunohistochemistry and ligand binding 
methods. The data were derived from a Spearman rank correlation analysis of the 
results of both receptor measurement techniques. The number of tumours 
analysed, n, was defined by the exclusion criteria indicated. r2 is the square of the 
Spearman rank correlation coefficient and p is the level of significance.
u u u  —  
200 -  
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Radioimmunohistochemistry and ligand binding.
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Figure 6.3 : Plot of ligand binding and radioimmunohistochemistry results. 
Radioimmunohistochemistry (Rihc) is plotted on the x-axis with tumour results, as a 
% of A431 grain counts, plotted on a log^q sca le - Ligand binding (Lb) results, in 
fmol/mg membrane protein, from the LIGAND program are plotted on the y-axis. 
Note there is a break in this axis, this allows a useful presentation of the data set  
whilst including the single very high result.
As above, this relationship was analysed by Spearman rank correlation 
analysis.
exclusion criteria n r2 p
none 50 0.175 0.003
tumours with zero receptor by Lb 19 0.009 0.702
Table 6.3: Comparison of the radioimmunohistochemical and ligand binding 
methods. The data were derived from a Spearman rank correlation analysis of the 
results of both receptor measurement techniques. The number of tumours 
analysed, n, was defined by the exclusion criteria indicated. r2 is the square of the 
Spearman rank correlation coefficient and p is the level of significance.
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Radioimmunohistochemistry and conventional immunohistochemistry.
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Figure 6.4 Plot of conventional immunohistochemical and
radioimmunohistochemical results.
The histoscore, defined in the conventional immunohistochemistry (Cihc) protocol is 
plotted on the y-axis. Radioimmunohistochemistry (Rihc) is plotted on the 
x-axis with tumour results, as a % of A431 grain counts, plotted on a log^ q scale.
As above, this relationship was analysed by Spearman rank correlation 
analysis.
exclusion criteria n r2 p
none 50 0.695 < 0.0005
tumours with zero receptor by Cihc 24 0.838 < 0.0005
Table 6.4: Comparison of the radioimmunohistochemical and conventional 
immunohistochemical methods. The data were derived from a Spearman rank 
correlation analysis of the results of both receptor measurement techniques. The 
number of tumours analysed, n, w as defined by the caveat described under the 
exclusion criteria heading. r2 is the square of the Spearman rank correlation 
coefficient and p is the level of significance.
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Section iv: Results fo r  the tumour cell lines
The cell lines used for the invasion studies (Part 3) were assayed using the ligand 
binding and radioimmunohistochemical protocols.
a) Ligand binding studies
Protein (pg/ml) Receptor (fmol/mg)
line Run 1 Run 2 Run 1 Run 2 combined
BT20 560 134 2340 4119 2628
BT474 440 114 513 1074 788
MDA-MB-231 420 420 1503 429 685
MCF7-ADR 460 92 389 2061 594
SKBR3 490 490 671 421 524
MCF7 780 780 5 - 29
MDA-MB-453 716 716 21 - 28
ZR75 1215 1215 19 12 25
MDA-MB-361 200 50 11 _ _
Table 6.5 : Ligand binding studies of the breast cancer cell lines
Protein (pg/ml) refers to the concentration of membrane protein in the assay  volume. 
Receptor (fmol/mg) is the concentration of receptor per milligram of membrane protein as  
determined by the LIGAND program. The s y m b o l m e a n s  that the LIGAND program could 
not fit a curve to the data from the assay, these assays all produced a very low value for 
R1 indicating very low receptor levels. The LIGAND program allows both sets of ligand 
binding data to be 'combined', using this technique produced the results in the column 
headed 'combined'.
O f the 9 cell lines, EGF receptor was measurable in 8 . 'Run 1' was performed on a 
membrane preparation of high protein content, with any excess membrane protein 
used for 'run 2'. Four assays in 'run 2' were performed on membrane preparations 
of less then 200jug/ml, 3 of these had measurable receptor and the last had a very 
low receptor density in 'run 1 '.
The results for 'run 1' and 'run 2' reveal considerable variation in measured 
receptor levels; results varied by a mean factor of 2.6, range 1.6 to 5.3 for each 
cell line. Despite this, both runs showed a degree of concordance and Spearman 
rank correlation analysis was statistically significant (r^=0.604, p=0.014).
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b) Radioimmunohistochemical studies
line counts
BT20 1753
MDA-MB-231 901
BT474 475
SKBR3 231
MDA-MB-453 114
ZR75 104
MDA-MB-361 82
MCF7 -40
MCF7-ADR _
Table 6.6 : Radioimmunohistochemical results for the tumour cell lines
The counts refer to the number of silver grains counted by the image analysis system
per unit area per hour of emulsion exposure, this is proportional to the number of EGF
receptors present. No results were available for the MCF7-ADR line for technical
reasons.
The raw data from which these results are generated is presented in Appendix 1. 
The negative value for the MCF7 cells indicates that counts for the control section 
were higher than in the test sections, this implies that, at these very low levels of 
receptor expression, the sensitivity o f the assay was exceeded.
The figure overleaf is intended to provide a graphic impression of the relative 
levels of receptor expression using the different measurement methods, it should 
be noted that receptor is measured in distinct units for the two methods. Because 
the MCF7-ADR line was not studied using the radioimmunohistochemical method 
there are only 8  cell lines for which the results can be directly compared, Spearman 
rank correlation analysis, r^=0.615, p=0.023.
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Figure 6.5 : Plots of cell line receptor expression measured by ligand binding and 
radioimmunohistochemistry.
o
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cell line
Solid circles represent radioimmunohistochemical results, open circles represent the 
results of the ligand method. Receptor levels for the ligand binding and for 
radioimmunohistochemistry are shown in fmol/mg membrane protein and as grains per 
mm^ per hour respectively.
The results presented in this chapter are discussed in the next.
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Chapter 7: 
Discussion; receptor measurement
Section i: Radioimmunohistochemical measurement o f  EGF receptor
We have established, and validated, a radioimmunohistochemical method of 
measuring EGF receptor (Stanton 1994) (and c-erbB-2 encoded 
receptor - Reeves 1996). By this method EGF receptor was measurable in nearly 
all tumour specimens. In comparison, using conventional immunohistochemistry 
and ligand binding techniques receptor could not be measured in most o f the 
tumour samples.
Using this method, it was clear that receptor expression was down-regulated in the 
vast majority of breast cancers (see Figure 6.1). The fact that normal breast 
showed detectable expression of EGF receptor has been noted in past reports 
(Dittadi 1993, Chrysogelos 1994). The assumption has been made that levels of 
expression in normal breast, whilst detectable, are low (Rajkumar 1994), and that 
tumours with assayable levels of EGF receptor are therefore overexpressing this 
marker relative to their tissue of origin. In keeping with previous reports (Dittadi 
1993, Ozawa 1988) our radioimmunohistochemical results were not compatible 
with this. What we take to be low or high levels of receptor expression is 
obviously arbitrary, but within this series all but 5 tumours showed levels of 
expression below those o f normal breast. This fitted well with the low incidence 
of EGF receptor gene amplification in breast cancers (Slamon 1987). However, 
these low levels of receptor expression may still be o f functional significance as 
indicated by the prognostic significance of EGF receptor expression in previous 
studies (Sainsbury 1987, Harris 1989, Klijn 1992), and the relationship to adverse 
grade and oestrogen receptor status in this series. The low levels of EGF receptor 
detected in the tumours which we have studied was consistent with at least two 
explanations. It was possible that large amounts of ligand was present within the 
tumours, the binding of which may be resulting in internalisation of most of the 
receptors. That is, that the low number of cell surface receptors was a reflection of 
high receptor turnover (Rios 1992), rather than of low receptor production. 
Alternatively, there may have been low receptor production, that is true 
underexpression. This may have important implications for the use of this receptor 
as a target for tumour therapy.
It can be argued that tissue from reduction mammoplasty specimens is not the 
ideal control for breast cancer specimens. These patients are younger than the
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majority of cancer cases, and it is possible that, in normal breast lobules, receptor 
expression changes with age. This raises the issue of what truly normal breast 
tissue is available to use as a control. Histologically normal breast tissue in the 
cancer specimens showed the same levels of expression as our controls, however 
these areas may have been subject to some o f the genetic changes that had resulted 
in the adjacent pathology. This argument is less strong for breast adjacent to 
benign lesions, however these also tend to occur in younger age groups. Very 
rarely is completely normal breast tissue removed from middle aged or older 
women. The other potential problem with the use of reduction mammoplasty 
specimens as a control is the indication for the operation itself; it is possible that 
breasts in these patients are very large because of overexpression of growth factor 
receptors. There is to our knowledge absolutely no evidence that this is so and as 
we have suggested areas of histologically normal breast within the tumours 
showed similar receptor densities. Since the consensus origin of breast carcinoma 
is at the level of terminal ductulo-lobular unit (Davidson 1993, Wellings 1990) 
lobular tissue from the reduction mammoplasty specimens was used for our 
control measurements.
Section ii: Comparison o f  measurement methods
Most reports o f EGF receptor expression in breast cancer have used conventional 
immunohistochemical or ligand binding methods. In our series, Chi-square 
analysis of the results of these methods suggests a high degree of concordance 
(p=0.0006), however, for 13 of the tumours (26%) the results did not concur. This 
level of variation would account for some of the discrepancies in publications on 
EGF receptor.
O f the panel of 50 tumours, 38% and 48% were positive for EGF receptor using 
the ligand binding and conventional immunohistochemical methods respectively 
(Table 6.1). These rates are similar to those in the studies reviewed by Klijn 
(1992); 45% and 42% mean receptor positivity respectively. However, our panel 
of tumours was not selected in an entirely random fashion. Large tissue sections 
were required for ligand studies and, since all three measurement techniques were 
to be used, larger cancers were selected. Further, the intention of this study was to 
compare results of receptor measurement using the different methods, this 
required that a number o f the tumours were receptor positive. Therefore, 10 
tumours (t41 to t50) were chosen as, using radioimmunohistochemistry, they were 
strongly receptor positive (The investigator was unaware of this selection bias
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until the assays were completed.). Excluding these tumours, 23% using ligand 
binding and 33% using conventional immunohistochemistry were receptor 
positive. These results, particularly for the ligand technique, are at the lower end 
of the range reported in Klijn's review (1992). This may reflect small sample size, 
and for the ligand method a lack of familiarity with a relatively complex 
methodology. There are, however, other important factors that can effect studies 
using these methodologies.
One of these is the technique used to label the EGF ligand. The EORTC adopted 
EGF receptor measurement protocol (Leake 1993) advocates use of an iodine 
monochloride method for EGF iodination. The authors state that alternative 
methods oxidised the EGF molecule, causing non-equivalent binding of iodinated 
compared to non-iodinated ligand. This could result in a reduction in measured 
receptor, however, Klijn's review paper (1992) pre-dates the EORTC report and 
many o f the reviewed studies did not use the iodine monochloride method. Our lab 
had extensive experience with the iodogen method but none with iodine 
monochloride, the former was therefore used to label ligand for our studies.
Another technical problem was that the tissues used for the ligand studies, 
although from the same tumour sample, were retrieved at a later date than the 
consecutive sections used for the immunohistochemistry. This introduced the 
problem of tumour heterogeneity; tumour cells within the same cancer need not 
express receptor uniformly, possibly reflecting different tumour cell clones 
(Brockhoff 1998, Beviglia 1997, Szollosi 1995). This is a problem for both ligand 
binding and immunohistochemistry studies. It can be argued that, since ligand 
studies are performed on a mass of tissue, they might more accurately reflect 
overall tumour EGF receptor levels. However, this has not been corroborated by 
better prediction of outcome in studies using ligand methodologies. Additionally, 
analysis o f a mass of tissue introduces heterogeneity of a different type, since 
samples will include tissue other than breast.
Other studies may have under-estimated receptor expression by including assays 
performed on small tumour samples with insufficient membrane protein (Koenders
1992). Our ligand studies were performed, almost without exception (96%), on 
samples of more than the advised 200pg/ml membrane protein. Further, the mean 
membrane protein concentration in those tumours which had no measurable 
receptor was 856pg/ml as opposed to 688pg/ml in those in which receptor was
71
Chapter 7
measurable. Therefore, it was unlikely that sample weight was too small in our 
study.
For 8 tumours^ counts were higher in the control tubes, 9 and 10, (estimates of 
non-specific binding) than in tube 5 (see Appendix 1). Since excess cold antibody 
was added to control tubes this, in theory, should not have occurred. That it did 
may reflect pipetting error, despite efforts to minimalise this source of error (noted 
in table 5.2). It may also reflect sample loss, either through adherence to the 
eppendorf or during the repeated washing of the HAP precipitate. With greater 
experience of the ligand binding technique such errors might be reduced, however, 
that they could occur may be considered a failing of the technique itself.
Further, the ligand protocol stipulated that the counts added to the control tubes 
and tube 5 should be the same. A crude evaluation of the data can be made by 
comparing the results for these tubes. If the measured counts from tube 5 were 
greater than those in the control tubes, it might be expected that the tumour would 
have measurable receptor. Thirty tumours were identified in this manner, these 
included all o f those identified as EGF receptor positive by the LIGAND program 
but also 11 others^. Estimating receptor content from a single measurement point, 
like this, is considered to be less accurate (Leake 1993) than using a multi-point 
assay but several published studies have used assays with fewer than the 8 points 
advocated by the EORTC.
Even 8 points may be insufficient. We know this receptor exists in two affinity 
states, and the fact that a single site model proved superior to one with two sites 
indicates the imprecise nature o f the ligand protocol. To achieve accurate 
measurement of receptor in a two binding site model, would require an assay with 
many more than eight points. Tumour samples would have to be much larger to 
maintain membrane protein content, and thereby assay sensitivity. Increased use 
of screening mammography means that smaller cancers are being resected, and, in 
future, clinicians are unlikely to jeopardise routine, but valuable, histological 
information to provide large amounts of tissue for EGF receptor measurement.
cp Six tumours, 2 positive and 4 negative by the LIGAND program, were excluded from 
these analyses as one or more of the binding data were unavailable (see Appendix 1 for raw 
data).
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The variability of results using the ligand technique was amply demonstrated by 
the cell line studies. Results for the same membrane preparations, with the same 
protein concentrations, varied by more than 3.5 fold (Table 6.5). Yet, when the 
LIGAND program was used to analyse the data from both cell line 'runs', these 
combined results demonstrated a good accord with those from 
radioimmunohistochemistry (see Figure 6.5). With limited clinical material, 
however, repeating assays is not practical. This means that the variability seen 
between results for each analysis of the cell lines was likely to be reflected in the 
results for the tumours. For all fifty tumours, Spearman rank correlation o f ligand 
binding and radioimmunohistochemical results revealed a high degree of 
correlation but this is misleading. Using ligand binding, receptor could not be 
measured in a significant proportion of these tumours. If these were excluded, 
then for the remaining tumours, there was no correlation between the techniques 
(Figure 6.3). Challenging the ligand technique in this fashion assumes the 
radioimmunohistochemical method to be accurate. This is justified by the cell line 
studies, where the correlation between the results of the combined analysis of 
ligand data and radioimmunohistochemistry was good (Figure 6.5).
In a similar comparison of the results of radio- and conventional
immunohistochemistry there was a high degree of correlation (Figure 6.4). 
However, at lower levels of receptor expression, radioimmunohistochemistry 
continued to differentiate between tumours whereas the conventional method 
failed to do so. It is worth noting that those tumours with low or no receptor by 
the conventional method amounted to more than half (52%) of those studied and
that these had an almost 1 0  fold variation in receptor expression using
radioimmunohistochemistry. Again, this assumes that the 
radioimmunohistochemical method was accurate and that at these lower receptor 
levels it remained sensitive. Good evidence supports this contention. Our studies 
o f c-er6B-2, in this same tumour series, have demonstrated a statistically robust 
inverse correlation between EGF receptor and pl85c-er&B-2 (Robertson 1996). 
Although these receptors are known to interact (Earp 1995), this inverse
correlation was previously unreported and was identified as a direct consequence 
of the accuracy of the radioimmunohistochemical method.
Conventional immunohistochemistry's lack of sensitivity is compounded by its 
lack of objectivity. Non-linear amplification systems are used to visualise the 
primary antibody and interpretation of the method product is, at least in part, 
subjective. In our series, all of the immunohistochemical scoring was performed
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by a single experienced investigator (Dr J Reeves). This may account for the very 
close correlation between the radio- and conventional immunohistochemistry 
results, but it is a luxury not universally available. Other authors have alluded to 
the difficulty of satisfactorily grading immunohistochemical staining (Sallinen 
1994, van Diest 1996). Clearly this could effect the reproducibility o f study 
results, a problem that also afflicts the ligand method. Leake (1993), using the 
EORTC ligand protocol, reported considerable inter-laboratory variation and 
suggested extended quality control was imperative. Inter-observer variation is 
further complicated by tumour heterogeneity. Both problems can be reduced by 
computer assisted scoring systems (Sullinen 1994). These obviate tedious scoring 
and can reduce the influence o f heterogeneity by analysing large areas o f tumour. 
With computer assisted scoring and standard sections, 
radioimmunohistochemistry could facilitate multi-centre studies.
Overall, radioimmunohistochemistry had a number o f advantages over 
conventional methods. It was more sensitive, both conventional methods failed to 
detect receptor in most of the tumour samples. Also, it was more reproducible. 
Finally, the use of computer assisted scoring made it more accurate.
Did these improvements translate into clinical advantage? This question is 
addressed in the subsequent chapters.
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Chapter 8: 
EGF receptor; relation to clinical variables and outcome
Section i: Database construction
Data for the 203 tumours studied using immunohistochemistry were collected. 
These tumours were all surgical treated at Glasgow Royal Infirmary between 1984 
and 1993. Pathological details were recorded by the pathologist reporting on that 
specimen. Tumour size was taken as the largest diameter, determined 
macroscopically, and was recorded in millimetres. The TNM classification was 
used to categorise tumours for statistical analysis. The T4 category, extension to 
chest wall or skin, could not be reliably determined from the case records or 
pathology reports and was not used. Numbers of nodal metastases and nodes 
sampled were taken from the routine pathology reports. During the period over 
which the tumours were collected there was a shift in practice from node sampling 
toward axillary clearance and this was reflected in the numbers of nodes retrieved. 
In the early part of the study period, oestrogen receptors were assayed in frozen 
tumour samples using the dextran coated charcoal method with a cut off of 
20 fmol/mg. Later this method was replaced by an immunohistochemical 
technique. Using this tumours were scored from 0-300 in a analysis similar to that 
described for conventional immunohistochemical measurement o f EGF receptor 
(Chapter 5, section iv). Data from both methods were used in the analyses. 
Modified Bloom and Richardson grade (Elston 1991) was recorded by the 
pathologist reporting the specimen. Prior to 1992 this parameter was not routinely 
measured and the grade of these tumours was assessed retrospectively by one 
pathologist (Dr James Going).
Follow-up data were obtained from the patients' medical records. Glasgow Royal 
Infirmary breast cancer patients are reviewed at a dedicated clinic and in keeping 
with this these patients have breast clinic case records as well as general records. 
Both sets of records were used to provide comprehensive follow-up information. 
Clinical correspondence was copied to the investigators who also had access to the 
case records. In this manner the database was kept up to date. Collated 
information included end points; local recurrence, distal recurrence and death, and 
adjuvant therapy; tamoxifen, radiotherapy and chemotherapy. Death was not 
always available from the case records and was confirmed using the cancer 
registry at the Cancer Surveillance Unit at Ruchill hospital, Glasgow (Dr D Hole). 
From the International Classification of Diseases (ICD) codes it was possible to 
determine if death was breast cancer related or otherwise. Scottish Cancer
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Registry data were recognised to be of high quality, serious discrepancies 
occurring in as few as 2.8% of records (Brewster 1994).
Data were stored in a relational database using the Microsoft Access program 
(Version 2.00, Copyright © 1989-1994 Microsoft Corporation, USA). The 
database was established in 1994 and, for the purposes of this report, was closed 
on 1st January 1998. The relationship between EGF receptor expression and other 
prognostic factors was studied using the Minitab for Windows software (Release 
9.2, Copyright © 1993, Minitab Inc.). The life table analyses were performed 
using the SPSS program (SPSS for Windows, Release 6.1.3, Copyright © SPSS 
Inc. 1989-95). Appendix 2 contains the raw data for the studies presented in this 
chapter.
Section ii: Results - prognostic factors
O f the 203 tumours studied, nine were excluded from subsequent analyses. Eight 
o f  these because the patients had had a previous breast cancer resected and one 
because the tumour was thought to be a metastasis from an oesophageal primary. 
Mean age of the patients was 61 years (range 28 to 87 years). Median EGF 
receptor density was 5% of levels found in normal breast (range 0 to 707%, see 
Figure 6.1). The relationships between receptor expression and prognostic factors 
are summarised in table 8 .1 .
Tumour size was available for all but 5 tumours. Median tumour size was 25mm 
(range, 6  to 130). Using the TNM classification there were 44, 121 and 24 tumours 
o f  T l, T2 and T3 stages respectively. There was no significant difference in the 
median level of EGF receptor in the three T-stage groups, however, tumour size, in 
millimetres, correlated directly to EGF receptor expression (Spearman rank 
correlation analysis, p=0.049, n=188, r^=0.021). This relationship is plotted in 
figure 8 .1 .
Modified Bloom and Richardson grade was available for all but one cancer. There 
were 25 (13%), 73 (38%) and 95 (49%) tumours of grade 1, 2 and 3 respectively. 
Tumours classified as grade 2 expressed lower levels of receptor than did those of 
grade 1, but this difference did not achieve statistical significance (Mann Whitney 
U  test, p=0.723). However, grade 3 tumours expressed much more receptor than 
those o f either grade 1 or 2, and this finding was statistically significant (Table 
8.1). The lack of an increment in receptor expression with each grade may reflect
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the small number of tumours categorised as grade 1. Overall, higher grade, more 
poorly differentiated cancers tended to express the highest levels of EGF receptor.
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Figure 8.1: Plot of EGF receptor (radioimmunohistochemical measurement) and tumour 
size (millimetres). Spearman rank analysis p=0.049, n=188, r^=0.021.
Table 8.1: Relationship between prognostic factors and EGF receptor expression.
n (%)
Tumour size 
(n=189)
T1
T2
T3
44 (23) 
121 (64) 
24 (13)
medianEGFr 
(x normal) 
0.041 
0.048 
0.045 p=0.392
Hist. Grade 
(n=193)
Gl
Gil
Gill
25 (13) 
73 (38) 
95 (49)
0.047
0.035
0.078 p=0.005
ER status 
(n=140)
neg
pos
61 (44) 
79 (56)
0.194
0.032 p<0.0005
Nodal status 
(n=170)
neg
pos
83 (49) 
87 (51)
0.043
0.056 p=0.074
For tumour size and Histological grade Kruskall-Wallis analysis was used, for Nodal status 
and ER status Mann-Whitney U test w as employed. The TNM classification w as used for 
tumour size and Modified Bloom and Richardson score (Elston 1991) for histological (Hist.) 
grade. ER and EGFr indicate oestrogen and EGF receptors respectively.
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As indicated above oestrogen receptor status was determined using two different 
methods. In total, it was available for 151 (78%) of the tumours. O f these, seventy 
were studied using both techniques. All tumours that were oestrogen receptor 
positive using the dextran coated charcoal method were positive using 
immunohistochemistry. Three tumours were receptor negative by the former 
technique but were positive by the latter, for purposes of statistical analysis these 
were considered receptor positive. With receptor expression categorised as 
positive or negative, there was a strong indirect relationship between EGF and 
oestrogen receptor.
To further analyse this relationship, measured receptor levels, for the oestrogen 
receptor positive tumours, were compared. For the ligand method there was no 
correlation (Spearman rank correlation analysis, p=0.282, n=74, r^=0.002), but 
results of the immunohistochemical method correlated indirectly with EGF 
receptor levels (Spearman rank analysis, p=0.032, n=53, r^=0.069).
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Figure 8.2: Plot of oestrogen receptor levels (measured using conventional
immunohistochemistry) and EGF receptor levels (shown as log^o °f  
radioimmunohistochemistry (Rihc)). Spearman rank analysis p=0.032, n=53, r2=0.069.
Information on node sampling was available on 186 (96%) of the tumours. In 
16 o f these no nodal tissue was found by the pathologist. The mean number of 
nodes retrieved was 5.9 (range, 0 to 24 nodes). Therefore nodal information was 
available for 170 of the cancers, of which 87 (51%) were node positive. 
In 31 tumours (18%) more than three nodes were involved. For those tumours 
with available nodal information, node involvement bore no statistically 
significant relationship to EGF receptor expression levels.
78
Chapter 8
For any given tumour the number of sampled nodes varied widely and a sub­
analysis of tumours with 4 or more sampled nodes was performed. Tumours were 
categorised as node negative, 1 to 3 nodes involved and more than 3 involved 
nodes, these groupings define cohorts with distinct prognoses; 1 0  year survival o f 
64.9%, 37.5% and 13.4% respectively (Miller 1994). Two analyses were 
performed. In the first, tumours were categorised as node negative or node 
positive, as above. In the second, the node positive group were split into those 
with fewer than 4 involved nodes and those with 4 or more involved nodes. The 
table below shows the results
Table 8.2: Subanalysis of nodal status
Nodal status 
(n=128)
neg
pos
n (%)
63 (49) 
65 (51)
median EGFr 
(x normal)
0.047
0.044 p=0.576
Nodal groups 0 63 (49) 0.047
(n=128) 1-3 34(27) 0.052
>3 31 (24) 0.041 p=0.680
Analysis w as limited to those ca ses  in which 4 or more nodes were sampled. In the 
analysis of nodal status cancers were coded as node negative or node positive. Statistical 
analysis w as by Mann-Whitney U test. In the second analysis, tumours were split into 
nodal groups, no nodes involved, 1-3 nodes involved and more than 3 nodes involved. A 
Kruskall-Wallis statistical analysis was applied to this study. EGFr indicates EGF receptor.
This sub-analysis confirmed that there was no statistically significant relationship 
between EGF receptor expression and nodal status.
Section iii: Results - adjuvant therapy
Adjuvant systemic therapy, tamoxifen or chemotherapy, was prescribed for 
148 (76%) patients. Only 13 (7%) patients had no adjuvant systemic therapy (data 
unavailable for 33). 130 patients received adjuvant tamoxifen therapy and 35 did 
not (data unavailable for 29). Chemotherapy was prescribed for 26 but not for 138 
(data unavailable for 30). Only one patient received both. The mean age o f those 
receiving tamoxifen was 64 years (range, 42-87) and those receiving 
chemotherapy was 47 years (range, 29-68). Radiotherapy was prescribed for
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61 patients (31%), 102 patients (53%) did not have this treatment whilst for 31 the 
case records failed to make it clear if  radiotherapy had, or had not, been given.
No further analysis of adjuvant therapy data was made for reasons given in 
Chapter 9.
Section iv: Results - outcome
Follow-up commenced at the date of histological diagnosis or surgery. End points 
were local recurrence, distal recurrence and death. For purposes o f analysis data 
collection continued until the end of 1997. Data were available for all but 3 
patients. Case sheets for these patients could not be traced, but none was recorded 
as dead at the cancer registry. They were therefore assumed to be alive. At the end 
of 1997, 91 patients (47%) were alive. The mean duration of follow-up for this 
cohort, excluding the 3 cases with no follow-up, was 2282days (range, 162 to 
4445). In total, 103 patients (53%), with a mean follow-up of 1145days, had died. 
These patients could be dichotomised using the cancer deaths registry data to 
those who had breast cancer related deaths and those who did not. 81 patients 
(42%) died from causes directly attributed to breast cancer, mean follow-up 
1120days (range, 89 to 2804). Those whose death certificates did not register 
breast cancer numbered 22 (11%), mean follow-up 1236days (range 21 to 3138). 
Survival analyses were performed on groups defined by both breast cancer related 
deaths (Disease specific survival) and all deaths (Overall survival).
Many publications measure outcome in terms of recurrence (i.e. disease free 
survival) as well as death. To monitor disease recurrence, the breast cancer clinic 
at Glasgow Royal Infirmary had a surveillance policy. All patients had 
mammography at 3 year intervals, those who had had local resections underwent 
annual mammography for 5 years. Ideally, all patients had annual chest and pelvic 
x-rays as well as liver function tests. However, the enthusiasm with which this 
protocol was applied varied with the reviewing clinician. Use of other diagnostic 
tools was prompted chiefly by clinical suspicion. Most frequently, these were fine 
needle aspiration biopsies of suspected local recurrence, and for distal disease, 
bone scans, liver ultrasonography and brain CT scans.
For the purposes of this study, local recurrence was recorded if histologically 
proven or if  there was a high index of clinical suspicion, most often resulting in a
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modification of therapy. Distal recurrence was rarely histologically determined 
and was based chiefly on results of symptom prompted diagnostic imaging.
In subsequent analyses, those patients with breast cancer related deaths were 
considered to have recurred at a distant site. Those alive, at the termination of the 
study, in whom recurrent disease was not diagnosed, were considered to be free of 
recurrence. Recurrence of any kind occurred in 99 patients (51%) at a mean 
duration of 767days. Distal recurrences occurred in 90 patients (46%) at a mean 
duration o f 884days (range 0 to 2485) and local recurrences in 48 patients (25%) 
at 806days (range 43 to 3235).
On the following pages are the results of both univariate (Kaplain-Meier) and 
multivariate (Cox regression) analyses of the follow-up database. Patients were 
divided into groups of equal number using the radioimmunohistochemical 
measure o f EGF receptor content of their tumours; 2 groups of 97 cases (cut-off 
0.047 times normal breast levels), 3 groups, 65, 65 and 64 cases (cut-offs 0.030 
and 0.079 times normal breast levels) and 4 groups, 48, 49, 48 and 49 cases (cut­
offs 0.022, 0.047 and 0.158 times normal breast levels). Both statistics and 
graphics were generated using the SPSS program. Appendix 2 contains the raw 
data for these studies.
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a) Univariate analyses
The aims o f this thesis relate to the EGF receptor, therefore most of the 
analyses concern this variable. However, to characterise the database analyses 
o f tumour size, oestrogen receptor content, histological grade and nodal 
involvement were performed.
Figure 8.3 : Kaplan-Meier analysis of the relationship between T stage and survival.
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D isease specific survival is indicated on the y-axis, the scale shows the proportion of 
patients remaining alive at the follow-up time point indicated, in days, on the x-axis. 
Tumours were classified into three groups, one to three, of progressively larger size using 
the TNM classification (no tumours were categorised as T4).
Tumour T stage (TNM) strongly predicted for death from breast cancer related 
causes (Kaplan-Meier statistic 22.15, d.f. 2, p<0.00005). It remained a strong 
predictor of survival when all deaths were considered (Kaplan-Meier 
statistic 26.63, d.f. 2, p<0.00005).
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Figure 8 .4  : Kaplan-Meier analysis of the relationship betw een histological grade and
survival.
Histological grade
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D isease specific survival is indicated on the y-axis, the scale shows the proportion of 
patients remaining alive at the follow-up time point indicated, in days, on the x-axis. 
Tumours were classified into three groups, one to three, of progressively poorer 
differentiation using a modified Bloom and Richardson grading system (Elston 1991).
Histological grade also proved a good predictor of outcome in terms of breast 
cancer related deaths (Kaplan-Meier statistic 12.30, d.f. 2, p=0.0021) and deaths 
from all causes (Kaplan-Meier statistic 9.86, d.f. 2, p=0.0072).
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Figure 8 .5  : Kaplan-Meier analysis of the relationship betw een oetrogen receptor status
and survival.
Oestrogen receptor (ER)
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D isease specific survival is indicated on the y-axis, the scale shows the proportion of 
patients remaining alive at the follow-up time point indicated, in days, on the x-axis. 
Oestrogen receptor status was determined as described above. ER +ve and ER -ve 
indicate those tumours identified a s oestrogen receptor positive and negative respectively.
Oestrogen receptor status was an exceptionally strong predictor of death from 
breast cancer related causes (Kaplan-Meier statistic 37.77, d.f. 1, p<0.00005). It 
remained so when all deaths were considered (Kaplan-Meier statistic 34.90, 
d.f. 1, p<0.00005).
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Figure 8 .6  : Kaplan-Meier analysis of the relationship betw een nodal status and survival.
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D isease specific survival is indicated on the y-axis, the scale shows the proportion of 
patients remaining alive at the follow-up time point indicated, in days, on the x-axis. 
Tumours were classified as having histologically confirmed nodal m etastases, node +ve, 
or as being free of nodal m etastases, node -ve.
Presence o f nodal metastases predicted breast cancer related mortality (Kaplan- 
Meier statistic 23.39, d.f. 1, p<0.00005). It also predicted overall survival 
(Kaplan-Meier statistic 18.76, d.f. 1, p<0.00005).
85
Chapter 8
Figure 8 .7  : Kaplan-Meier analysis of the relationship betw een nodal groups and survival.
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D isease specific survival is indicated on the y-axis, the scale shows the proportion of 
patients remaining alive at the follow-up time point indicated, in days, on the x-axis. 
Tumours were classified into three groups determined by the number of histologically 
determined nodal m etastases; no nodal m etastases (0 nodes), one to three involved 
nodes (1-3 nodes) and more than three nodal m etastases (>3 nodes).
Analysing the tumours depending on the number of involved nodes also 
predicted breast cancer related deaths (Kaplan-Meier statistic 28.58, d.f. 2, 
p<0.00005). For overall survival these groupings also proved predictive (Kaplan- 
Meier statistic 28.45, d.f. 2, p<0.00005).
The unusually strong predictive power of oestrogen receptor status in this series 
is discussed in chapter 9. The results for the remaining conventional prognostic 
factors reflect those reported in the literature. Subsequent univariate analyses 
explored the relationship between EGF receptor expression and outcome.
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Survival Analysis - Disease specific and Overall survival
Figure 8.8 : Kaplan-Meier analyses of the relationship between survival and EGF receptor. 
Patients were split into; 2 groups, 3 groups and 4 groups, using the levels of EGF receptor 
expression in their tumours.
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EGF receptor expression: 4 groups
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D isease specific survival is indicated on the y-axis, the scale shows the proportion of 
patients remaining alive at the follow-up time point indicated, in days, on the x-axis. 
Groups are categorised, in ascending order of expression, as; low, moderately low, 
moderately high and high. Plot annotations refer to the line to which they are closest. 
Dotted and dashed lines have been used where there is overlap to try and minimise 
confusion.
The Kaplan-Meier analyses are summarised below.
Kaplan-Meier statistic d.f. p value
2 groups / d isease specific survival 2.51 1 0.1130
2 groups / overall survival 4.10 1 0.0429
3 groups / d isease specific survival 12.50 2 0.0019
3 groups / overall survival 10.70 2 0.0047
4 groups / d isease specific survival 17.14 3 0.0007
4 groups / overall survival 16.48 3 0.0009
For disease specific survival, splitting EGF receptor expression into two groups 
did not produce a statistically significant separation of survival curves. For 
overall survival this dichotomy was just significant. When receptor expression 
was split into 3 groups these had a statistically different outcome. For 4 groups 
the statistical power seemed greater but the survival curves for the moderately
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high and moderately low cohorts overlapped so that the relationship between 
outcome and receptor expression was not incremental.
Survival Analysis - Disease free survival
Figure 8.9 : Kaplan-Meier analyses of the relationship between d isease free survival and 
EGF receptor.
EGF receptor expression: 2 groups
1.0
Lew
co
I
1
8b
o 1000 2000 3000 4000 5000
Days
EGF receptor expression: 3 groips
p = 0.0072
IxwCO
I
8
CO
$b
- +■  +
Mxterate* - 1
0.0
1000 2000 3000 4000 50000
Days
89
Chapter 8
EGF receptor expression: 4 groips
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Patients were split into; 2 groups, 3 groups and 4 groups, using the levels of EGF receptor 
expression in their tumours. Axes and figure annotations are similar to those in Figure 8.8
The Kaplan-Meier analyses are summarised below.
EGF receptor expression Kaplan-Meier statistic d.f. p value
2 groups 4.03 1 0.0446
3 groups 9.88 2 0.0072
4 groups 15.79 3 0.0013
The statistical power of these analyses increased with the number of groups into 
which tumours were divided. As before, there was some overlap o f the survival 
curves and this was most prominent when the tumours were split into 4 groups. 
In the analysis of 3 groups the low and moderate expression curves follow a 
similar course until approximately 5 years of follow-up, they then begin to 
diverge.
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Survival analysis - Local recurrence
Figure 8.10 : Kaplan-Meier analyses of the relationship between local recurrence and EGF 
receptor. Patients were split into; 2 groups, 3 groups and 4 groups, using the levels of EGF 
receptor expression in their tumours. Axes and figure annotations are the similar to those in 
Figure 8.8
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EGF receptor expression: 4 groups
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The Kaplan-Meier analyses are summarised below.
EGF receptor expression Kaplan-Meier statistic d.f. p value
2 groups 2.93 1 0.870
3 groups 4.03 2 0.1334
4 groups 6.60 3 0.0857
None of these analyses was statistically significant. However, the curves 
themselves tended to suggest that local recurrence was more frequent in those 
tumours with higher receptor expression.
b) Multivariate analyses
Cox regression, performed in a forward stepwise conditional manner, was used for 
all analyses. The variables included in these studies were; T stage, nodal status, 
oestrogen receptor status, histological grade and EGF receptor expression. The 
last was analysed in 2 groups (EGFr-2), 3 groups (EGFr-3), 4 groups 
(EGFr-4), and as a continuous variable (as a factor of levels in normal breast, 
EGFr-c).
Note that, for all these analyses, relative risk is expressed as a factorial increase in 
risk for each unit increment of the appropriate variable. For nodal status this 
increment was a change from node negative to node positive (NO to N l), for 
oestrogen receptor, it was a change from oestrogen receptor positive to negative.
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An increase o f one TNM stage, and one modified Bloom and Richardson grade, 
was used for T-stage, and Grade, respectively. When EGF receptor expression was 
analysed in groups risk was expressed for each increment o f one group. When it 
was studied as a continuous variable, the risk increment was one times the mean 
level o f receptor in normal breast (as measured in Chapter 6 ).
Analysis o f  all factors
Table 8.3 : Cox regression analysis of d isease specific survival - analysis of all prognostic 
factors
Variables in the equation p value Relative risk 95% Cl
ER status <0.00005 4.7 2 .5 -8 .7
Node status 0.0009 3.0 1.6 - 5.7
T stage 0.0158 1.8 1 . 1 - 2 . 8
Variables not in the equation p value
EGFR-2 0.7421
EGFR-3 0.7954
EGFR-4 0.7262
EGFR-c 0.4784
Grade 0.3766
For tables 8.3 and 8.4, 123 ca ses with 49 breast cancer related deaths and 126 c a se s  with 60 
recurrences, were analysed, respectively. In both tables, the relative risk is the increased risk
for each unit increase in that variable. EGF receptor expression levels were used to split the 
patients into groups of equal size; 2 groups (EGFR-2), 3 groups (EGFR-3) and 4 groups 
(EGFR-4). EGF receptor levels were also studied as a continuous variable (EGFR-c). The other 
variables are defined at the beginning of this section. The 95% Cl is the 95% confidence 
interval for the relative risk. Relative risk, and its confidence limits, are given only for those 
variables included in the equation (i.e. predictive of outcome).
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Table 8.4: Cox regression analysis of d isease free survival - all prognostic factors
Variables in the equation p value Relative risk 95% Cl
ER status <0.00005 3.1 1 . 8 -5 . 2
Node status 0.0041 2.3 1 . 3 -4 . 0
T stage 0.0047 1.8 1 . 20 -2 . 7
Variables not in the equation 
EGFR-2
p value 
0.6812
EGFR-3 0.7436 - -
EGFR-4 0.6744 - -
EGFR-c 0.7109 - -
Grade 0.0603 _ _
The key to Table 8.4 is given below Table 8.3
Analysis of overall survival produced similar results. 126 cases were studied with 
58 deaths. The same prognostic factors were predictive: ER status, p<0.00005, 
relative risk 4.3, 95% Cl, 2.4 - 7.5; Node status, p=0.0047, relative risk 2.3, 95% 
Cl, 1.3 - 4.0; T stage, p=0.0060, relative risk 1.8, 95% Cl, 1.2 - 2.7.
Subgroup analysis - node status
In most series, presence of nodal metastases is the prognostic feature with greatest 
predictive power and may influence adjuvant therapy decisions. To ascertain if 
EGF receptor expression might determine prognostic subgroups within patient 
populations determined by lymph node status the survival analyses were repeated 
in patient groups defined by nodal status. (Tables 8.5 and 8 .6 )
Table 8.5: Cox regression analysis of d isease specific survival - node status
Lymph node negative tumours (59 ca ses with 13 events)
Variable ER status T stage Grade EGFr-2 EGFr-3 EGFr-4 EGFr-c
p-value 0.0006 0.4260 0.5923 0.7635 0.8590 0.8858 0.1731
relative risk 14.0 -
95% Cl 3.1-63.3 - - - - -
Lymph node positive tumours (64 ca ses  with 36 events)
Variable ER status T stage Grade EGFr-2 EGFr-3 EGFr-4 EGFr-c
p-value 0.0004 0.0533 0.4226 0.9925 0.9897 0.9527 0.2642
relative risk 3.5
95% Cl 1.7-7.0 - - - - -
94
Chapter 8
Table 8.6: Cox regression analysis of d isease free survival - node status 
Lymph node negative tumours (59 ca ses with 18 events)
Variable ER status T stage Grade EGFr-2 EGFr-3 EGFr-4 EGFr-c
p-value 0.0348 0.0290 0.3273 0.8696 0.8176 0.8785 0.3793
relative risk 2.9 2.3
95% Cl 1.1-7.9 1.1-5.0 - - - - -
Lymph node positive tumours (65 ca ses with 42 events)
Variable ER status T stage Grade EGFr-2 EGFr-3 EGFr-4 EGFr-c
p-value 0.0017 0.0761 0.0963 0.6365 0.5668 0.4728 0.4135
relative risk 2.8
95% Cl 1.5-5.2 - - - - -
In both tables, relative risk is the increased risk for each unit increase in that variable 
(defined in the legend of page 92). Relative risk, and its confidence limits, are given only 
for those variables predictive of outcome.
Analysis o f overall survival showed that ER status was the only predictor of 
outcome: in node negative disease; p=0.0004, relative risk 5.7, 95% Cl, 2.2-15.0, 
and in node positive disease; p=0.0001; relative risk 3.8, 95% Cl, 1.9-7.5
Subgroup analysis - oestrogen receptor status
The predictive value of EGF receptor expression might vary within groups defined 
by oestrogen receptor status. This possibility was explored by repeating the 
survival analyses for cohorts with oestrogen receptor positive and negative 
tumours respectively. Results are shown in tables 8.7 and 8 .8 .
Table 8.7: Cox regression analysis of d isease specific survival - oestrogen receptor status 
Oestrogen receptor positive tumours (73 ca ses with 15 events)
Variable nodal status T stage Grade EGFr-2 EGFr-3 EGFr-4 EGFr-c
p-value 0.0049 0.1451 0.2001 0.7146 0.8871 0.6078 0.0015
relative risk 8.5 - - - - -  7 2 . 8
95% Cl 1.9-38.1 - - - - -  5.1-1030.1
Oestrogen receptor negative tumours (50 ca ses  with 34 events)
Variable nodal status T stage Grade EGFr-2 EGFr-3 EGFr-4 EGFr-c
p-value 0.0483 0.1706 0.8625 0.5716 0.2363 0.4400 0.7286
relative risk 2.1
95% Cl 1.0-4.4 - - - - -
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Table 8.8: Cox regression analysis of d isease free survival - oestrogen receptor status 
Oestrogen receptor positive tumours (73 ca ses with 23 events)
Variable nodal status T stage Grade EGFr-2 EGFr-3 EGFr-4 EGFr-c
p-value 0.1744 0.0004 0.0809 0.6983 0.3605 0.5317 0.0017
relative risk - 2.8 39.0
95% Cl - 1.6-4.9 . . .  . 4.0-384.3
Oestrogen receptor negative tumours (53 ca ses with37 events)
Variable nodal status T stage Grade EGFr-2 EGFr-3 EGFr-4 EGFr-c
p-value 0.0327 -
relative risk 2.2 - - - - - -
95% Cl 1.1-4.5 - - - - -
In this and the following table (Tables 8.7 and 8.8), the relative risk is the increased risk for 
each unit increase in that variable (defined in the legend of page 92). The 95% Cl is the 
95% confidence interval for the relative risk. Relative risk, and its confidence limits, are 
given only for those variables predictive of outcome.
If, for oestrogen receptor positive cases, overall survival was analysed, 
EGFr-c remained a significant predictor of outcome: p=0.0006, relative risk, 71.7, 
95% Cl, 6.2-825.7. Nodal status lost its predictive power with T stage replacing it: 
p=0.0019; relative risk 2.7, 95% Cl, 1.4-5.0.
For oestrogen receptor positive tumours, exclusion of the EGFr-c categorisation 
did not make any other EGF receptor categorisation predictive of either survival 
or disease free survival. In a similar analysis of oestrogen receptor negative cases, 
nodal status remained the only factor that predicted outcome: p=0.0512; relative 
risk 2.0, 95% Cl, 1.0-3.9
Exclusion analyses - nodal status
It is currently accepted practice to establish axillary nodal involvement by 
sampling or clearance. This has not always been the case and it has been 
suggested that the features of the primary are paramount in determining prognosis 
(Harris 1989). This, and the present trend toward more conservative surgery, 
prompted an analysis o f the data excluding data on lymph node involvement. This 
analysis is presented in table 8.9
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Table 8.9: Cox regression analysis of d isease specific survival - excluding node status 
Breast cancer related deaths (133 ca ses  with 55 events)
Variable ER status T stage Grade EGFr-2 EGFr-3 EGFr-4 EGFr-c
p-value <0.00005 0.0158 0.4917 0.5397 0.4780 0.2848 0.2414
relative risk 4.6 1 . 7 -
95% Cl 2.7-9.0 1.1-2.6 - - - - -
Table 8.10: Cox regression analysis of d isease free survival - excluding node status 
D isease free survival (135 ca ses  with 65 events)
Variable ER status T stage Grade EGFr-2 EGFr-3 EGFr-4 EGFr-c
p-value <0.00005 0.0013 0.4226 0.9925 0.9897 0.9527 0.2642
relative risk 3.3 1.9 -
95% Cl 2.0-5.5 1.3-2.8 - - - - -
In both tables, the relative risk is the increased risk for each unit increase in that variable 
(defined in the legend of page 92). The 95% Cl is the 95% confidence interval for the 
relative risk. Relative risk, and its confidence limits, are given only for those variables 
predictive of outcome.
If all deaths were considered, the same factors were predictive o f survival: ER 
status, p<0.00005, relative risk, 4.1, 95% Cl, 2.5-7.0; T stage, p=0.0070, relative 
risk, 1.7, 95% Cl, 1.2-2.5.
Exclusion analyses - oestrogen receptor status
In our series ER status is the most powerful predictor of outcome. This, and the 
very strong inverse correlation between ER status and EGF receptor levels, made 
it unlikely that any categorisation of EGF receptor would be significant in an 
analysis that included ER status. Presented in tables 8.11 and 8.12 are the results 
o f outcome analysis excluding data on ER status.
Table 8.11: Cox regression analysis of d isease specific survival - excluding ER status 
Breast cancer related deaths (158 ca ses  with 68 events)
Variable node status T stage Grade EGFr-2 EGFr-3 EGFr-4
p-value <0.00005 0.0277 0.0020 0.4926 0.1953 0.1627
relative risk 3.3 1.5 1.8 - - -
95% Cl 1.9-5.7 1.0-2.1 1.2-2.7 - _ -
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Table 8.12: Cox regression analysis of d isease free survival - excluding ER status 
D isease free survival (161 ca ses  with 80 events)
Variable node status T stage Grade EGFr-2 EGFr-3 EGFr-4 EGFr-c
p-value 0.0001 0.0022 0.0060 0.5903 0.4169 0.3691 0.4982
relative risk 2.7 1.7 1.7
95% Cl 1.7-4.4 1.2-2.3 1.2-2.4 -
In both tables, the relative risk is the increased risk for each unit increase in that variable 
(defined in the legend of pqge 91). The 95% Cl is the 95% confidence interval for the 
relative risk. Relative risk, and its confidence limits, are given only for those variables 
predictive of outcome.
If overall survival was considered, these three factors remained predictive and 
EGFr-c also became predictive: Nodal status, p=0.0002, relative risk, 2.4, 
95% Cl, 1.5-3.9; T stage, p=0.0043, relative risk, 1.6, 95% Cl, 1.2-2.2; Grade, 
p=0.0039, relative risk, 1.7, 95% Cl, 1.2-2.4; EGFr-c, p=0.0314, relative risk, 1.4, 
95% Cl, 1.0-1.9.
As before if the EGFr-c categorisation was excluded then no other EGF receptor 
categorisation became predictive.
Analysing fo r  EGF receptor
The aims of this thesis relate to the expression of EGF receptor, therefore some 
analyses were performed to assess if this variable had a value in predicting 
outcome. Cox regression analyses were repeated withdrawing the most significant 
variable at each step. For disease specific survival, oestrogen receptor status and 
then nodal status had to be excluded before EGF receptor expression became a 
significant predictor of outcome. Even then T stage and grade were o f greater 
significance. The first categorisation of EGF receptor expression to gain 
significance was EGFr-c, but if  excluded it was replaced by EGFr-4. In an 
analysis of overall survival EGFr-c was again the first EGF receptor categorisation 
to gain significance, but only required exclusion of oestrogen receptor status. 
However, nodal status, T stage and grade were all of greater significance.
For disease free survival the picture was similar. Oestrogen receptor status, nodal 
status and T stage all had to be excluded before EGF receptor (EGFr-4) expression 
gained significance. Even then grade had greater significance.
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Considering only the categories of EGF receptor expression, the following results 
were obtained. For disease specific survival, EGFr-3 and EGFr-c were predictive: 
p=0.0210, relative risk, 1.4, 95% Cl, 1.1-1.9; p=0.0583, relative risk 1.3, 95% Cl, 
1.0-1.8. For death from all causes, only EGFr-4 predicted outcome: p=0.0011, 
relative risk, 1.4, 95% Cl, 1.1-1.6 and for disease free survival it remained the 
only predictive variable: p=0.0019, relative risk 1.4, 95% Cl, 1.1-1.6.
Multivariate analysis for local recurrence was not performed as no EGF receptor 
grouping predicted local recurrence in univariate analyses.
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Chapter 9: 
Discussion; outcome and clinical parameters
Section i: Relationship to prognostic indicators
Our radioimmunohistochemical results largely corroborate reports in the literature 
(reviewed in Chapter 2, section ii).
♦ There was a strong inverse correlation between EGF receptor and oestrogen 
receptor expression.
♦ Poorer histological grade was associated with higher levels o f receptor 
expression.
♦ EGF receptor expression was not associated with T stage.
♦ Receptor levels did not correlate with the presence of nodal metastasis.
Much conjecture surrounds the relationship between nodal involvement and 
receptor expression. In our study, lymph node metastases were not analysed and 
comment on this aspect of the relationship was not possible. Analysis of all 
tumours for which nodal status was available hinted at a possible association 
(p=0.074), but this statistic may have been compromised by nodal data for 
tumours with few or even just one (n = ll)  sampled node. For this reason, a sub­
analysis of tumours with 4 or more sampled nodes was undertaken. The choice of 
four nodes was not accidental; this number provide similar prognostic information 
to axillary clearance (Steele 1985), and also allowed categorisation into distinct 
prognostic groups (Miller 1994). However, this sub-analysis simply confirmed 
that there was no statistically significant association between nodal status and 
EGF receptor expression.
It appeared, then, that the improved accuracy of radioimmunohistochemistry, 
compared to conventional techniques, was not advantageous. However, because it 
provided accurate receptor measurement and did not simply dichotomise tumours 
to receptor positive or negative, it was possible to perform some further analyses.
EGF receptor is known to mediate a mitogenic signal (Stoscheck 1986, 
Hamburger 1981, Singletary 1987) and it might seem reasonable that tumour size 
should correlate with EGF receptor expression. Such a relationship was found 
when tumour size was analysed in millimetres (Spearman rank analysis, p=0.049). 
A similar finding has been reported (Sainsbury 1987), but using a categorisation 
of tumour size that was not justified (<15, 16-35, 36-50 and >50mm). 
Additionally the relationship was reported in terms of EGF receptor positivity 
rates rather than actual levels of receptor. Using radioimmunohistochemistry a
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more precise analysis was possible. Although statistically significant, the 
relationship was not strong (Fig. 8.1). This may be because cellular proliferation is 
influenced by a number o f factors and tumour size will reflect a balance between 
proliferation and cell loss.
The precision of radioimmunohistochemistry also allowed assessment o f the 
relationship between oestrogen receptor levels and EGF receptor content. By 
consensus there is an inverse relationship between these receptors, however, this is 
based on a categorisation of expression of both receptors as positive or negative. 
Less is known of their relative levels of expression. Koenders et al (1991) 
reported that EGF receptor levels were higher in oestrogen receptor negative 
tumours than their positive counterparts. Nicholson et al (1994), graded 
immunohistochemical measurement o f both receptors as none, low or high, and 
presented data suggesting that receptor levels might be inversely correlated. 
Radioimmunohistochemistry enabled this inverse correlation to be corroborated 
(Spearman rank analysis p=0.032). It is worthy o f mention that statistical 
significance, although weak (Fig. 8.2), was apparent only in tumours with 
oestrogen receptor content measured using immunohistochemistry. Possibly some 
o f the frailties of the EGF receptor ligand binding technique also applied to the 
ligand protocol used to measure oestrogen receptor.
This inverse relationship is at odds with the suggestion that no phenotype with 
positivity for both receptors exists (Sharma 1994). Nicholson's group (1994) 
identified a number of tumours that appeared to have this phenotype but suggested 
that this resulted from clonal mixing of tumour cells positive for one receptor but 
negative for the other. Despite this they identified 4 patients in whom endocrine 
therapy induced complete remissions of tumours 'positive' for both receptors. This 
they interpreted as indicating either that oestrogen receptor negative, EGF receptor 
positive cells could respond to endocrine therapy, or that this clone could reverse 
to an oestrogen receptor positive one. Our results suggested that receptor 
expression within a tumour was interdependent. If correct, this infers that tumour 
cells can express both receptors, and also that modulation of expression of one 
could alter expression of the other. This balance of expression may offer a 
therapeutic target and is worthy of further study.
Section ii: Adjuvant therapy
Prescription of adjuvant therapy reflected the prevailing clinical practice of the 
time. Younger patients (pre-menopausal) tended to be prescribed adjuvant
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chemotherapy whilst older patients (post-menopausal) received tamoxifen. Direct 
comparison of chemotherapy versus non chemotherapy groups, and tamoxifen 
with non-tamoxifen groups, was difficult. This was because of the factors that 
influenced the prescription of these medications. Further, statistical analysis was 
hindered by the fact that cohorts defined by these treatments were very 
disproportionate. For these reasons no further analysis was attempted.
Analysis o f the prescription of radiotherapy posed similar problems. During the 
study period, 1984 to 1993, prescribing practice changed considerably. Improved 
radiotherapy techniques resulted in increasing numbers of patients being referred, 
particularly after wide local excision, a form of therapy that became more 
prevalent as the study progressed. The changing approach to the axilla also 
influenced prescription. Following axillary node sampling those with nodal 
disease tended to be referred for radiotherapy, but as more axillas were cleared the 
rate of referral declined, chiefly due to the fear that this treatment combination 
might induce lymphoedema. This variation in clinical practice, together with some 
difficulty in determining retrospectively if radiotherapy had been to axilla or chest 
wall, made more detailed statistical analysis inappropriate.
Section iii: Outcome
Collecting data, and particularly outcome data, in a retrospective fashion is 
notoriously hazardous. To minimise errors the data were collected by two 
investigators independently and discrepancies were checked. Compounding this 
technical difficulty is the clinical problem of determining recurrence, particularly 
distal but also local. The follow-up surveillance program (mammography, chest 
x-ray, Pelvic x-ray and liver function tests) was not adhered to religiously, partly 
as its sensitivity was poor. Additionally, patients were often elderly with 
significant co-morbidity, and the diagnosis of asymptomatic recurrence was 
unlikely to significantly modify their management. Not surprisingly, then, in 
many patients who died breast cancer related deaths, distal metastases had not 
been diagnosed or were identified only in the terminal phase of illness. Death, 
because of its unequivocal nature, was, therefore, the most reliable endpoint. In 
this regard, our study benefited from the confirmed accuracy o f the Scottish 
Cancer Registry (Brewster 1994).
Using the ICD codes deaths were dichotomised to those breast cancer related and 
those of other causes. Separating deaths in this manner can lead to difficulties
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since it may be difficult to attribute a particular death to the diagnosis o f breast 
cancer. For example, one patient died in a house fire, the cancer deaths registry 
did not record breast cancer as a possible cause. However, although an extreme 
example, it is possible this patient had cerebral metastases and succumbed to 
these, thereby allowing the fire to escape control. For this reason all deaths, as 
well as those directly attributed to breast cancer, were considered in the statistical 
analyses.
a) Characterising the database
Univariate analyses of conventional prognostic indicators were performed to 
confirm that our patient cohort was representative o f breast cancer in general. 
Both T-stage and histological grade predicted a similar outcome, in our patients, 
to that observed by others (reviewed by Miller et al 1994). Nodal metastases, 
studied as involvement and as numbers of nodes involved, also produced very 
similar results. Overall, our patients had a slightly poorer prognosis but this may 
have related to social deprivation (Schrijvers 1995); the catchment area for 
Glasgow Royal Infirmary was relatively poor. The only routine prognostic factor 
which differed to any degree from those in Miller's review was oestrogen receptor. 
Our patients that were oestrogen receptor positive had a 5 year survival o f greater 
than 80% (as opposed to less than 75%), and our receptor negative patients had an 
approximately 30% survival (as opposed to 55%).
Multivariate analysis of our data revealed 3 predictors of survival and disease free 
survival. In descending order of significance, these were oestrogen receptor status, 
nodal status and T stage. Alderson et al (1971) had found the most important 
factors influencing prognosis, in decreasing order of significance, were, lymph 
node status, tumour size, stromal reaction and histological grade. Haybittle et al 
(1982) also found lymph node status, histological grade and tumour size 
predictive. This raises the possibility that our patients are not representative of the 
general experience of this disease. However, exclusion of oestrogen receptor data 
made nodal status strongest predictor of outcome and introduced grade as a third 
predictive parameter. Interestingly, Haybittle (1982) had found the converse, 
reporting that oestrogen receptor status 'strongly correlated with tumour grade' 
and, therefore, inclusion of grade had reduced the value of oestrogen receptor data 
in their multivariate analysis..
The Nottingham prognostic index (Haybittle 1982) and the Yorkshire Breast 
Cancer Group index make use of a combination o f nodal involvement, histological
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grade and tumour size, weighting their prognostic value in that order. The 
Nottingham prognostic index has been validated (Todd 1987, Balslev 1994) and 
can be used to identify good, moderate and poor prognosis groups. In Table 9.1 
the Nottingham data (taken from Todd 1987) are compared to our own.
Table 9.1: Comparison of our patients with those from the Nottingham studies.
% of patient population in each category
Nodes involved A B C
Nottingham 55 28 17
Our series 49 27 24
Histological grade 1 2 3
Nottingham 18 39 43
Our series 13 38 49
Tumour size (mm) <21 21-50 >50
Nottingham 49 43 8
Our series 38 49 13
Survival (5 year) good moderate poor
Nottingham 88 69 22
Our series 84 69 21
The Nottingham group a ssessed  nodal involvement using a three node biopsy technique; 
no nodal involvement (A), involvement of a low axillary node (B) and apical or superior 
internal mammary node involvement (C). This technique was not employed in our practice 
and nodes were classified as no nodes involved (A), 1-3 nodes (B) and more than 3 nodes 
(C) involved (Nodal d isease was classified in this way by Balslev 
et al 1994). Modified Bloom and Richardson score (Elston 1991) was used for histological 
grade. The survival analysis were performed using the Nottingham prognostic index which 
defines 3 prognostic groups, good, moderate and poor. Kaplan-meier analysis was used to 
determine five year survival (Kaplan-Meier statistic 49.47, d.f. 2, p<0.00005).
In summary, there is a good level of accord. This is true not just of the profile of 
prognostic factors but also of the survival analysis. The implication is that our 
patients are reasonably representative of the general experience o f breast cancer. 
For our studies of EGF receptor, this is reassuring.
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Why, then, does oestrogen receptor status assume such predictive power in our 
study? Could our oestrogen receptor data be unusual? In most reports oestrogen 
receptor positivity rates vary between 50 and 80% (Osborne 1998), in our series it 
was 56%. Further, of 151 tumours in which this receptor was measured, two 
different techniques were used for 70 with accord for all but 3 (96%). This implies 
our data are robust. It has been suggested, as with EGF receptor, that the reported 
variation of the prognostic value of oestrogen receptor expression may be due to 
variation in the method of its measurement and the 'cut-off used to define receptor 
positivity (Osborne 1998). In the Nottingham series, oestrogen receptor was 
measured using a dextran coated charcoal method with a cut-off o f 5fmol/mg 
(Haybittle 1982), compared to our cut-off of 20fmol/mg. It has also been 
suggested that the prognostic value of oestrogen receptor status reduces with 
duration of follow-up (reviewed in Osborne 1998, Fox 1994). The hypothesis 
being that it influences the rate o f tumour growth but does not correlate to 
metastatic potential and, therefore, does not determine long term survival. 
Fox et al found oestrogen receptor expression lost its predictive power between 5 
and 10 years of follow-up. Median duration o f follow-up in our study was 
approximately 4.5years. Finally, ours is not an entirely unprecedented finding, in a 
multivariate analysis including lymph node status, tumour size, histological grade, 
oestrogen receptor status and EGF receptor status, Fox et al found only lymph 
node status and oestrogen receptor status predictive o f relapse free survival 
(1994).
b) Univariate (Kaplain-Meier) analyses
It was our hope that the accuracy of radioimmunohistochemistry would clarify the 
controversy over the relationship between receptor expression and outcome. In 
Klijn's review (1992), mean receptor positivity using conventional 
immunohistochemistry was approximately 42% and with radio-ligand methods 
was 45%, therefore, splitting the continuum of radioimmunohistochemical results 
about their median effectively mirrored these techniques. Doing so revealed that 
EGF receptor expression did predict outcome if death from all causes was the 
outcome measure, but failed to do so if only breast cancer related deaths were 
considered. Similar incongruities had been demonstrated in Fox's review (1994), 
with univariate analysis predictive in 10 of 16 studies. Therefore, despite the 
greater accuracy of receptor measurement in our study, this analysis of our results 
only fuelled the controversy.
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Conventional measurement techniques designate tumours as receptor positive or 
negative. However, the radioimmunohistochemical method made it possible to 
reliably apportion tumours to narrow bands of receptor expression. Dividing the 
tumours into 3 and 4 groups increased the power of the univariate analysis. 
Perusal o f the survival curves (Figure 8 .8 ) revealed two features:
1 . that further divisions more clearly defined a poor risk group, and
2 . that survival curves for all but the poorest risk group overlapped.
It was tempting to speculate that the first observation was due to inclusion, in the 
poorest risk group, of a relatively greater proportion of tumours with amplification 
o f the gene coding EGF receptor. However, amplification rates are very low 
(Slamon 1987) and only 5 tumours expressed more receptor than normal breast in 
our study. The statistical impact of so few tumours, in groups of approximately 50 
to 1 0 0 , was unlikely to be large.
The simplest explanation of the overlaps was that EGF receptor levels were poorly 
predictive of survival, but this ignored the statistical significance o f the analysis, 
and in particular the clear relationship between higher receptor levels and poor 
outcome. Various explanations were considered, most rational of which may be 
that small study size had obscured the true relationship.
It was, however, possible that the overlaps were true findings. If this was the case, 
then moderate levels of receptor expression conferred an initial survival
advantage. Could this be a 'time-lag' effect? Also, from the analysis of 4 groups, 
moderate expressing tumours dichotomised to high expressing good risk and low 
expressing poor risk tumours. We have demonstrated that, in most breast cancers, 
expression of EGF receptor and Q-erbB-2 encoded receptor is interdependent 
(Robertson 1996). Could these observations reflect receptor interdependency - 
possibly with EGF receptor a less dominant predictor of outcome than other 
linked factors? Unfortunately, with the available data, no satisfactory explanation 
was discernible. Additionally, considering moderately expressing tumours as a 
separate entity, either temporally or geneotypically, could not be justified on the 
basis of our data. This group were not distinct in the histogram of EGF receptor 
expression, nor in terms of their association with other prognostic factors.
For disease free survival, there was also an increase in statistical power as the 
tumours were divided into more groups. Further, the disease free survival curves 
(Figure 8.9) followed the same overlapping pattern. This was not surprising. O f 
the 99 patients with disease recurrence, 81 were included in the analysis of
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survival and many of the distal recurrences were diagnosed near, or at, the time of 
death. We might have expected this since disease recurrence, even local (Whelan 
1994), is often a harbinger of death. However, our findings were not borne out in 
the literature. In the reviews of Klijn (1992) and Fox (1994) there was no report 
that determined an association between EGF receptor expression and survival that 
did not also find a similar significant relationship to disease free survival. The 
converse was not true. Fox's, review (1994), larger and more recent, included 16 
studies, 10 reported a relationship with disease free survival but only 3 with 
overall survival. In these studies, follow-up varied not only in duration but also in 
the manner in which it was reported; mean, median, maximum, and minimum. 
These studies were, therefore, difficult to compare, but, assuming the disease in 
each to be similar, an estimate of the study power could be made from duration of 
follow-up and study size. In the table below an attempt is made to compare those 
studies that reported a predictive value for EGF receptor, using univariate 
analysis, that also provided a mean or median follow-up. Our own study (Rihc) is 
included for comparison.
follow-up (t) patients (n) t x n
Predicting DFS only
Costa 1988 median 12 376 4512
Toi 1991 median 31 135 4185
Osaki 1992 median 32 115 3680
Spyratos 1990 mean 60 109 6540
Gasparini 1992 mean 36 164 5904
Predicting Survival & DFS
Nicholson 1991 median 45 231 10395
Koenders 1993 mean 24 376 9024
Rihc median 55 194 10670
Rihc mean 54 194 10476
Table 9.2 : Studies reporting a predictive value for EGF receptor using univariate analysis. 
The first column indicates those studies (first author and year of publication) that predicted 
d isease free survival (DFS) or survival and d isease free survival. Rihc indicates our 
radioimmunohistochemical study. Follow-up (f) is given in months.
The table shows that a relationship to survival was identified in larger studies with 
a longer follow-up (greater t x n). Fox did not report this observation, but it might
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be expected. Recurrence most frequently occurs in years immediately following 
primary resection (Karabali-Dalamaga 1978, Willner 1997), however, the time 
from its diagnosis to death may be protracted (McArdle 1990). This may account 
for the preponderance of reports of a relationship to disease free survival but not 
to survival itself. With almost 200 cases and a median follow-up of more than 
4.5years, this was not a problem in our study.
On review of the literature, summarised in Chapter 2, no report was found o f EGF 
receptor specifically predicting local recurrence. Although the life tables, in our 
series, suggested a trend to more frequent local recurrence with higher levels of 
receptor, none of the statistical analyses was significant. This may reflect the 
relatively low incidence of this endpoint (48 cases) and a larger study might reveal 
an association.
In summary, EGF receptor estimation by radioimmunohistochemistry was a 
significant predictor of survival and disease free survival using univariate analysis. 
The next goal was to determine if it could predict outcome in a multivariate 
analysis, and thereby provide an advantage in the clinic.
c) Multivariate (Cox regression) analyses
In multivariate analysis that included oestrogen receptor status, lymph node status, 
histological grade, tumour size (TNM) and EGF receptor expression, no 
categorisation of EGF receptor levels was significant.
Conventional prognostic indicators, particularly nodal status, are used to 
determine adjuvant therapy. Identification of high or low risk groups within these 
conventional subgroupings could be useful when planing treatment. For this 
reason our data were analysed in subgroups. Published reports of such analyses 
(reviewed in Chapter 2 section iii) have been contradictory. This is particularly the 
case for sub-analyses based on oestrogen receptor status, but less so for lymph 
node negative disease, where EGF receptor may have a predictive value 
(Sainsbury 1987, Nicholson 1990, Spyratos 1990, Fox 1994). In our series, EGF 
receptor expression failed to determine outcome in either node negative or 
positive subgroups. A similar analysis of oestrogen receptor positive, and 
negative, disease showed that only in the former did EGFr-c have predictive 
power. Clinically this categorisation was not very useful since 97% of tumours, 
those expressing less than normal breast levels of EGF receptor, were classified 
together.
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Therefore, if  routine prognostic indicators were available, EGF receptor 
measurement provided no clinical advantage. However, Harris et al (1989) had 
pointed out that nodal information was not always available. In our study, 
exclusion of lymph node status did not make EGF receptor predictive. Although 
more difficult to justify, a similar analysis was performed excluding oestrogen 
receptor status. Radioimmunohistochemistry had revealed a strong inverse 
relationship between oestrogen receptor status and EGF receptor expression, it 
was, therefore, unlikely that both factors would be significant in a multivariate 
analysis. Without oestrogen receptor data, EGF receptor predicted deaths from all 
causes but not breast cancer related death or disease free survival. Only the 
EGFr-c categorisation was predictive but was less so than nodal status, T stage 
and grade. As indicated above this categorisation o f EGF receptor has little 
clinical value. If not included in the analysis then no other EGF receptor 
categorisation replaced it. Overall, EGF receptor expression was the least 
significant predictor of outcome in our multivariate analysis.
In summary, radioimmunohistochemical measurement of EGF receptor did not 
provide useful prognostic information using a multivariate analysis that included 
routine prognostic factors.
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PART 3
EGF RECEPTOR 
AND
BREAST CANCER CELL INVASION
Overview of invasion studies
This second experimental part o f the thesis takes cognisance of the documented 
influence o f EGF receptor on breast cancer prognosis and explores the possibility 
that this relates to an effect on tumour cell invasion.
The assay used for these invasion studies had not previously been reported and the 
first subsection (Chapter 10) documents the problems overcome in its 
development and provides evidence o f its reproducibility. The second subsection 
(Chapter 11) includes the results of the invasion studies for the different breast cell 
lines. It also includes experiments that confirm that invasion is EGF receptor 
mediated. Finally, efforts were made to abrogate the invasive response using 
agents with therapeutic potential.
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Chapter 10: 
Developing the invasion assay
Section i: Available tissues
Since the intention of this work was to try and ascertain the role o f EGF receptor 
in human breast cancer, cell lines established from human breast cancers were 
studied. These were; MCF7, ZR75.1, SKBR3, MDA-MB-361, MDA-MB-453, 
MDA-MB-231, BT20, MCF7ADR (see Table 10.1). All the lines were available 
locally (Institute for Cancer Research at the Cancer Research Campaigns Beatson 
laboratories, Garscube Estate, Glasgow) and, with the exception of MCF7ADR, 
were available from the American Type Culture Collection (ATCC). The 
MCF7ADR cell line was produced by culture of MCF7 cells with increasing 
amounts of Adriamycin (Vickers 1988). The passage number of the cell lines was 
not available but was likely to be high.
Cells were maintained in culture medium, Dulbeccos Modified Eagle's Medium 
(DMEM) or RPMI 1640 (RPMI), composition shown below. The 
MDA-MB-361, MDA-MB-453 and BT 474 lines were maintained in DMEM. The 
remaining lines were grown in RPMI. Both media were supplemented with 10% 
foetal bovine serum and the cells were cultured in 95% air, 5% CO2  at 
37°C. Flasks were grown to sub-confluence and cells were then split using a 
trypsin solution. In this manner the cell lines were maintained until completion of 
the experimental work.
Section ii: Materials
Growth factor reduced Matrigel® (Collaborative Research, Becton Dickinson) is a 
soluble basement membrane extract of the Engelbreth-Holm-Swarm tumour, it is 
liquid at -20°C but solidifies at room temperature (Kleinman 1986). The main 
components of Matrigel are laminin, collagen IV, entactin and heparan sulfate 
proteoglycan (Kleinman 1982, Bissel 1987). Growth factor reduced Matrigel®, as 
its name implies, has reduced concentrations of growth factors compared to 
Matrigel® (see Table 10.3). Since these include EGF, it was used for the 
experiments presented below and is referred to hereafter as Matrigel. Matrigel 
matrix has been used extensively as an in-vitro barrier to study the metastatic 
potential of tumour cells (Taniguchi 1989, Terranova 1986, Albini 1987, 
Hendrix 1987).
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Table 10.1: Characteristics of the studied cell lines.
Cell line Origin Morphology in-vitro
BT20 Primary Typical adenocarcinoma
BT474 Primary Epithelial, multi-layered colonies
MCF7 Pleural effusion Epithelial like
MCF7ADR Pleural effusion Epithelial like
ZR75.1 Ascitic effusion Adenocarcinoma
MDA-MB-231 Pleural effusion Anaplastic adenocarcinoma
MDA-MB-361 Brain metastasis Epithelial like
MDA-MB-453 Pleural / pericardial effusion Epithelial like patches, single spheres
SKBR3 Pleural effusion Adenocarcinoma
3T3* Mouse embryo Fibroblast-like
* This cell line was used to produce fibroblast conditioned medium for use as a 
chemoattractant.
Table 10.2: Composition of the tissue culture media
DMEM
Sterile water 800ml
DMEM (x10 conc.) 100ml
RPMI (x10 conc.)
Foetal calf serum 100ml
Glutamine (200mM) 10ml
Pyruvate (100mM) 10ml
Sodium Bicarbonate (8.4%) 40ml
Hepes Buffer (1M)
Sodium Hydroxide (1M) 8ml
Steptomycin / Penicillin 10ml
RPMI
800ml
100ml
100ml
10ml
10ml
40ml
20ml
10ml
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Table 10.3: Composition of reduced growth factor Matrigel
Constituent Growth factor reduced Matrigel 
<0.5EGF (ng/ml) 
bFGF (pg/ml) 
IGF-1 (ng/ml) 
PDGF (pg/ml) 
TGF-p (ng/ml)
0- 0.1
< 0.2
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% protein that gels 83
Costar's Transwell™ cell culture chamber inserts were used as assay chambers
(Catalogue No. 3422, Costar Europe Ltd.) (see Figure 10.1). Sterile 24 well 
cluster plates were supplied with 12 inserts. These inserts have a polycarbonate 
membrane base which is suspended above the well floor by a flange at the top o f 
the insert. The polycarbonate base is 6.5mm in diameter and has pores o f 8 pm 
diameter, this is referred to hereafter as the filter. The remainder o f the 
construction is transparent polystyrene. The lower part o f the wall o f the insert is 
non-porous; thus the filter separates a 300pl upper compartment (within the insert) 
from a lower lOOOpl compartment (the well). Air can circulate from the insert to 
the well via holes in the upper part of the insert.
(8pm pores]
Figure 10.1: Schematic cross section of a Costar Transwell cell culture chamber 
Section iii: Establishing the Invasion assay
The invasion assay used in this series of experiments was a modification of an 
assay which had been developed under guidance from Dr. Bradford Ozanne 
(Hennigan 1994). This assay differed from those previously reported, in that;
1. it utilised a thick layer of Matrigel,
2. assay analysis was performed on an intact 3-dimensional Matrigel layer.
insert 
y r  (300pl capacity)
well
(1 OOOpI capacity)Filter ^
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A full description of the assay protocol, as used for these breast cell line studies, is 
provided at the end of this chapter, but to facilitate understanding of the 
experiments that led to this protocol, a brief description of the original, as 
described by Hennigan (1994), is given here. Matrigel was added to the Costar 
Transwell inserts and allowed to gel. The inserts were then inverted and a 
suspension of the cells under study was added to the filter base. The gelled 
Matrigel did not slip out of the insert and the cells applied to the filter bottom 
adhered to it. The inserts were then inverted again, returning them to their original 
orientation, and were placed in the Costar Transwell wells, to which had been 
added culture medium. Chemoattractant in culture medium was then added above 
the Matrigel layer. After incubation, the assay was fixed using ice cold acetone, 
cells were stained with propidium iodide, and the assay was read using the 
confocal microscope.
The original assay protocol was developed to assess the invasive capacity of fo s  
transformed fibroblasts and required considerable modification before it could be 
applied to the breast cancer cell lines under study in this work. This chapter 
reviews some of the experimental work which led to the final invasion assay 
protocol. What follows is a description of the experiments that justified these 
modifications and the problems that these overcame. Some assays were repeated 
when protocol modifications were introduced, others were not. Many of the assays 
addressed more than one issue and some were used to corroborate other results. 
Some results in this section may seem contradictory but this reflects the changing 
protocol. The series of assays presented in Chapter 11 were all performed using 
the final assay protocol. The experimental results used to produce the plots in 
chapters 10 and 11 are contained in Appendix 3, results for any particular 
experiment are in tables named after the plots they were used to produce.
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a) Problem - would EGF stimulate invasion in this assay?
The aim of the initial experiments was to determine if  the assay system could be 
used to study an invasive response stimulated by EGF.
Experiments
A variety o f chemoattractants were added to the upper chamber o f the assay 
system. The results of these first experiments are summarised in the plot below.
go-|
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Figure 10.2: Invasion using different chemoattractants
This plot shows the results for the MDA-MB-231 cell line. Each of the lines represents a 
separate assay. The y-axis shows invasion expressed a s the sum of the percentage 
fluorescing pixels in each of six optical sections. Readings were taken in 5pm steps, from 
the optical section judged to be at the level of the filter, for 25pm (6 optical sections). The 
x-axis shows the chemoattractant placed above the Matrigel layer. Culture medium with 
1% foetal calf serum was used as a control (1% S). The chemoattractants were; culture 
medium augmented with 20ng Epidermal Growth Factor (EGF), 1ng Transforming Growth 
Factor-peta (TGF), 10ng acidic Fibroblast Growth Factor (FGF), 10% foetal calf serum 
(10% S) and fibroblast conditioned medium (CM).
Whilst the plots for each assay followed similar profiles the magnitude o f invasion 
varied. This is a problem which is addressed later in this section.
These data suggested that addition of EGF above the filter stimulated cells to 
invade into the Matrigel layer (Figure 10.2). A similar effect was suggested for 
TGF and fibroblast conditioned medium. The results for both 10% foetal calf 
serum and acidic fibroblast growth factor were more difficult to interpret.
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Figure 10.3: Using 1% foetal calf serum and 20ng EGF a s  chemoattractant.
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The x-axis shows the chemoattractant placed above the Matrigel layer; 1% foetal calf 
serum (1%S) and 1% foetal calf serum augmented with 20ng EGF (EGF). On the y-axis is 
invasion. This is shown as the mean and interquartile range of the sum of the fluorescing 
pixels, from the 4 experiments plotted above. Analysis of variance gives a p value of 
0.067.
The results of Analysis of Variance for each of the tested chemoattractants versus 
1%S (designated the control) are shown below.
nt n mean St. Dev. P
1% S 4 15.62 11.77 -
EGF 4 40.55 18.95 0.067
TGF 4 27.67 14.29 0.241
FGF 4 23.05 19.98 0.546
10% S 4 29.62 17.00 0.224
CM 4 22.23 18.21 0.565
Conclusions
The initial experiments suggested that EGF might stimulate breast tumour cell 
invasion. It is true that a similar effect with the other chemoattractants could not 
be excluded on the basis of the data presented; only one concentration of each 
chemoattractant was used (albeit a concentration chosen after careful 
consideration and perusal of the literature). However, the chief interest o f the 
investigator was the role of the EGF receptor and the cost, both in time and 
materials, o f pursuing experiments with other chemoattractants, in an assay 
system that was still not proven, was considered unjustifiable.
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b) Problem - what control to use?
Without some foetal calf serum there was concern that cells might not survive 
over the incubation period (7 days), but foetal calf serum contains a variety of 
factors which could influence the assay. Parish et al (1992) reported that exclusion 
of foetal calf serum from the assay did not significantly alter the invasion o f rat 
mammary carcinoma cell line 13762 MAT. They interpreted this to mean that 
foetal calf serum did not contain enzymes that had a role in basement membrane 
degradation. However, Imamura et al (1991) found that without serum supplement 
there was marked reduction of invasiveness of both rat hepatoma cell line, 
AH130, and human small cell lung cancer line, OCIO.
Experiments
A range o f different serum concentrations were studied to ascertain the optimal 
concentration for the final assay protocol (see Figure 10.4).
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Figure 10.4: Determining a control for the invasion assays
Results shown are for the MDA-MB-231 cell line. Data is depicted as the mean and 
interquartile range. Invasion, plotted on the y-axis, is shown as the mean and interquartile 
range of five readings from each of two assays. Only the percentage fluorescing pixels in 
the optical section at the level of the filter was determined. Shown on the x-axis is the 
medium used for the assay; culture medium with no foetal calf serum (0), culture medium 
with 1% foetal calf serum (1 %s), culture medium with 10% foetal calf serum (10%s), 
culture medium with 1% foetal calf serum and 20ng EGF added above the Matrigel (EGF- 
1%s), culture medium with 10% foetal calf serum and 20ng EGF added above the 
Matrigel (EGF-10%s).
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Though cells in the Matrigel layer are difficult to assess using light microscopy, 
those that fall from the filter base into the lower assay chamber can be studied. 
These cells were poorly viable at the end o f incubation if  no serum supplement 
was used. Using medium augmented with 1% foetal calf serum, cells remained 
viable and invasion was minimal in the absence o f EGF.
Conclusion
Culture medium with 1% foetal calf serum was used as a control.
It is worth reiterating that the experiments used to establish the assay protocol 
were not always analysed in the same manner - reflecting the development of the 
assay protocol. Additionally, the experiments are not presented in strict 
chronological order. This has resulted in variation in the manner o f data 
presentation. On this occasion, invasion is recorded as fluorescence at the level of 
the filter alone (preceding figures showed invasion as the sum of fluorescence in a 
stack o f optical sections). To minimise confusion, each plot is accompanied with a 
comprehensive description o f what is presented.
c) Problem - which cell lines could be studied?
The next experiments were to determine which cell lines would be suitable for 
study using this assay. Results are summarised in Table 10.4. The recorded results 
are o f the best invasive response to EGF. Morphology refers to appearance of cells 
in the assay wells, viewed with conventional light microscopy prior to fixation, 
and cells in the inserts, viewed post fixation, with fluorescent light 
microscopy/confocal microscopy.
Conclusion
It was evident that some cell lines would not cross the filter using this assay 
system and others would only cross the filter but did not seem to invade into the 
Matrigel layer. However, there were no cell lines that crossed the filter in response 
to a chemoattractant other than EGF that did not also respond to EGF. This 
observation is open to the criticism voiced above; that a failure to respond to a 
single concentration o f chemoattractant does not exclude a response at different 
concentrations. However, as before, the aim of this work was to assess the EGF 
receptor and these early experiments did not suggest that these other 
chemoattractants were likely to induce invasion that could then be modulated by 
EGF binding of EGF receptor.
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Table 10.4: Characteristics of the cell lines studied in the invasion assay.
cell line morphology
MDA-MB-231 Cells, with pseudopods extending, were
seen  high in the Matrigel layer. Below 
the filter there was a confluent layer of 
cells.
MCF7ADR Cells grew in mounds but som e invasion
into the Matrigel was evident. Below 
the filter there was a confluent layer of 
cells.
BT20 Som e cells crossed the filter and som e
were apparent above the filter. Cells 
below the filter were subconfluent.
MDA-MB-361 Som e cells crossed the filter but there was
no convincing evidence of invasion 
into the Matrigel. Cells below the filter 
were subconfluent.
SKBR3 Few cells crossed the filter. Cells below the
filter were poorly subconfluent.
MDA-MB-453 No cells were above the filter. Mounds of
cells grew down below the filter.
ZR75.1 No cells were above the filter. Cells were
confluent on the underside of the filter 
BT474 No cells were above the filter. Mounds of
cells grew down below the filter.
MCF7 No cells were above the filter. Cells were
confluent on the underside of the filter.
Table 10.4 (continued): Characteristics of the cell lines studied in the invasion assay.
* Invasion increased from '+' t o '+++', no invasion is indicated by
Invasion*
+ + +
d) Problem - could invasion be increased using an altered assay orientation?
Unlike fibroblasts in the original studies, breast cancer cells invaded to a limited 
extent. If  a greater invasive response could be induced then this would be easier to 
study. The protocol required plating of tumour cells onto the bottom of the filter 
and Matrigel above it. The filter, so interposed, could itself be an obstruction to 
invasion. Experiments were, therefore, undertaken to try and modify the invasion
1 2 0
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assay in order to place a monolayer of study cells in direct contact with the 
Matrigel layer.
Experiments
Several approaches were adopted. Cells were plated onto the upper surface o f the 
filter and Matrigel was added above this layer. This proved unsatisfactory as even 
careful application o f the Matrigel resulted in cells becoming dislodged from the 
filter surface and trapped within it. Even allowing the cells to adhere to the filter 
overnight did not obviate this problem.
An alternative approach was to add cells above the Matrigel layer (with the 
chemoattractant in the assay well). This was unsuccessful as the cells failed to 
form a monolayer over the Matrigel but clumped together at the lowest point of 
the Matrigel meniscus. This may, in part, be due to gravity but there is also 
evidence to suggest that breast cells grown on Matrigel form lobuloalveolar-like 
aggregates (Streuli 1991, Darcy 1991).
In a further experiment, Matrigel was applied, and allowed to gel, to the underside 
of the filter with the study cells then added to the bottom of this layer. This also 
proved unsatisfactory as the cells seemed reluctant to adhere to the Matrigel and, 
when excess cell suspension was removed from the Matrigel coated filter bottom, 
the Matrigel was in danger o f becoming dislodged.
Finally, since it was possible that cells might occlude the filter pores (Parish 
1992), preventing, or reducing, invasion, filters with larger, 12pm, pores were 
tried. However, cell lines that failed to cross the 8 pm pores would not cross the 12 
pm pores, a finding in concordance with the reports o f others (Simon 1992).
Conclusion
The premises of these experiments had been:
1 . to induce an invasive response in the cell lines that would not cross the filter 
using the original assay protocol,
2 . to determine if removing the filter barrier would increase the invasive response 
in those cell lines that did cross the filter.
Neither objective was achieved and despite the paucity of cell lines that could be 
studied, the original assay orientation using filters with 8 pm pores was adopted 
for the remainder of the invasion studies.
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e) Problem -what was the significance o f  the EGF concentration gradient?
Since EGF is a relatively small molecule, 53 amino acids, and the assay was 
incubated for 7 days, it was probable that a concentration gradient existed for only 
a part of the total incubation time.
Experiments
To ascertain the significance of the concentration gradient a series of experiments 
was conducted comparing the effects of placing EGF in the upper and lower assay 
chambers. The results are shown in the Figure 10.5.
Figure 10.5: Determining the significance of the concentration gradient.
This boxplot shows the mean and interquartile range. Invasion, on the y-axis, is presented  
as the sum of the pixels above the filter (8 optical sections). The x-axis depicts the amount 
of EGF added; '-10' indicates that 10ng EGF was added above the filter, in the remaining 
assays EGF (ng) was added to the lower assay chamber (well). The lower assay  chamber 
volume was approximately 3 times that of the upper chamber.
Conclusion
This plot suggested that the chemoattractant placement was important, placing it 
above the Matrigel appeared to generate a concentration gradient which did 
influence the extent of tumour cell invasion.
f)  Problem - what was the significance o f  the Matrigel meniscus?
The viscous Matrigel produced a visible meniscus; thicker at the periphery than at 
its centre. As the preceding work had demonstrated the EGF concentration 
gradient influenced the degree of Matrigel invasion. The natural syllogism was 
that invasion would vary across the meniscus.
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One method, for reducing the meniscus effect, was to coat the inside walls o f the 
insert with a water repellent. This technique had been described by Imamura et al 
(1994). They rubbed a block of paraffin wax on the inner wall o f the inserts of 
Chemotaxicell chambers, 8 mm diameter (8 pm pores), (Kubota Co., Toyko, 
Japan), using cotton to remove any excess. Using this method, they demonstrated 
that a reduced meniscus depth had an effect on the invasive response. This they 
achieved by adding erythrocytes (diameter 7pm, filter pores 8 pm) to the upper 
assay chamber and counting those that crossed the filter. Wax, so applied, reduced 
by 5-fold the number of erythrocytes crossing a filter coated with a 70pl aliquot of
0.2mg/ml Matrigel protein. The explanation of this observation was that the 
central portion of the Matrigel barrier was deficient. In our protocol, this problem 
was potentially compounded since the filter insert was inverted to seed test cells 
onto its underside; an attenuated or deficient Matrigel layer might allow cells to 
cross the filter at this stage.
I *
Figure 10.6: Schematic of the Matrigel m eniscus and the effect of gravity. Inversion 
increased the height (h) of the m eniscus and reduced the depth (d) of the Matrigel layer.
Imamura also reported that the magnitude of the invasive response varied across 
the meniscus; describing a uniform pattern of cells crossing the filter when the 
meniscus was minimised, as opposed to a central preponderance without wax 
application. In our protocol, the pattern of invading cells seemed relatively 
uniform, however, formal assessment o f this potentially serious problem was 
required.
Experiments
By reducing the Matrigel concentration it was possible to reduce the meniscus 
curve, therefore, assays with reduced concentrations of Matrigel protein were 
tested. However, dilutions of greater than 1 part Matrigel to 2 parts culture 
medium failed to remain adherent when the insert was inverted for cell seeding. 
For the subsequent studies a ratio of 1 volume Matrigel to 1 volume medium was 
used.
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The next experiment addressed the possibility that cells crossed the filter whilst it 
was inverted. Several inserts were set up but, after seeding cells and before 
reverting the insert, the filter was wiped to remove cells on its underside. Any 
cells which had crossed the filter would not be effected by this manoeuvre. 
Control filters were not wiped. Wiped, and unwiped, filters were then incubated 
with lOng EGF as a chemoattractant. No cells were evident, in the wiped assays, 
at one week. Thus cells did not cross the filter during the period of cell seeding.
Imamura had reported that, with lOOpl of 1 mg/ml Matrigel protein, no 
erythrocytes crossed the filter. Using our protocol, 80pl of approximately 5mg/ml 
Matrigel protein was used; approximately 4-times more than that which produced 
zero erythrocyte counts in Imamura's study. This, in conjunction with the 
experiment above, suggested that the Matrigel layer was not deficient.
Next, a Pap pen, instead of wax, was used to reduce the meniscus depth. Although 
macroscopically effective there were misgivings. In our hands it proved 
technically difficult to apply the repellent to the well sides evenly without also 
applying it to the filter surface. This might jeopardise the uniformity of the assays, 
a prime advantage o f the Matrigel assay model. Further, there was concern that the 
process o f repellent application might lead to an increase in infected well systems 
or that the repellent itself might effect, either, the Matrigel or the study cells. 
Because o f these concerns, and hypothesising that the central preponderance of 
invasion reported by Imamura (1994) reflected a deficiency in the Matrigel layer 
which did not occur with our protocol, experiments were performed to assess the 
significance of the meniscus in our protocol.
A number of filters were studied across their diameter. A millimetre scale was 
placed, on the confocal microscope stage, adjacent to the filter. The centre point of 
the filter was determined grossly and readings were taken from this point (0 ) and, 
using the microscope stage controls to move the stage in one plane only, readings 
were taken from 1 and 2mm either side of this central point. This experiment was 
performed in triplicate and results are shown below.
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Figure 10.7: Determining the significance of the Matrigel m eniscus
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On the x-axis, invasion is depicted as the sum of pixels in 6 optical sections. The y-axis 
shows the position across the meniscus from which the readings were taken. Data is 
presented as the median and 95% confidence limits. Analysis of Variance p=0.66.
The results revealed no significant variation in invasive response across the 
meniscus. This clearly contradicts Imamura's results, but probably reflected both 
the low protein content of his barrier and his own evidence that this layer could be 
deficient. That there is no effect on the invasive response in our protocol, maybe 
because EGF placed above the Matrigel equilibrates through it, reducing the 
significance of concentration gradient in any part of it. (The preceding experiment 
revealed that placing the EGF above the Matrigel encouraged most invasion, this 
may have been because the EGF adhered to the Matrigel components.) Another 
possibility was that the depth o f the Matrigel meniscus, obvious with a 
Matrigel/air interface, was reduced by the addition of chemoattractant containing 
culture medium above the Matrigel (the depth of the meniscus at the interface of 
two fluids relates to their relative densities, personal communication from B Scott, 
Professor of Mechanical Engineering, University of Glasgow).
Immediately adjacent the periphery of the filter the optical image did appear 
distorted. The cause of this problem was not formally elucidated but was 
attributed to a 'meniscus effect', although an optical component, from the 
polystyrene wall o f the filter assembly, may have contributed. It was decided to 
avoid accumulating data from points at the immediate periphery of the filter.
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Conclusions
The Matrigel layer provided an intact barrier to invading cells. To ensure 
uniformity in the assay system, and to avoid the problems outlined above, the 
presence o f a meniscus was accepted. The final assay protocol required that 
readings were taken from around the central portion of the filter. Fields were 
selected in a random manner; between readings, the filter assembly was moved 
slightly without visualising the selected field. Three to five fields were analysed 
for each assay. The reliability o f the assay was based on replicating measurements 
(Mackinnon 1992).
g) Problem -what was the optimal incubation period?
Albini's (1987) original Matrigel/Boyden chamber assay was described as 'rapid 
in-vitro assay' and the short incubation period, 6  hours, was considered to be one 
o f its merits. Subsequent modifications o f the assay system have included more 
prolonged incubation periods, up to 72 hours (Repesh 1989, Imamura 1994). In all 
reported protocols, the quantity o f Matrigel applied to the filter has been 
considerably less than in our protocol, therefore, a further series of experiments 
was conducted to determine optimum incubation period.
Experiments
Since duration of incubation could alter the degree of invasive response, cell lines 
that did not cross the filter, as well as those that did, were studied. Initially assays 
were incubated for 4, 7 and 10 days. Results for the MDA-MB-231 cell line are 
shown below.
Cells in the Matrigel layer are difficult to visualise using light microscopy, 
however, cells accumulating in the wells, having fallen from the filter, could be 
assessed in this manner. In assays incubated for 10 days, examination o f these 
cells revealed that many were dead. Repeating the assays, this time replacing the 
medium in the well at 7 days, reduced this problem but prolonging the incubation 
from 7 to 10 days did not greatly increase invasion and there was an increased 
attrition, with assay chambers succumbing to infection. Additionally, cell lines 
that failed to invade with a 7 day incubation did not invade with a prolonged 
incubation.
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Figure 10.8: Altering the duration of the a ssa y  incubation.
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Invasion, on the y-axis, is represented by the mean and interquartile range of the sum  
of fluorescing pixels in 6 optical sections. The x-axis indicates the number of days of 
incubation before the assay was analysed.
Conclusion
For the remainder of the studies an incubation period of 7 days was used.
h) Problem - how best to collect optical sections?
Using the original assay protocol and fibroblast cell lines, invasion of up to 80pm 
was detected (Hennigan 1994). The maximum invasion of the breast cell lines was 
much less, approximately 30-40pm. For this reason the step between optical 
sections, which had been 5pm in the original assay, was reduced to 3pm. This in 
turn generated another problem; with invasion extending for only 20-30pm small 
errors in determining the filter (0 ) level could have profound effects on 
interpretation of the extent of invasion.
Difficulty in determining the base level stems from the fact that the filter itself 
was not, or was only poorly, visible using fluorescent microscopy. Marking the 
filter with a fluorochrome was one possibility, but there would then be a risk that 
this chemical might influence the assay (it would need to be applied prior to 
setting up the assay), or that its application might damage the fragile filter. This 
problem was solved by what came to be known as the 'bottom wipe'. This 
involved gently wiping the bottom of the filter with lens cleaning tissue. This 
action removed all the cells below the filter, thereby providing two advantages;
1 . that the level of the filter could be determined, accurately and reproducibly,
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2 . that fluorescence from cells below the filter would not compromise 
measurement of fluorescence from invading cells.
Experiments
Three assays (1-3) were analysed both unwiped, 'u', and wiped, 'w \ The same field 
was analysed 5 times, each time the filter (0) level was reassessed.
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Figure 10.9: Wiping the filter bottom improves assay accuracy
The x-axis shows the assay number (1-3) and also whether the readings were taken from 
the well before wiping (u) or after wiping (w). Variation, y-axis, is reported as the % of field 
pixels fluorescing at the filter (0) level divided by the mean of this value for the five 
readings. Results for each assay are shown as median and interquartile range.
Conclusion
Figure 10.9 clearly shows that wiping the bottom of the filter reduced variation in 
the assay analysis. This technique was, therefore, adopted for the final assay 
protocol.
i) Problem - how could different assay results be compared?
Assessment of the results of the early experiments revealed that pixel counts, 
reflecting cell numbers, in each optical section varied for experiments that were 
intended to be identical. Overall trends for the experimental series would be 
similar but pixel values could be quite different (evident in Figure 10.2: Invasion 
using different chemoattractants). There were a number o f possible causes for this 
observation - EGF that was thawed and re-frozen might be less efficacious in later 
assays; protein content of the Matrigel might vary; pressure on confocal
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microscopy time meant that the time between assay fixation and assay reading 
varied, etc.
Conclusion
Because o f these difficulties, and following the precedent of Parish et al (1992), 
results for repeated assays were standardised. This meant that results from each 
assay series would assume equal significance, facilitating data accrual to 
strengthen particular arguments and allowing results from different assay series to 
be directly compared. The final protocol required that results be standardised so 
that maximal invasive response was recorded as 1 and the minimum as zero.
Section iv: Interpretation o f  assay results
There were no previous reports of the use of confocal microscopy, to measure 
tumour cell invasion in a thick Matrigel layer. Using this technique, very thin 
optical sections were analysed and the image analysis software recorded the 
percentage o f the confocal field that fluoresced above a selected intensity. 
Propidium iodide was used as the fluorochrome because it adhered to DNA but 
did not attach to the Matrigel, filter or polystyrene insert. The fluorescence 
threshold was selected so that cells were clearly visible but background noise was 
minimal. Thus the percentage of the confocal field that fluoresced above this 
threshold was proportional to the number o f cells in that section. Maintaining the 
fluorescence threshold for all the inserts in a given assay allowed results for each 
insert to be directly compared.
Cells that crossed the filter were considered to have demonstrated an invasive 
response. The sum of the pixels, in each optical section, above the filter was 
considered to reflect a combination of invasion and proliferation. Unlike 
previously reported assays, our protocol could be used to assess the progression of 
cells within the Matrigel layer. This could usefully be measured by comparing the 
number of cells at higher levels in the Matrigel layer with those at lower levels. 
This ratio was considered to be indicative of the degree of tumour cell invasion 
induced by the chemoattractant.
Whilst this ratio proved useful in interpreting some invasion assays, care in its use 
was required. If there was very little invasion in an assay the ratio could become 
misleading. Consider an extreme example; if  there is no invasion, then the sum of 
pixels at lower and higher levels in the Matrigel layer will have the same
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background count, the ratio is then one (background over background). For this 
reason it was important to calculate the total sum of pixels above the filter and on 
some occasions determining the ratio was not helpful. Occasionally, interpreting 
results of one method was facilitated by the results of the other.
Consider Figure 10.10, produced from the experimental results shown in 
Figure 10.5: Determining the significance of the concentration gradient.
Figure 10.10: Comparing the methods of assay  interpretation.
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In both plots, the x-axis indicates the amount of EGF (ng) added to the assay; EGF was 
added to the well, that is below the filter, except for the assays indicated by the negative 
precursor, where the EGF was added above the Matrigel. The y-axis depicts invasion but 
this is measured in different ways in each plot. In the upper plot, it is the sum of fluorescing 
pixels above the filter, in the lower plot invasion is represented as a ratio of fluorescing 
pixels higher in the Matrigel layer over pixels at lower levels in the Matrigel. In both 
boxplots data is shown as median and interquartile range.
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In the upper plot, the y-axis shows the sum of pixels in all optical sections above 
the filter. The lower plot presents the results for the same assay but shows the ratio 
o f pixels in higher optical sections over those in lower sections, termed hereafter, 
the standardised ratio.
These plots suggested that similar numbers of cells crossed the filter in the control 
(0) assay as did with EGF added above the filter (-10), but those cells in the latter 
had invaded further into the Matrigel layer. The caveat indicated above probably 
applied to the wells with EGF added below the filter; there were few cells crossing 
the filter causing the ratio to be misleading.
Section v: Reproducibility
It is obviously important to establish the reproducibility o f both the experimental 
results and the assay technique. The latter was addressed by repeatedly reading a 
single field in one insert. Between taking each series of readings the microscope 
stage was moved down and the base (0 ) level re-established as described above. 
The results confirmed that the method of reading an assay insert was reproducible 
(Figure 10.11).
Figure 10.11: Reading the sam e confocal field.
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The x-axis indicates the assay  analysed. The y-axis show s the variation in the sum of 
pixels measured in each of 5 assays of a single confocal field. To make the graphic 
representation of this data simpler results for each assay are standardised by dividing by 
the mean. The plot shows the median result and the 95% confidence limits. The table, 
below, shows the un-standardised results.
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Assay Readings mean Std. Dev.
1 5 55.5 6.26
2 5 43.7 3.31
3 5 39.2 3.33
The reproducibility of the optical analysis was assessed by a similar experiment 
on three different assays (figure 10.12). Having identified the filter (0) level, the 
series of optical sections was collected on 5 separate occasions, the results show 
95% confidence limits for the standardised sum of pixels above the filter 
( 8  confocal sections, 0-2 lpm). There was clearly very little variation.
Figure 10.12: Reading the sam e optical section series.
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The x-axis indicates the assay analysed. The y-axis shows the variation in the sum of 
pixels measured in each of 5 analyses of the sam e stack of optical sections. To make the 
graphic representation of this data simpler results for each assay are standardised by 
dividing by the mean. The plot shows the median result and the 95% confidence limits. 
The table below shows the un-standardised results.
Assay Readings mean Std. Dev.
1 5 88.1 3.26
2 5 58.7 4.86
3 5 89.9 2.99
The reproducibility of the experiments was confirmed by performing repeat 
experiments, the results shown in Chapter 11 are for experiments performed at 
least twice and often three times.
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Figure 10.13: Median and 95% confidence intervals for the first a ssa y  of MDA-MB-231.
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On the x-axis is the amount of EGF (ng) added above the Matrigel layer. The y-axis shows 
the ratio of the sum of fluorescing pixels in the confocal fields at 15, 18 and 
21pm divided by the sum of fluorescing pixels at 0, 3 and 6pm.
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Figure 10.14: Median and 95% confidence intervals for the second assay of MDA-MB-231. 
The data are presented in the sam e fashion as above (Figure 10.13).
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Figure 10.15: Median and 95% confidence intervals for the third a ssa y  of MDA-MB-231.
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The data are presented in the sam e fashion as above (Figure 10.13).
Figure 10.16: 95% confidence intervals for the combined MDA-MB-231 assays.
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This assay shows the combined results for the three assays shown above. Results are 
standardised (facilitating their direct comparison and presentation in a single graphic). The 
symbol denotes an outlier. The standardised data is also presented in the table below.
EGF (ng) Readings mean Std. Dev.
0 15 0.04 0.046
1 15 0.16 0.094
5 15 0.37 0.164
10 15 0.64 0.255
30 15 0.27 0.104
50 10 0.25 0.106
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These results indicated that the assay technique was reproducible and also that the 
experimental results were reproducible.
Section vi: Invasion assay protocol
All pipettes and containers were kept on ice and the assay protocol was performed 
in a laminar flow tissue culture hood. Culture media for the assay protocols were 
supplemented with 1% serum. Since inserts occasionally became infected or the 
Matrigel dislodged, all assays were run in duplicate.
♦ Matrigel was removed from -70°C storage and placed in 4°C refrigeration 
overnight to allow it to liquefy.
♦ An aliquot was then diluted, 1:1, with culture medium appropriate to the cell 
line to be studied.
♦ 80 pi of the resultant Matrigel solution was added to the top of the filter in each 
Transwell insert.
♦ The Matrigel was then 'gelled' in a humidified incubator at 37°C for one hour.
♦ Sub-confluent culture flasks of the tumour cell lines to be tested were 
trypsinised. Cells, re-suspended in culture medium, were counted using a 
haemocytometer and further diluted, with medium, to produce a suspension of 
approximately 5 x 1 0  ^ cells per ml. (Rarely, to achieve the necessary cell 
concentration, it was necessary to centrifuge the suspended cell solution and 
remove supernatant.)
♦ The Transwell inserts were recovered from the incubator, inverted and, to the 
filter base, was added lOOpl of the tumour cell suspension.
♦ The inserts were returned, in their inverted position, to the incubator for a
further 1 hour to allow the cells to adhere to the filter.
♦ Thereafter, inserts were removed from the incubator and excess cell 
suspension was aspirated from the filter.
♦ 750pl of cell culture medium was then added to the wells. Inserts were re­
inverted, returning them to their original orientation, and placed in the wells 
thereby immersing the filter base.
♦ Quantities of EGF (or other chemoattractant), made up to a 200pl volume with 
culture medium, were then added above the Matrigel.
♦ Assays were then returned to the humidified incubator at 37°C, 5% CO2  for 7
days.
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At the end of 7 days assays were fixed.
♦ Wells of a new 24 well plate were filled with 70% ethanol at room 
temperature. Test inserts were immersed in these for 20 minutes.
♦ Inserts were then washed in PBS (phosphate buffered saline) for 5 minutes.
♦ Cell nuclei were stained by immersing the inserts in a propidium iodide 
solution (500pg propidium iodide per litre) for 20 minutes.
♦ This was followed by three further washes of 5 minutes in PBS.
♦ Finally, inserts were placed in a further 24 well plate immersing the filter in 
approximately 500pi of PBS. They were then stored in a darkened 4°C 
refrigerator until they were read.
To prevent contamination, new wells were used at all stages of the fixation 
process.
Protocol for reading the fixed assay.
♦ The filter base was wiped to remove cells which had not crossed the filter.
♦ Filter units were then placed onto a drop of PBS on a glass coverslip on the 
stage of the BioRad MRC 600 laser scanning confocal microscope. The same 
scope settings were used for all readings in each of the assays.
♦ The 20x objective lens and a DM850 filter were selected; this allowed the 
propidium iodide to be visible as an orange fluorescence.
♦ Manually, the focus wheel was rotated to take the plane of focus below the 
filter. Using the computerised focus control, readings were then taken at 2pm 
steps starting below the filter, until the point of maximum fluorescence was 
determined. This was the base (0) level for further readings.
♦ Readings were then taken at 3 pm steps, through the Matrigel layer. Starting at 
the base level and moving upwards, 8  readings, from 0  to 2 1 pm, were taken 
for each assay.
♦ The computerised image analysis system was used to determine the number of 
fluorescing pixels in each confocal section.
Each well was read repeatedly, normally 3-5 times. Between each reading the well 
was moved slightly, without viewing the field, to try and randomly select fields. 
To ensure intra-assay standardisation the number of confocal laser scans was 
always three, the selected level of fluorescence was maintained throughout the 
assay series and all filter units for a given assay were read at one sitting. Results 
for repeated assays were standardised as described above.
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Interpreting the assay results
1. The sum of pixels at all levels reflected the total number of cells crossing the 
filter. This value (total pixels) represented a combination of invasion and 
proliferation.
2. The ratio of cells at higher levels in the Matrigel layer over those at lower 
levels was also determined (sum of pixels at 15pm+18pm+21pm divided by 
sum of pixels at 0pm+3pm+6pm). This ratio was considered to indicate the 
degree of tumour cell invasion induced by the chemoattractant.
Figure 10.17 shows, for a typical assay, the optical sections produced using the
invasion assay protocol.
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Figure 10.17: Optical sections obtained from an assay of MDA-MB-231 cells using 10ng of EGF as 
chemoattractant.
These images were obtained using the BioRad MRC 600 laser scanning confocal microscope, a 20x objective 
and a DM850 filter. Cells were stained with propidium iodide and sections were taken at 3nm steps, from the 
level of the filter (Opm) to 21pm. Each image is annotated with its position In the optical stack. Images were 
computer analysed and stored on optical disc.
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Chapter 11:
Results of the invasion studies
Section i: Using EGF as a chemoattractant
Having established that only certain cell lines would cross the filter, efforts were 
made to identify maximal invasion for further study. To do this varying 
concentrations of EGF were used as chemoattractant.
Figure 11.1: EGF stimulated invasion of the MDA-MB-231 cell line.
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The x-axis shows the amount of EGF added above the Matrigel layer. The y-axis in the 
upper boxplot shows the sum of fluorescing pixels in 8 optical sections above the filter. In 
the lower boxplot the y-axis shows the ratio of fluorescing pixels in the higher optical 
sections over those in lower optical sections. Both boxplots show medians and 
interquartile ranges. The plot shown is derived from standardised data from 3 experiments. 
The symbol denotes an outlying result.
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Interpretation
Both boxplots demonstrate a dose-response curve; more invasion was produced by 
increasing amounts of EGF up to approximately lOng, higher levels stimulated 
less invasion. This observation was more apparent in the second boxplot. This 
may result from an EGF concentration gradient in the Matrigel layer; increased 
EGF added above the filter generating an increased gradient and greater invasion 
o f those cells that crossed the filter. The reduced invasion observed with higher 
concentrations may result from cells succumbing to toxic levels of EGF. This 
dose-response profile, with cells responding to lower EGF concentrations but 
failing to do so to higher concentrations, has been reported in studies of tumour 
cell proliferation (Osborne 1980).
Maximal invasion was produced by adding lOng of EGF above the filter. This 
amount was used in subsequent assays in which modulation of invasion was 
studied.
Figure 11.2: EGF stimulated invasion of the BT20 cell line.
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Figure 11.2 (continued): EGF stimulated invasion of the BT20 cell line.
The results shown here are for the BT20 cell line (2 experiments). They are presented in 
the sam e manner as those, above, for the MDA-MB-231 cell line (Figure 11.1).
Interpretation
The upper boxplot demonstrates a clear dose response curve with l-5ng of EGF 
provoking the greatest invasive response. The lower boxplot is more difficult to 
interpret; there is no obvious difference between the groups, this may be due to the 
relatively low magnitude of invasion induced by any of the EGF concentrations.
Figure 11.3: EGF stimulated invasion of the MCF7ADR cell line.
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Figure 11.3 (continued): EGF stimulated invasion of the MCF7ADR cell line.
These results are for the MCF7ADR cell line (2 experiments). They are presented in the 
sam e manner as those, above, for the MDA-MB-231 cell line (Figure 11.1).
Interpretation
Again there was relatively little invasion in this assay series making the results 
more difficult to interpret than for the MDA-MB-231 cell line. The upper boxplot 
shows relatively few cells crossed the filter; in the control assay and that with lng 
o f EGF there was invasion, but when further EGF was added fewer cells crossed 
the filter. The results shown in the lower boxplot suggested that, compared with 
the control, addition of lng of EGF stimulated invasion further into the Matrigel 
layer.
Summary
All three cell lines produced an invasive response which was modulated by EGF. 
The magnitude of this response varied with the cell line, but in all cases addition 
of EGF increased invasion. Invasion was most evident with MDA-MB-231 cells 
and these were used for subsequent experiments.
Section ii: Antibody experiments
The aim of these experiments was to determine if invasion was mediated via EGF 
receptor. If invasion could be abrogated using monoclonal antibody directed at, 
and inhibitory to, EGF receptor then this would support the contention that the 
invasive response was the result of EGF stimulation of EGF receptor.
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ICR9 and ICR16 antibodies were used (a kind gift from Dr C Dean, ICR Sutton). 
Both are rat monoclonal antibodies of the IgG class, they bind a 170kD protein in 
Western blots and in Scatchard analysis they compete with EGF to bind EGF 
receptor (Modjtahedi 1992). Modjtahedi et al described 8  antibodies (Modjtahedi 
1992), o f these ICR16 demonstrated greatest inhibition of EGF binding and ICR9 
enhanced ligand binding. They also reported the effects these molecules had on 
cellular proliferation. ICR9 stimulated proliferation, most efficaciously in cell 
lines expressing low levels of EGF receptor. ICR16 reduced proliferation.
Figure 11.4: Adding ICR16 above the Matrigel layer.
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The y-axis reports the sum of pixels in a stack of 8 optical sections. The x-axis, the amount 
of ICR16 added above the Matrigel. The plots are of the median and interquartile ranges. 
Analysis of Variance is reported (excluding the 5000ng group).
Adding 5000ng ICR16 reduced the number of cells that crossed the filter, but 
there were few cells in the well below the filter and these appeared poorly viable. 
This was interpreted as a non-specific toxic effect o f this concentration o f 
antibody. For this reason, those assays to which 5000ng were added were 
excluded form the statistical analysis, The results demonstrated that antibody did 
not reduce invasion (Analysis of variance p=0.289). This was not the expected 
result and raised the possibility that the antibody, a molecule very much larger 
than EGF, might have been unable to diffuse through the Matrigel layer. The 
experiments were, therefore, repeated, this time adding antibody to the lower 
chamber. Results are shown below.
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Figure 11.5: Adding antibody below the Matrigel layer.
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The upper boxplot is for the antibody ICR9 and the lower plot for ICR16. For both, the x- 
axis shows the amount of antibody (ng) added to the assay well. The y-axis in the ICR9 
plot shows the median and interquartile ranges of the sum of pixels in the 8 optical 
sections, 0-21 pm, above the Matrigel layer. In the ICR16 plot the data depicted is the 
median and interquartile ranges of the pixels at the filter, 0pm, level only. Standardisation 
of results allowed data from 3 experiments to be shown. Outlying results are indicated by 
the symbol.
The ICR9 plot shows that invasion was minimally effected by low concentrations 
o f this antibody, but at higher concentrations there appears to be reduced invasion. 
Modjtahedi, presenting data for three cell lines, had reported that ICR9 increased 
EGF binding o f the EGF receptor (Modjtahedi 1992). His results for both HN5 
and A431 cell lines suggested that higher concentrations of antibody further 
increased ligand binding of receptor. Addition of ICR9 might, therefore, have 
been expected to increase invasion in our studies. However, Modjahedi also
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reported that for EJ cells, those with fewest receptors and most reflective of levels 
in breast cancer, increased antibody concentration increased EGF binding only to 
a point, after which further increases reduced ligand binding. This could account 
for the reduced invasion seen at higher ICR9 concentrations (Figure 11.5). An 
alternative explanation is that Modjtahedi's fibroblast experiments were not 
augmented with EGF and, as he reported, ICR9 stimulated less proliferation than 
EGF alone. Our invasion studies were augmented with EGF, and the invasion so 
stimulated may have exceeded that that could be induced by ICR9.
Adding ICR16 antibody to the assay well produced very little invasive response 
and, therefore, the boxplot for this antibody shows the results of the pixel counts 
at the filter (0 ) level, rather than, as previously, the sum of pixels in 8  optical 
sections above the filter. To allow direct comparison of results for both antibodies, 
the ICR9 data was analysed in a similar manner. Plots of the median pixel counts 
for each antibody are superimposed below.
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Figure 11.6: Plot of the median standardised pixel counts for the ICR antibodies.
The continuous line represents ICR9, the broken line ICR16. On the x-axis is the amount 
of antibody added to the assay well. On the y-axis is the median pixel count at the filter, Op 
m, level. To allow the plots to be superimposed the results are standardised (data from 3 
experiments). The symbol denotes an outlier.
Interpretation
Demonstrated clearly was that both antibodies reduced invasion, and that this 
effect was more pronounced at lower concentrations with the ICR16 antibody. 
The ICR9 control produced a differential reduction in invasion which inferred the 
former was not a non-specific toxic effect of the IgG class of antibody. Note that
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the x-axis is non-linear and that reduction in invasion produced by ICR16, 
compared to ICR9, is more pronounced than is immediately evident.
Summary
These experiments demonstrated that EGF induced invasion could be abrogated 
using monoclonal antibody directed to EGF receptor, and thus that this receptor, at 
least in part, modulated the invasive response.
Section Hi: Tyrosine kinase inhibitor experiments
The majority of tyrosine kinase inhibitors function by competing with the 
enzyme's ATP binding site (reviewed in Levitski 1995) and it has proved possible 
to produce inhibitors specific to individual tyrosine kinases, including that o f EGF 
receptor. Since higher levels of EGF receptor expression are associated with poor 
prognosis in many human cancers, there has been considerable interest in the 
therapeutic potential of this group of drugs (Buchdunger 1994, Zhang 1995, 
Shawver 1994). The aim of these experiments was to establish that tumour cell 
invasion could be obviated by targeting the intra-cellular signalling of the EGF 
receptor.
The tyrosine kinase inhibitor used was 4,5-Dianilinophthalimide (DAPH). This 
agent has been shown to selectively inhibit ligand induced EGF receptor 
autophosphorylation (Buchdunger 1994), and was a kind gift from Dr Nicholas 
Lydon (CIBA-Geigy, Basel, Switzerland). Experiments were conducted in a 
manner similar to those for the antibodies. DAPH was placed above the Matrigel; 
DAPH molecules are very much smaller (Molecular weight of 337, Buchdunger 
1994) than the large antibody molecules (approximately 1300 amino acids, 
Alberts 1989) and there was, therefore, not the same concern that they might fail 
to diffuse through the Matrigel. MDA-MB-231 cells were used for these studies.
DAPH was supplied as a lOmM solution in Dimethyl sulphoxide (DMSO). To 
ascertain the effect of this solvent an experiment was conducted growing 
MDA-MB-231 cells in varying concentrations of DMSO. Aliquots o f a cell 
suspension were incubated in RPMI augmented with 10% foetal calf serum and 
DMSO. After one week cells were trypsinised, re-suspended in a uniform volume 
and counted on a haemocytometer. Prior to trypsinisation cells were viewed with a 
light microscope. Results are shown in Table 11.1.
146
Chapter 11
Concentration of DMSO Haemocytometer counts Light microscopy 
(%) (mean)
0 14.4 normal cell appearance, confluent
0.25 14.0 normal cell appearance, confluent
0.5 13.4 normal cell appearance, confluent
1 16.0 normal cell appearance, confluent
2 13.0 cells appeared less healthy and were
sub-confluent
Table 11.1:  Determining the significance of DMSO on MDA-MB-231 cell proliferation.
This experiment indicated that cells proliferated at a normal rate in concentrations 
o f up to 2% DMSO, (Analysis of Variance for cell counts, p = 0.127). At higher 
concentrations, light microscopy revealed cells appeared less healthy. Since the 
effect o f DMSO on invasion was unknown, its concentration was kept constant in 
the subsequent invasion studies. DMSO was added to the aliquots containing 
DAPH to produce a final concentration of 0.5% DMSO (v/v).
The invasion assay was repeated varying the concentration of tyrosine kinase 
inhibitor added above the Matrigel (Figure 11.17). No invasion was recorded at 
the 50 and lOOpM concentrations of inhibitor which are therefore not plotted.
Figure 11.7: Using tyrosine kinase inhibitor in the invasion assay
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The boxplot shows the medians and interquartile ranges. The x-axis shows the 
concentration of tyrosine kinase inhibitor (pM) in the 200pl aliquot added above the 
Matrigel layer. The y-axis shows invasion as the standardised (2 experiments) total 
fluorescing pixels. The symbol denotes an outlier.
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Interpretation
In the antibody experiments ICR9 functioned as a control molecule and was used 
to show that reduced invasion seen with low levels of ICR16 was not due to a non 
specific toxic effect. No such simple control was available for the tyrosine kinase 
inhibitor experiment. The first such experiment indicated that at concentrations of 
50pM and lOOpM, no cells crossed the filter. This might have resulted from a 
non-specific toxic effect and, to address this possibility, filters from the second 
assay were studied before the 'bottom wipe'. Fluorescent and light microscopic 
examination of the filters was performed. The assay wells were also assessed.
Inhibitor (pM) CELLS IN THE ASSAY WELLS APPEARANCE AT THE FILTER
0 Moderate numbers of cells which were Moderate numbers of cells
bipolar
5 Moderate numbers of cells which were Possibly more cells than at OpM
bipolar inhibitor
10 Moderate numbers of cells which were Moderate numbers of cells
bipolar
50 Reduced numbers of cells which were Reduced numbers of cells
rounded
100 Very few cells Virtually no cells
Table 11.2: Appearance of the cells in the tyrosine kinase inhibitor experiments.
At concentrations of 5 OpM, or above, the tyrosine kinase inhibitor significantly 
reduced the number of cells growing in the assay. This may have been either 
through its function as a tyrosine kinase inhibitor or via a direct toxic effect. 
Tyrosine kinase inhibitor concentrations up to lOpM did not appear to 
significantly reduce the numbers of cells in the assay.
In an effort to quantify these observations readings were taken from the unwiped 
filter base. The usual protocol was used to identify maximum fluorescence which 
was considered to reflect the number of cells growing on the underside of the 
filter. This method had the advantage that it was simple and that it maintained the 
integrity of the filter/Matrigel assembly which could then be studied in the usual 
fashion. There were, however, a number of reservations. As indicated above 
(Figure 10.7), determining the level of the filter, without wiping its base, was 
difficult. Additionally, cells showed some propensity to grow down from the filter 
in clumps (evident using light microscopy) and cells in these clumps might not be 
included in the thin optical section that included the filter. Further, no
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measurement of the cells in the assay well was available. Despite these 
reservations the measurements were considered to provide a relative, if  crude, 
estimate of the number o f cells growing at the filter. The results are shown below.
Figure 11.8: Invasion and proliferation in the tyrosine kinase inhibitor experiments
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The plot shows, on the y-axis, the median pixel count of three assays and on the x-axis, 
the concentration of tyrosine kinase inhibitor (pM) in the 200pl aliquot added above the 
Matrigel layer. Three lines are plotted. The solid line depicts the sum of pixels above the 
filter (a measure of invasion), determined after wiping the filter. The broken line is the pixel 
count below the unwiped filter. The dotted line is the sum of pixels above and below the 
filter (an estimate of the total number of cells in the assay). (These data are from one 
experiment).
Summary
No cells crossed the filter at Tyrosine kinase inhibitor concentrations o f 50pM or 
greater. At lower concentrations, up to approximately 5pM, the inhibitor reduced 
the number o f cells invading the Matrigel layer but did not appear to effect 
cellular proliferation. These results indicated that EGF receptor specific tyrosine 
kinase inhibitor could reduce breast tumour cell invasion. The inhibitor, used in 
the experiments above, has been shown to produce potent in-vivo anti-tumour 
activity (Burchdunger 1994). This was measured as a reduction in volume of 
implanted tumour xenografts. Our studies suggest that reduced tumour cell 
invasion may, at least partly, explain any clinical benefit from these drugs.
149
Chapter 11
Section iv: Alternative chemoattractants
The assay protocol was developed chiefly to analyse the effect of EGF on EGF 
receptor, however, it was possible to study invasion induced by other attractants.
In-vitro studies provide evidence that Transforming Growth Factor Beta (TGF-P) 
increases cellular proteolytic activity and increases metastatic potential (Welsh
1990). At a cellular level, TGF-p from MCF7 cells induces fibroblasts to produce 
the stromal protein, tenascin, this in turn causes breast tumour cells to lose cell to 
cell, and cell to substrate, contacts (Chiquet-Ehrismann 1989). In the clinical 
setting, breast tumours expressing higher levels of TGF-p have a higher incidence 
o f nodal metastases (Walker 1992). Thus TGF-P may have a role in the process of 
invasion and the assay was repeated substituting TGF-P for EGF.
80 —| 
W 7n —
S
fj- 60 HTO
2  5 0 -
E  4 0 -
"8 3Q , 
E 3° H
05 2 0 -  
10 -
1.0 H
o
% 0.5 H 
to
Em
0.0 -I
T
“I-------1”
0.0 0.5
I l
0.0 0.5
” 1 1 1---------- 1—
2.5 5.0 10.0 30.0
TGF(ng)
- r ~
2.5
T
-| 1-------1—
5.0 10.0 30.0
One way analysis of 
Variance, 
p = 0.229
One way analysis of 
Variance, 
p < 0.0005
TGF(ng)
Figure 11.9: Invasion induced by TGF-p
MDA-MB-231 cells were used for these (2) experiments. Results are presented in a similar 
fashion to those in Figure 11.1
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Interpretation.
The upper boxplot (Figure 11.9) shows no obvious difference in the numbers of 
cells that crossed the filter, however, analysis of the ratio, indicated that TGF-P 
stimulated cells that did cross the filter to invade into the Matrigel layer. These 
results, using TGF-p as chemoattractant supported the hypothesis that this 
molecule does promote tumour cell invasion. They also demonstrated that the 
assay protocol was suitable for assessing different chemoattractants.
Additionally, these results can be used to support the proposed methods of assay 
interpretation. The MD-MB-231 cell line is oestrogen receptor negative and 
TGF-P has been shown to inhibit the proliferation of oestrogen receptor negative 
cell lines (Arteaga 1988) but, as indicated above, it may promote tumour cell 
invasion. In this assay, the upper boxplot shows increasing TGF-p concentrations 
had minimal effect on the number of cells above the filter, with a trend to 
reduction at the 30ng concentration. However, the ratio shown in the lower boxplot 
suggests this molecule could induce invasion.
151
Chapter 12
Chapter 12:
Discussion; invasion studies
Section i: Establishing the invasion assay
Epithelial cells require intact basement membrane for anchorage and growth 
(Kleinman 1981, Wicha 1980), and in invasive carcinoma the normality o f both of 
these cell attributes is characteristically lost, as is the integrity of the basement 
membrane layer (Liotta 1984). Scanning electron microscope images of 
carcinoma in-situ reveal focal defects in the basement membrane and this may 
represent the earliest stages of progression to invasive carcinoma (Liotta 1986). 
These observations have encouraged cancer scientists to explore the relationship 
between cancer cells and basement membrane and specifically the former's 
invasion o f the latter.
Appropriate invasion models of human cancers, and particularly breast cancer 
with its protracted clinical course, have been difficult to develop. The ideal 
invasion model would:
♦ allow study of specific phenotypic conversions observed in human carcinoma 
in-vivo,
♦ take into account the complex interactions between cells and micro­
environment,
♦ allow easy experimental manipulation of genetic information and micro­
environment.
At present no such assay exists.
Animal models fail to satisfactorily reflect human disease. O f the in-vitro 
techniques, the biological invasion assays, which might most accurately reflect 
in-vivo events, are poorly reproducible. Thus, despite some concern that they 
might poorly reflect the behaviour of human carcinoma in-vivo (Noel 1991), 
reconstituted basement membrane methodologies have provided much of our 
understanding of the genotypic, and phenotypic, changes that result in invasive 
cancer.
A large number o f reconstituted basement membrane assays have been described 
and this probably reflects the fact that none is ideal. The assay protocol, described 
in this work, is o f novel design and addresses some of the difficulties encountered 
with previous methodologies. The protocol was developed under supervision from 
Dr B Ozanne at the Beatson Institute for Cancer Research (Hennigan 1994). Its
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principle differences, compared to existing protocols, relate to the depth of the 
Matrigel layer and the technique used to measure invasion.
Previous reports describe the use of a thin Matrigel layer, containing relatively 
little Matrigel protein. In these assays invasion has been measured as numbers of 
cells crossing the filter, or has been defined in terms o f Matrigel degradation. 
Neither technique allows study of cells actually invading the basement membrane 
barrier. Our protocol, by incorporating a thick Matrigel layer, offered the 
opportunity to study the progress of tumour cells as they passed through this 
barrier. To be realised, this advantage required that invasion be measured within 
an intact Matrigel layer. This problem was overcome by the use of confocal 
microscopy. Coupled to computer assisted image analysis, confocal scans 
provided an estimate of the number of cells in progressive, thin optical sections 
through the Matrigel layer. This method of measuring invasion had not previously 
been reported.
Using confocal microscopy allowed estimation of invasion at higher levels, 
compared to that at lower levels, in the Matrigel. This ratio, as opposed to the total 
number o f cells at all levels above the filter, provided evidence that the assay did 
measure invasion and did not simply reflect proliferation. Thus, our results 
suggested that EGF receptor stimulation mediated an invasive response that was 
independent o f cellular proliferation. This corroborated published work comparing 
invasion of wild type and mitogenically active but motility deficient EGF receptor 
(Xie 1995). Subsequently, in the same lab and using a similar invasion assay, 
Brunton demonstrated that EGF can be used to promote invasion of a colorectal 
cancer cell line. This second study used both [^H] thymidine incorporation and 
tetrazolium dye reduction assays to demonstrate that invasion was independent of 
proliferation (Brunton 1997).
A further fundamental variation in this assay system, as opposed to those 
previously reported, was the orientation of the assay components; cells, filter and 
Matrigel. In conventional assays cancer cells have been seeded above the Matrigel 
layer, which coats the upper surface o f the filter. In the protocol used in this series 
of experiments, Matrigel was added above the filter and cells were seeded on the 
filter under-surface. By seeding them below the filter, cells invading the Matrigel 
had to pass through 8 pm pores. This required them to do so as individual cells and 
may have allowed better appreciation of their invasion than when cells were 
plated above the Matrigel, with which they interact forming multicellular
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aggregates, resembling in structure, benign breast (Streuli 1991, Darcy 1991). For 
those cell lines that did invade, fewer than the 5 x 1 0 ^ cells seeded onto the filter 
under-surface will have adhered to it and during the week long incubation only 
some of these entered the Matrigel layer. The proportion that did so could not be 
determined accurately since, after incubation, cells above the filter were likely to 
reflect invasion and proliferation; cells within the Matrigel seemed contiguous 
(Figure 10.17). In fact, in-vivo invasion by breast cancer is likely to reflect a 
combination o f these attributes, both of which characterise carcinoma cells.
Another prime advantage of reconstituted basement membrane assays is that they 
generate results that are reproducible (reviewed in Hendrix 1989). Although the 
confocal technique for measuring invasion was relatively complex and required 
special equipment, our data showed that it was reproducible. In addition the use of 
a thick Matrigel layer circumvents concerns regarding the integrity of the Matrigel 
barrier and may have improved the reproducibility o f this technique over those 
employing a thin layer.
Relatively few breast tumour cell lines produced an invasive response that was 
detectable using our assay; only three of nine cell lines. Whilst this finding was 
disappointing, it was not entirely unexpected. It is notoriously difficult to culture 
malignant cells from primary breast tumours (Wolman 1985) and many of the 
commonly studied breast tumour cell lines are poorly representative o f cells found 
in the breast carcinomas of patients (reviewed in Taylor-Papadimitriou 1993). The 
initial hope, that this assay might be applied to primary breast cancers, providing 
an insight into their likely clinical behaviour, proved to be unrealistic. This stated, 
the assay was reproducible and proved relatively robust, allowing study o f various 
chemoattractants. It was also easily modified to study manipulation of the invasive 
response.
Section ii: Results o f  the invasion assay
Up-regulated EGF receptor signalling has been correlated with tumour 
progression in human neoplasia, however, the cell behaviour which is promoted 
remains undefined. There is considerable evidence that migration and invasion of 
malignant cells may be partly dependent on local chemotactic factors (Terranova 
1986, Hujanen 1985). Similarly there is good evidence that breast tumours with 
cells expressing higher levels of EGF receptor (reviewed in Klijn 1992) and 
tumours with high EGF content (Kamameris 1993) are associated with poor
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prognosis. The purpose of this series of experiments was to explore the possibility 
that EGF binding of EGF receptor might convey an increased invasive potential 
on breast cancer cells.
In Chapter 4 (Breast tumour cell invasion and EGF receptor) a number of 
references are cited that indirectly support the contention that elevated levels of 
EGF receptor correlate with increased invasion in a number of malignancies. 
There are, however, relatively few reports directly linking up-regulated EGF 
receptor signalling to increased tumour cell invasiveness. The experiments, 
presented in this work, indicated that EGF interaction with the EGF receptor 
induced invasion of human breast cancer cells. Blocking this response with both 
receptor directed antibody and tyrosine kinase inhibitor demonstrated that 
invasion was mediated via the EGF receptor.
The MDA-MB-231 cell line was stimulated to invade more than the others, but 
invasion was also seen with the BT20 and MCF7 Adriamycin resistant lines. 
Although few tumour cell lines invaded, those that did expressed higher levels of 
EGF receptor (see Chapter 6, section iv). This concords with recent reports that 
EGF receptor expression directly correlates with metastatic potential in colorectal 
carcinoma (Radinsky 1995). However, the relationship, between receptor 
expression and invasion, was not absolute and the degree of invasion was not 
proportional to the level of receptor expression. Thus it would appear that, whilst 
EGF receptor stimulation has a role in tumour cell invasion, there are other factors 
which are important.
The cellular morphology of the MDA-MB-231 line was unlike those of the other 
lines studied (Table 10.4). It has been suggested that breast cancer cells undergo 
an 'epithelial to mesenchymal transition' and in doing so become more invasive 
(Bae 1993); this may explain the high level of invasion seen with these cells 
which are elongate with pseudopods.
Mesenchymal morphology, in breast cancer cells, has been associated with 
oestrogen receptor negative/vimentin positive phenotype (Sommers, 1989). 
Vimentin is an intermediate filament glycoprotein which is important in cell 
morphology and motility. Elevated expression of vimentin in breast cancer cells 
has been associated with increased tumour cell invasiveness (Thompson 1992, 
Bae 1993) and poor prognosis (Domagala 1990). In turn, elevated EGF receptor 
expression has been associated with vimentin expression. Syllogistically, EGF
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receptor signalling may influence cell motility, possibly via an action on vimentin. 
Supporting this hypothesis is the observation that mesothelial cells, stimulated to 
rapid growth by EGF, increase vimentin expression and decrease cytokeratin 
expression (Connell 1983).
Brunton's group reported a model for the adenoma to carcinoma sequence in 
colorectal disease (Brunton 1997). A corollary for breast carcinoma is provided by 
studies o f MCF7 and MCF7ADR lines. The MCF7ADR line, derived from MCF7 
cells by incubation with increasing concentrations of adriamycin (Vickers 1988), 
has gained vimentin expression and lost oestrogen receptor expression (Thompson 
1992), thereby, gaining an invasive phenotype (Bae 1993) and an elevated level of 
EGF receptor expression. This concurs with the experimental results reported 
above; the MCF7 line failed to invade the Matrigel layer but the adriamycin 
resistant derivative, expressing eight times as much EGF receptor (Vickers 1988), 
produced a dose related invasive response to EGF. It appears, therefore, that EGF 
receptor stimulation may influence invasion, and that this influence may, in part, 
be via an action on vimentin expression. However, attributing EGF promoted 
invasion solely to an effect on vimentin expression is not justified.
For example, Brunton's group also demonstrated that EGF induced an increase of 
c-Src activity, relocation of the c-Src to focal adhesions and phosphorylation of 
focal adhesion kinase (FAK) in invading carcinoma cells. This did not occur in the 
non-invading adenoma cell line. FAK is a tyrosine phosphorylated protein, 
localised to adhesions; discrete cellular regions where intergins interact with 
extracellular proteins. Fibroblast studies indicate that FAK deficient cells have 
reduced motility (Ilic 1995), in epithelial cells FAK phosphorylation and 
expression correlates with increased cell motility (Akasaka 1995, Matsumoto 
1994). Furthermore increased expression of FAK is associated with invasive 
tumours of breast (and colon) (Owens 1995).
There is also evidence to suggest that EGF receptor signalling may have an effect 
on cadherin mediated cell to cell adhesion (Shiozki,1995). EGF stimulation of 
TE-2R oesophageal cancer cells resulted, not in down-regulated expression of 
E-cadherin, but in its relocation within the cell. It would appear, therefore, that 
EGF receptor stimulation influences tumour cell invasion via a number of 
complex intracellular signals which result, not only in altered expression, but also 
in relocation o f cellular proteins. The precise signalling interactions remain far 
from clear.
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Since expression of the EGF receptor correlates with poorer prognosis, this 
receptor represents an obvious target for therapeutic intervention. A number of 
studies have explored the use of antibodies targeted at EGF receptor to reduce 
growth of cancer cells in-vitro and in-vivo (reviewed in Modjtahedi 1994). 
Antibodies can effect this action by blocking ligand binding, thereby reducing 
receptor signalling, or, in-vivo, by stimulating the host immune system, in which 
event they are directing the host system to EGF receptor bearing cells. The most 
efficacious antibodies function in both ways (Modjtahedi 1993).
The invasion assay could only address the effect of reduced receptor signalling, 
but the antibody experiments clearly demonstrated that tumour cell invasion could 
be reduced by monoclonal antibody directed against, and inhibitory to, the 
receptor. Clinical use of immunotherapy has focused on the use o f combinations 
o f antibody and cytotoxic agents. The use of these compounds is, however, 
limited by difficulties using mouse or rat antibodies to which the host produces an 
immune reaction. Although this may initially direct the host immune system to 
tumour cells it can limit the effectiveness of repeated treatments by inducing 
anaphylaxsis (Modjtahedi 1994). Whilst these difficulties may be overcome by 
using humanised antibodies or genetically engineered antibody fragments there 
are other problems with the use of larger combined molecules.
EGF receptor expressed by most cancer cells, including breast cancer cells, 
appears to be of wild type. Selective targeting of cancer cells is therefore difficult. 
This problem is compounded by the fact that hepatocyte borne EGF receptors can 
clear large quantities of circulating EGF (Yanai 1990). Thus any targeting reagent 
must extravasate rapidly to minimise liver clearance. This criterion is met by low 
molecular weight molecules, such as the tyrosine kinase inhibitors. These small 
molecules also overcome a further problem for targeted therapies, that of 
penetration of solid tumours. Tyrosine kinase inhibitors are therefore generating 
considerable clinical interest (reviewed in Davies 1996).
Interpretation of signal transduction blockade is complicated by the web of 
interactions arising from receptor activation, but, in this regard, the tyrosine kinase 
inhibitors have the advantage that they block the initiating intracellular signal. 
Receptor blockade also produces the potential for lateral signal transduction and, 
thereby, unexpected in-vivo results. This stated, experiments using DAPH showed 
that tumour cell invasion could be reduced significantly by relatively small drug
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concentrations. Therefore, this group of drugs may have potential, both to reduce 
metastasis from established cancers, and as prophylaxis in patients at high risk of 
developing breast carcinoma.
Radioimmunohistochemical studies, of both primary breast cancers and normal 
breast tissues indicated that most breast cancers express very much lower levels of 
EGF receptor than does normal breast (Figure 6.1). This concurs with other 
reports (Dittadi 1993) and, in conjunction, with in-vitro evidence that the efficacy 
o f EGF-bound toxins was directly related to receptor levels (Kirk 1994), it might 
appear that the EGF receptor is a poor therapeutic target in breast cancer. 
However, animal studies o f EGF receptor directed toxins are encouraging (Pai
1991) and there is also evidence that cancer cells with fewer EGF binding sites, 
may be more susceptible to therapeutic targeting than normal cells (Kameyama 
1994). The latter provides the potential advantage of a reduced therapeutic dose 
and reduced systemic side effects.
Whilst accepting that tumour cell invasion is the culmination of a large number of 
cellular processes, the data presented in this section does suggest that EGF 
receptor signalling has a role in breast cancer cell invasion. This may be the 
mechanism of the prognostic significance of higher levels of EGF receptor 
expression in breast cancer and abrogation of this invasive response would appear 
to be an desirable therapeutic goal.
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DISCUSSION
The 'specific aims' o f the thesis were, to a greater or lesser extent, fulfilled:
♦ EGF receptor was quantified in a large series of primary breast cancers.
♦ It was possible to demonstrate the superiority of the 
radioimmunohistochemical method over more conventional techniques.
♦ The accuracy of this method did allow observations that could not have 
otherwise been determined.
♦ It was also possible to demonstrate that receptor might influence breast tumour 
cell invasion.
Yet, the role of EGF receptor in breast tumour cell biology remained elusive. This 
requires that we consider the value of accurate measurement of factors, such as 
EGF receptor, in clinical specimens.
Was it reasonable to assume that more accurate receptor estimation would 
translate to clinical benefit?
Higher levels o f receptor expression did predict poorer outcome but the clinical 
value of this observation is questionable given that more established, more easily 
obtained, prognostic indicators are much better predictors of outcome. Clearly, 
outcome is dependent on a host of biological characteristics both of the tumour 
and patient. Assessment of any feature in isolation is akin to trying to deduce the 
outcome of a football match by watching a single player. For the type I tyrosine 
kinase receptors this analogy may be particularly valid since we know that 
members of this receptor family interact functionally and, 
radioimmunohistochemistry suggests, that their expression is interdependent. 
Further, within a tumour there will be a number o f genotypically distinct clones. 
Sampled tissue is, therefore, not necessarily representative o f the tumour or 
indicative o f its clinical course. Equally, assessment o f the whole tumour mass, 
not withstanding its impracticality, is unlikely to be fulfilling since prognosis will 
be determined by 'aggressive' genotypes that may be poorly represented in the 
tumour as a whole. Although this appears discouraging, it should not detract from 
efforts to measure biological markers more accurately. After all, it is probable that 
any clinical advantage gained from these markers will not pertain to their 
measurement per se, but rather to an improved understanding of tumour biology.
Did more accurate receptor measurement improve our understanding o f  breast 
cancer?
In recent years, there has been little improvement in the prognosis of those 
patients diagnosed with breast cancer. We now accept that this disease is the 
culmination of a series of genetic events and these will need to be unravelled if
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treatments are to become more sophisticated. This, in turn, will require more 
accurate assessment of the cellular changes that occur in cancer. Limitations in 
measurement methods, together with a perceived lack of value o f more accurate 
quantification, has caused many biological markers to be categorised, positive or 
negative. This is clearly artificial as most biological characteristics are subject to a 
range o f values. This is no less true of the EGF receptor than of other biological 
characteristics and more accurate receptor measurement certainly provided our 
most interesting results;
♦ a direct relationship between tumour size, in millimetres, and EGF receptor 
expression,
♦ an inverse relationship between expression levels of EGF receptor and 
oestrogen receptor,
♦ and, although not specifically reported in this work, an inverse relationship 
between EGF receptor and c-er6B-2 encoded receptor, in those tumours 
without c-erbB-2 gene amplification (Robertson 1996).
Inter-relationships such as these offer new avenues for further study. Their 
identification may begin to allow us to piece together the molecular signalling that 
defines the behaviour o f tumour cells. They also offer therapeutic potential, if  
drug induced modification of one factor can militate another. These observations 
were achieved only by analysis of EGF receptor expression as a continuum. This, 
in turn, was only possible because of the accuracy o f the 
radioimmunohistochemical method.
How can experimental studies pertain to clinical practice?
If better understanding of molecular signalling is to be of value then its effect on 
tumour cell behaviour must be discerned. This is an exacting task. Human biology 
is immensely complex and our understanding of tumour biology remains 
rudimentary. This makes it difficult to ascertain the function of single molecules 
and has necessitated a reductionist approach utilising experimental models. The 
invasion studies exemplify this, focusing on a single cellular function, invasion, 
and a solitary molecule, EGF receptor. However, invasion is only one element of 
the composite that is metastasis, and isolation of receptor function is untenable for 
the very reason that its interaction with other factors defines its function. This 
means that interpretation of such studies is fraught with difficulty and must be 
considered in the light of the study's limitations. These limitations also require 
that we continue clinical studies since these will promulgate appropriate 
experimental questions. EGF receptor, down regulated in nearly all breast cancers, 
might appear a poor therapeutic target. However, the invasion studies demonstrate
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that it may remain a functionally valid target. From the clinical study, its 
relationship with tumour size fits with the mitogenic signal that is known to result 
from EGF receptor stimulation. This, together with this receptors confirmed 
predictive value on survival, suggest that abrogation of EGF receptor signalling 
could be a useful therapeutic goal. This has been substantiated by experimental 
work utilising immunotherapy and tyrosine kinase inhibitors. Work that 
exemplifies the improvements in patient management that could be achieved with 
an improved understanding of molecular signalling.
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